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Abstract 
Advances in dementia research have shifted attention towards earlier stages in the natural 
history, such as Mild Cognitive Impairment. The current gold standard outcome measure, 
the Alzheimer’s Disease Assessment Scale-Cognitive Subscale, is not optimally 
responsive to changes in pre-dementia populations. Modifications to scoring methodology 
and content have improved the measurement performance of the ADAS-Cog. However, 
no published modifications have addressed a second key shift in the field towards 
understanding motor function as an important component of dementia and pre-dementia 
syndromes. This thesis used a Pooled Index approach to combine an ADAS-Cog-Proxy 
measure with assessments of gait velocity and dual-task cost. The responsiveness of the 
PI to baseline discrimination between older adults with normal cognition, Subjective 
Cognitive Impairment, and MCI was similar to the ADAS-Cog-Proxy. The PI 
demonstrated greater responsiveness than the ADAS-Cog-Proxy to change over 6mo. and 
48mo., but not 36mo. of follow-up. Overall, motor function assessments improve ADAS-
Cog responsiveness. 
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Chapter 1  
1 Introduction 
The purpose of Chapter 1 is to provide a brief overview of this thesis. Three outcome 
measurement challenges will be addressed, which are currently present in the field of 
dementia research.  
1.1 Epidemiology of Dementia  
Dementia is a syndrome characterized by deterioration in cognitive abilities such as 
memory, praxis, and language, and in the ability to perform everyday activities.1,2 The 
worldwide prevalence of dementia is 47 million people, with an estimated incidence rate 
of 9.9 million cases per year.1 In 2016, an estimated 564,000 people living in Canada had 
dementia, costing an annual $10.4 billion.3 The prevalence of dementia in Canada is 
expected to reach 912,000 cases by 2030.3 There is no known cure. Hence, much research 
is aimed at trying to better understand dementia syndromes and develop effective 
treatment approaches.  
1.2 Outcome Measurement Challenges 
The quality of any research study is influenced by the measurement tools employed to 
assess constructs of interest.4,5 Because a construct is a hypothetical concept, a 
fundamental challenge lies in valid and reliable measurement.6 In the context of health 
research, constructs are often aspects of disease pathology or encapsulate the impacts that 
pathology may have on one’s experience of life; they are dynamic yet bounded by the 
current understanding of a health condition or state. In some cases, a ‘gold standard’ or 
best possible outcome measure has been established. Beyond individual study quality, 
gold standards help to increase consistency and comparability throughout a body of 
literature, which is especially important when evaluating novel treatment approaches. 
However, as a field advances the understanding of a health condition or state, including 
what constitutes pathology or burden, and ultimately treatment benefit, may change. If a 
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gold standard is not harmonious with these advancements, the quality and relevance of 
research findings, and by extension the speed with which a field progresses, may be 
limited.  
The circumstance of a long-standing gold standard in a rapidly advancing field is the first 
of three challenges pertaining to outcome measurement that this thesis will address. The 
second is how an outcome measure may be modified for improvement if the original 
version is deemed unsatisfactory for use in a particular population or context. The third is 
when all necessary outcome measures for a research objective are not available in a single 
database, but a preliminary test of hypotheses is desired before investing the time and 
resources required to run a new study that would collect all measures together.   
1.3 Outcome Measurement Challenges in Dementia 
Research  
These three measurement challenges will be examined in the field of dementia research, 
where the gold standard for assessing the efficacy of antidementia therapies is the 
Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog).7 Although the 
ADAS-Cog works well for studies on dementia populations, the research field is 
changing in such a way that the ADAS-Cog is now being used in contexts that it was not 
originally developed for.  
More specifically, two important advancements in the field of dementia research have 
occurred since the adoption of the ADAS-Cog in the 1980s. First, research interest has 
shifted to pre-dementia stages of disease progression, such as Mild Cognitive Impairment 
(MCI), where impairment is more mild than in dementia.8-13 It is thought that intervening 
to slow or stop the progression of disease will be more effective than waiting until severe 
neuropathology and dysfunction have developed.8,11,14-16 Thus, many research studies, 
both observational and experimental, are being conducted in pre-dementia 
populations.12,15,17-21 Outcome measures that work well for studies of older adults with 
dementia may not work well for studies of older adults with pre-dementia syndromes 
because the impairment that occurs in pre-dementia syndromes is more mild than the 
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impairment that occurs in dementia syndromes, and may differ in type. For example, 
memory is often impaired at early stages while language does not become impaired until 
more severe stages.22 It is important that outcome measures being used for pre-dementia 
populations can reflect a person’s level of cognitive ability, as well as changes in disease 
severity over time, otherwise disease progression or potential treatment benefits may be 
missed. Concerns have been raised about whether the ADAS-Cog, which was originally 
developed to assess dysfunction in mild to severe dementia, is able to detect important 
changes at earlier stages of disease progression.9,14,23,24 These concerns relate to the first 
measurement challenge introduced above, and motivated a literature review for this thesis 
that explores the measurement properties and performance of the ADAS-Cog in pre-
dementia populations. In accordance with the second measurement challenge, the review 
extends to document all modifications that have been made in an attempt to improve the 
ADAS-Cog. This literature review is presented in Chapter 3.  
The second advancement in the field of dementia research is the emergence of motor 
function decline as an early pathological manifestation, in addition to cognitive decline, 
of disease progression; at the time of ADAS-Cog development, cognitive and motor 
function decline were understood as separate processes. A seminal study in 1997 found 
older adults who stop walking while talking are at an increased risk of falls compared to 
those who do not stop.25 Since then, a literature base has been growing that supports an 
association of dementia and pre-dementia syndromes with both motor and cognitive 
decline, whereby these declines are understood as interrelated processes.26-41 For 
example, Buracchio et al. (2010) found walking speed begins to slow twelve years in 
advance of MCI diagnosis,26 Montero-Odasso et al. (2014) suggest that subtypes of MCI 
possess a unique “motor signature”,27 and Kueper et al. (2017) performed a systematic 
review that found poor lower limb motor performance is associated with an increased risk 
of incident dementia.28 Importantly, motor function and cognitive abilities together may 
provide the fundamental basis for functionality, or the ability to perform activities of daily 
living, the loss of which is a hallmark of disease severity.42-44 Motor function assessments 
may therefore be helpful for detecting important changes in pre-dementia syndromes, 
such as to evaluate whether a novel treatment approach is beneficial. However, the 
literature review on the ADAS-Cog did not find any modifications that incorporate motor 
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function assessments. The main question this thesis aims to address is whether adding 
assessments of motor function to the ADAS-Cog improves its ability to detect changes in 
pre-dementia syndromes. This research question is presented in Chapter 4 along with 
three formal objectives, which include developing an outcome measure and assessing its 
ability to detect two types of change in a pre-dementia sample. Chapter 5 includes a 
version of a manuscript centered around these objectives.  
The third measurement challenge presented above becomes relevant as this thesis relies 
on secondary data analysis, and no database contains both the ADAS-Cog and motor 
function assessments. A proxy ADAS-Cog was developed for use in a database that 
contains motor function assessments. The framework used to build this proxy ADAS-Cog 
may be followed for other, similar situations, and is covered in depth in Chapter 6 along 
with other detailed methods and results pertaining to the three objectives.  
1.4 Overview of Thesis 
The next chapter provides an introduction to outcome measurement terms and concepts 
that will be utilized throughout the remainder of the thesis, Chapter 3 presents a literature 
review on the ADAS-Cog, Chapter 4 states the research question and objectives, Chapter 
5 is an integrated article, Chapter 6 includes more detailed methods and results than are 
presented in Chapter 5, Chapter 7 provides an extended discussion, and the Appendices 
contain supplementary Tables and Figures.  
  
   5 
 
1.5 References  
 
1.  World Health Organization. Dementia. 
http://www.who.int/mediacentre/factsheets/fs362/en/. Published 2017. Accessed 
July 2, 2017. 
2.  Alzheimer Society of Canada. What is demenita? 
http://www.alzheimer.ca/en/About-dementia/What-is-dementia. Published 2017. 
Accessed July 2, 2017. 
3.  Chambers LW, Bancej C, Mcdowell I. Prevalence and Monetary Costs of 
Dementia in Canada. Toronto: Alzheimer Society of Canada; 2016. 
4.  Coster WJ. Making the best match: selecting outcome measures for clinical trials 
and outcome studies. Am J Occup Ther. 2013;67(2):162-170. 
doi:10.5014/ajot.2013.006015. 
5.  Fullerton JT. Evaluation of research studies Part IV: validity and reliability-
concepts and application. J Nurse Midwifery. 1993;38(2):121-125. 
6.  Binning JF. Construct. In: Encyclopedia Britannica Online. Encyclopedia 
Britannica Inc. 2017. https://www.britannica.com/science/construct. 
7.  Rosen WG, Mohs RC, Davis KL. A New Rating Scale for Alzheimer's Disease. 
Am J Psychiatry. 1984;141(11):1356-1364. doi:10.1176/ajp.141.11.1356. 
8.  Llano DA, Laforet G, Devanarayan V. Derivation of a new ADAS-Cog composite 
using tree-based multivariate analysis: prediction of conversion from Mild 
Cognitive Impairment to Alzheimer Disease. Alzheimer Dis Assoc Disord. 
2011;25(1):73-84. doi:10.1097/WAD.0b013e3181f5b8d8. 
9.  Podhorna J, Krahnke T, Shear M, E Harrison J. Alzheimer’s Disease Assessment 
Scale-Cognitive subscale variants in Mild Cognitive Impairment and mild 
Alzheimer’s Disease: change over time and the effect of enrichment strategies. 
Alzheimers Res Ther. 2016;8(1):8. doi:10.1186/s13195-016-0170-5. 
10.  Graham DP, Cully JA, Snow AL, Massman P, Doody R. The Alzheimer’s Disease 
Assessment Scale-Cognitive subscale: normative data for older adult controls. 
Alzheimer Dis Assoc Disord. 2004;18(4):236-240. 
11.  Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, 
memory, and Mild Cognitive Impairment. Int psychogeriatrics. 1997;9(Supp 
1):65-69. 
12.  Cooper C, Sommerlad A, Lyketsos CG, Livingston G. Modifiable predictors of 
dementia in Mild Cognitive Impairment: a systematic review and meta-analysis. 
Am J Psychiatry. 2015;172(4):323-334. doi:10.1176/appi.ajp.2014.14070878. 
13.  Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild 
Cognitive Impairment: a concept in evolution. J Intern Med. 2014;275(3):214-228. 
doi:10.1111/joim.12190. 
14.  Ueckert S, Plan EL, Ito K, Karlsson MO, Corrigan B, Hooker AC. Improved 
utilization of ADAS-Cog assessment data through Item Response Theory based 
Pharmacometric Modeling. Pharm Res. 2014;31(8):2152-2165. 
doi:10.1007/s11095-014-1315-5. 
15.  Mariani E, Monastero R, Mecocci P. Mild Cognitive Impairment: a systematic 
review. J Alzheimers Dis. 2007;12(1):23-35. 
16.  Grundman M, Petersen RC, Ferris SH, et al. Mild Cognitive Impairment can be 
   6 
 
distinguished from Alzheimer Disease and Normal Aging for clinical trials. Arch 
Neurol. 2004;61(1):59-66. 
17.  Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JPG, Mayeux R. Frequency and 
course of Mild Cognitive Impairment in a multiethnic community. Ann Neurol. 
2008;63(4):494-506. doi:10.1002/ana.21326. 
18.  Apostolova LG, Cummings JL. Neuropsychiatric manifestations in Mild Cognitive 
Impairment: a systematic review of the literature. Dement Geriatr Cogn Disord. 
2008;25(2):115-126. doi:10.1159/000112509. 
19.  Plassman BL, Williams JW, Burke JR, Holsinger T, Benjamin S. Factors 
associated with risk for and possible prevention of cognitive decline in later life. 
Ann Intern Med. 2010;153:182-193. 
20.  Tricco AC, Soobiah C, Berliner S, et al. Efficacy and safety of cognitive enhancers 
for patients with Mild Cognitive Impairment: a systematic review and meta-
analysis. CMAJ. 2013;185(16):1393-1401. doi:10.1503/cmaj.130451. 
21.  Reijnders J, van Heugten C, van Boxtel M. Cognitive interventions in healthy older 
adults and people with Mild Cognitive Impairment: a systematic review. Ageing 
Res Rev. 2013;12(1):263-275. doi:10.1016/j.arr.2012.07.003. 
22.  Association A. Stages of Alzheimer’s. 
http://www.alz.org/alzheimers_disease_stages_of_alzheimers.asp. Published 2017. 
Accessed August 23, 2017. 
23.  Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E. The Alzheimer’s 
Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the 
ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav. 2012;6:489-
501. doi:10.1007/s11682-012-9166-3. 
24.  Raghavan N, Samtani MN, Farnum M, et al. The ADAS-Cog revisited: novel 
composite scales based on ADAS-Cog to improve efficiency in MCI and early AD 
trials. Alzheimer’s Dement. 2013;9(10):S21-S31. doi:10.1016/j.jalz.2012.05.2187. 
25.  Lundin-Olsson L, Nyberg L, Gustafson Y, Himbert D, Seknadji P, Karila-cohen D. 
“Stops walking when talking” as a predictor of falls in elderly people. Lancet. 
1997;349:617. 
26.  Buracchio T, Dodge HH, Howieson D, Wasserman D, Kaye J. The trajectory of 
gait speed preceding Mild Cognitive Impairment. Arch Neurol. 2010;67(8):980-
986. doi:10.1001/archneurol.2010.159. 
27.  Montero-Odasso M, Oteng-Amoako A, Speechley M, et al. The motor signature of 
Mild Cognitive Impairment: results from the Gait and Brain Study. Journals 
Gerontol Ser A Biol Sci Med Sci. 2014;69(11):1415-1421. 
doi:10.1093/gerona/glu155. 
28.  Kueper JK, Speechley M, Lingum NR, Montero-Odasso M. Motor function and 
incident dementia: a systematic review and meta-analysis. Age Ageing. 2017:1-10. 
doi:10.1093/ageing/afx084. 
29.  Montero-Odasso M. Gait as a biomarker of cognitive impairment and dementia 
syndromes. Quo vadis? Eur J Neurol. 2016;23(3):437-438. doi:10.1111/ene.12908. 
30.  Montero-Odasso M, Verghese J, Beauchet O, Hausdorff JM. Gait and cognition: a 
complementary approach to understanding brain function and the risk of falling. J 
Am Geriatr Soc. 2012;60(11):2127-2136. doi:10.1111/j.1532-5415.2012.04209.x. 
31.  Beauchet O, Allali G, Montero-Odasso M, Sejdić E, Fantino B, Annweiler C. 
Motor phenotype of decline in cognitive performance among community-dwellers 
   7 
 
without dementia: population-based study and meta-analysis. PLoS One. 
2014;9(6). doi:10.1371/journal.pone.0099318. 
32.  Verghese J, Annweiler C, Ayers E, et al. Motoric Cognitive Risk Syndrome 
multicountry prevalence and dementia risk. Neurology. 2014;83(8):718-726. 
doi:10.1212/WNL.0000000000000717. 
33.  Montero-Odasso MM, Barnes B, Speechley M, et al. Disentangling Cognitive-
Frailty: results from the Gait and Brain Study. J Gerontol A Biol Sci Med Sci. 
2016;71(11):1476-1482.doi:10.1093/gerona/glw044. 
34.  Montero-Odasso M, Hachinski V. Preludes to brain failure: executive dysfunction 
and gait disturbances. Neurol Sci. 2014;35(4):601-604. doi:10.1007/s10072-013-
1613-4. 
35.  Allali G, Assal F, Kressig RW, Dubost V, Herrmann FR, Beauchet O. Impact of 
impaired executive function on gait stability. Dement Geriatr Cogn Disord. 
2008;26(4):364-369. doi:10.1159/000162358. 
36.  Allali G, Annweiler C, Blumen H, et al. Gait phenotype from MCI to moderate 
dementia: results from the GOOD initiative. Eur J Neurol. 2016;23(3):527-541. 
doi:10.1111/ene.12882. 
37.  Annweiler C, Beauchet O, Bartha R, et al. Motor cortex and gait in Mild Cognitive 
Impairment: a magnetic resonance spectroscopy and volumetric imaging study. 
Brain. 2013;136(3):859-871. doi:10.1093/brain/aws373. 
38.  Welmer AK, Rizzuto D, Qiu C, Caracciolo B, Laukka EJ. Walking speed, 
processing speed, and dementia: a population-based longitudinal study. J Gerontol 
A Biol Sci Med Sci. 2014;69(12):1503-1510. doi:10.1093/gerona/glu047. 
39.  Hausdorff JM, Buchman AS. What links gait speed and MCI with dementia? A 
fresh look at the association between motor and cognitive function. Journals 
Gerontol - Ser A Biol Sci Med Sci. 2013;68(4):409-411. 
doi:10.1093/gerona/glt002. 
40.  Muir SW, Speechley M, Wells J, Borrie M, Gopaul K, Montero-Odasso M. Gait 
assessment in Mild Cognitive Impairment and Alzheimer’s Disease: the effect of 
dual-task challenges across the cognitive spectrum. Gait Posture. 2012;35(1):96-
100. doi:10.1016/j.gaitpost.2011.08.014. 
41.  Montero-Odasso MM, Sarquis-Adamson Y, Speechley M, et al. Association of 
dual-task gait with incident dementia in Mild Cognitive Impairment. JAMA Neurol. 
2017;54(3):S154. doi:10.1001/jamaneurol.2017.0643. 
42.  Hausdorff JM, Yogev G, Springer S, Simon ES, Giladi N. Walking is more like 
catching than tapping: gait in the elderly as a complex cognitive task. Exp Brain 
Res. 2005;164(4):541-548. doi:10.1007/s00221-005-2280-3. 
43.  Lusardi MM, Pellecchia GL, Schulman M. Functional performance in community 
living older adults. J Geriatr Phys Ther. 2003;26(3):14-22. 
44.  Adams K, Bayliss E, Blumenthal D, et al. Universal health outcome measures for 
older persons with multiple chronic conditions. J Am Geriatr Soc. 
2012;60(12):2333-2341. doi:10.1111/j.1532-5415.2012.04240.x. 
   8 
 
Chapter 2  
2 Introduction to Outcome Measures 
The purpose of Chapter 2 is to review important concepts and terminology related to the 
development and use of outcome measures for health conditions involving latent traits, to 
outline approaches for improving pre-existing outcome measures, and to introduce three 
of the main cognitive outcome measures used today. 
The overall goal of a health-related outcome measure is to score specific traits to help 
determine whether a health condition is present, or to assess the relative severity of that 
health condition in an individual or group. The approaches and challenges differ 
depending on the nature of the outcome, specifically whether it is a manifest variable (e.g. 
a physical property, such as gait speed), or a latent trait (e.g. cognitive ability). Because 
manifest variables are often measured directly with instruments and devices, evaluating 
measurement is primarily a technical exercise concerned with reliability, accuracy, and 
precision. Latent traits are more difficult to evaluate. Section 2.1 will provide a brief 
overview of what latent traits are and how they can be modelled, and then Sections 2.2 
and 2.3 will describe two main measurement models used to assess measures of latent 
traits, namely Classical Test Theory (CTT) and Item Response Theory (IRT). 
2.1 Overview of Latent Traits  
In contrast to medical abnormalities that can be physically seen or detected, such as a 
broken bone, there are many health states or conditions, often with a strong psychological 
component, which cannot be directly observed.1,2 Rather, they are associated with some 
underlying ability that is not directly observable, such as cognition or personality, that 
drives people to behave or function in certain ways.1,2 Outcome measures can quantify 
these latent traits using multiple test items that capture observable manifestations of the 
latent traits.3-5 The covariation between a subject’s observed test item responses is 
assumed to be due to the latent trait.1-4 Latent traits can be modelled in three main ways: 
1) Categorical latent traits include discrete, mutually exclusive classes, that can be 
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used to separate a group of people who may appear similar based on observable 
traits (Figure 1).4,6 Members within each class share the same latent trait category, 
and are considered homogenous.4,6 
 
Figure 1 Categorical latent trait. 
 
2) Dimensional latent traits follow a single continuum spanning from low to high 
magnitude of the latent trait (Figure 2).4,6 Subjects can be given a quantitative 
score to indicate their placement on the continuum, and then compared to each 
other (e.g. Subject A has poorer short-term memory than Subject B), but no 
straightforward group classification is available.6 
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Figure 2 Dimensional latent trait. 
 
3) Factor Mixed Model latent traits include both a categorical and a dimensional 
structure (Figure 3).6 Factor mixed model latent traits categorize subjects into 
different latent classes (e.g. subject has Subtype A of Disease X), and within each 
latent class subjects can be organized along a latent trait continuum (e.g. to 
indicate within-class differences in level of disease severity).6 Characteristics of 
the dimensional latent traits may differ between categorical latent classes.6 
 
Figure 3 Factor mixed model latent trait. 
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Unidimensionality refers to the situation where one dimensional latent trait is 
responsible for all scores produced by an outcome measure or test (Figure 4).2-4,7 More 
specifically, the probability of responding a certain way on a test item is assumed to be a 
function of the underlying trait.4,6 The shape of the probability function will depend both 
on the underlying trait and on the format of the test question.5 For a unidimensional 
outcome measure where all items are designed to measure the same underlying trait, 
scores can be used to compare subjects’ relative abilities on the underlying trait.8  
 
Figure 4 Unidimensionality assumption.  
 
2.2 Classical Test Theory 
CTT is one of two main psychometric theories underlying outcome measurement, and is 
focused on the observed scores of an outcome measure.9 A subject’s observed score on 
any single measure administration is assumed to be composed of their “true score” and 
some error of measurement.2,8,9,10 True scores are sometimes referred to as “trait scores” 
as they are intended to relate to a subject’s latent trait ability.8 CTT maintains an 
assumption of unidimensionality.2,10 Measurement errors are assumed to be random, 
follow a normal distribution with mean of zero, and not correlate with the true score.2,5,9,10 
Xi = Ti + Ei 
Where Xi = Subject i’s observed total score on an outcome measure, Ti = Subject i’s true 
score or latent ability level, Ei = error of measurement. 
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Observed total scores are often obtained using an unweighted sum of all individual item 
responses on an outcome measure.2 This method assumes that all items are equally 
difficult and equally important, that the difference between any two response options is 
the same across all test items, that all items correlate equally with the latent trait, and that 
subjects have responded to all items on an outcome measure.2,10 Rarely are all 
assumptions of CTT met, but the CTT model cannot be disproved because the 
assumptions cannot be directly tested against an unknown latent trait.9 
Another limitation of CTT is the assumption of measurement invariance.2 An outcome 
measure is said to be invariant when it performs the same way regardless of what, or who, 
is being measured, because the method by which results are produced is independent of 
the individual object, construct, or person being assessed in any given testing 
situation.11,12 For example, a scale designed to assess Attribute X should be able to 
identify the same amount of Attribute X in two people who truly do have the same 
amount of Attribute X, but differ by age or education. In reality, properties of outcome 
measures constructed using CTT are dependent on the samples in which they were tested 
and validated.10 Thus, with CTT there is a circular dependency between outcome measure 
properties and subject attributes.10 While properties of the outcome measure such as 
reliability and validity depend on the sample composition, especially how homogenous 
the sample is, subject scores depend on the properties of the outcome measure.2,10 A final 
limitation of CTT is that different outcome measure scores obtained under CTT cannot be 
compared unless transformed to Z-scores, T-scores, or percentiles.10 This method of 
transformation requires the raw outcome measure scores to be approximately normally 
distributed.13  
2.2.1 Standardization  
Any random variable following a normal distribution, which is a bell-shaped probability 
distribution, can be standardized by subtracting the mean and dividing by the standard 
deviation so that it becomes a standard normal distribution with a mean of zero and 
standard deviation of one.13 The resulting standard scores, or Z-scores, can be expressed 
as percentiles and allow direct comparison of scores from outcome measures which 
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initially had different scoring methods, scales, means, and standard deviations.10  
2.2.2 Reliability  
Reliability is the ability of an outcome measure to give the same results for the same 
subjects, under different circumstances, assuming the underlying construct of interest has 
remained constant.10,14 Four main subtypes of reliability include:   
1) Inter-observer reliability indicates the degree to which two different people 
administering the same outcome measure to the same subject at the same time, 
will produce the same results.2,10,14  
2) Intra-observer reliability indicates the degree to which the same person 
administering the same outcome measure in two different circumstances, will 
produce the same results.10 
3) Test-retest reliability refers to the ability of an outcome measure to give the same 
results for the same subject at two different time points, assuming the subject 
remained stable for whatever the measure was designed to assess.2,10,14 If a subject 
has changed with regards to the construct of interest, then an outcome measure 
designed to assess change with high reliability should reflect this change in the 
final score.2,15 
4) The first three types of reliability apply to both single items and to scores based on 
several items. Internal consistency is applicable only to composite scores, and 
refers to whether all items of an outcome measure assess the same construct.2,10,14   
There are several approaches that can be used to assess reliability, and an outcome 
measure which shows high reliability for a certain population and context of assessment 
may not demonstrate similarly high reliability for a different population or context.2,10,15 
Hence, it is important to refer to reliability of test scores in specified populations and 
contexts, not the reliability of an outcome measure on its own.2,10 Reliability parameters 
range from zero to one, and will increase as between-subject variation increases and 
decrease as measurement error decreases2,10,16: 
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Reliability = σ2subject / [σ2subject + σ2error] 
Where σ2subject = True variance between subjects, σ2error = Measurement error variance. 
2.2.3 Precision  
Precision in the context of outcome measurement refers to the reproducibility of a score 
for a given subject in a given circumstance.17 Although similar to reliability, precision 
does not distinguish between score variability due to true subject differences and 
variability due to error.17 An outcome measure may demonstrate high precision but low 
reliability.10,17 For example, if a group of subjects all obtain very similar scores on an 
outcome measure there will be very little true subject variability and therefore low 
reliability, but high precision.17   
2.2.4 Standard Error of Measurement  
The Standard Error of Measurement (SEM) provides an absolute measure of the precision 
of individual subject scores, expressed in the same units as the outcome measure.10,16 As 
described above, under CTT the score on any single outcome measure administration 
consists of the true test score and measurement error. 2,8-10 If an infinite number of test 
administrations were performed for a subject, the average of the observed test scores 
would be the best single estimate of the true score for that subject.5,10,18,19 The true score 
in this sense is referring to consistency, not validity.19 The standard deviation of the 
sampling errors for the distribution of observed test scores from the hypothetical infinite 
number of administrations is the SEM.10,19 The SEM can be calculated as10,16:  
SEM = σx √1 − 𝑅 = √σerror2   
Where σx = Standard deviation of the observed scores over a population, R = Reliability, 
σ2error = Measurement error variance. 
2.2.5 Coefficient of Variation  
The coefficient of variation (CV) is a measure of intra-individual variability that accounts 
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for the overall performance of study participants on an outcome measure, calculated 
as20,21: 
CV= σ / μ  
Where σ = standard deviation, μ = mean. 
The CV is dimensionless and allows comparison of score variability for the same 
outcome measure administered to different samples, or comparison of variability for 
different outcome measures administered to the same or different samples.21  
2.2.6 Validity  
In general, validity is the extent to which an outcome measure evaluates what it was 
designed to measure, and is specific to both the population and context of 
assessment.2,10,18 Validity can be expressed as10: 
Validity = σ2construct of interest / σ2observed  
Where σ2observed = σ2construct of interest + σ2systematic error + σ2random error 
Validity exists on a continuum, and whether or not a measurement tool is “valid” for a 
particular population and context requires a decision based on results from a series of 
hypothesis tests that make up the process of validation.10,18 As knowledge of a health 
condition or state increases, or the theoretical framework underpinning a construct of 
interest changes, further validation will be required to determine whether a previously 
developed outcome measure remains valid enough for use in the current context and 
population of interest.10 If an outcome measure is designed to assess a multidimensional 
construct, then validation for each of the individual dimensions must be performed using 
separate hypotheses pertaining to each dimension.2,19 Three major subdomains of the 
validation process include:  
1) Content validation determines the extent to which an outcome measure assesses 
all important components of a health condition of interest.10,15,18,22 As more 
components are captured by an outcome measure, inferences about the true 
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underlying health of a subject obtaining a given score can become more 
comprehensive.10,15,22  
Content validation differs from other types of validity in two important ways. 
First, an outcome measure can have high content validity even with low 
reliability.10 Content validity is improved by including items to assess all 
important aspects of a health condition, but if these aspects are highly variable 
across individuals internal consistency may be compromised.10 Secondly, content 
validation is a non-empirical approach as it depends solely on the judgement of 
experts in the field or comparison with theoretical models, rather than on 
statistical tests of comparison with other measures of the health condition of 
interest.10,15,18,22 
2) Criterion validation assesses how well an outcome measure agrees with other 
well-established measures of the same health condition.10,15,18,22 Subtypes of 
criterion validation include concurrent validation, whereby the comparison 
between the two measures is made at the same point in time, and predictive 
validation, where the outcome measure under study is compared to some 
measured criteria that occurs in the future.18,22   
3) Construct validation assesses whether an outcome measure outperforms (rather 
than mimics as with criterion validation) the gold standard, or criteria currently 
believed to be the best possible assessment of a health condition of 
interest.10,15,22,23 Unlike criterion and content validation, which can be estimated 
for a particular population and context in a single appropriate study, construct 
validation is a continuous process and tests the theory and outcome measure at 
the same time.10 Construct validation requires both justification with explicit 
reference to evidence about the relevance of the components of an outcome 
measure to the health condition of interest, as well as statistical tests and 
numerical comparisons with measures of the health condition or individual 
components of it.22,23 As the theoretical framework of a health condition changes, 
hypotheses may change and further tests need to be conducted.10,22,23  
   17 
 
Construct validation may be further broken down into convergent and 
discriminant validation. Convergent validation tests how closely an outcome 
measure relates to other variables and measures of the construct it was designed to 
measure.10 Discriminant or divergent validation tests that the outcome measure 
undergoing validation does not correlate with measures of constructs hypothesized 
to not be part of the health condition of interest.10 An acceptable strength of 
correlation between the outcome measure undergoing validation and the other pre-
existing measures will depend on the relative importance of what is being assessed 
by the other measures for the health condition of interest.10 
2.2.7 Responsiveness  
Responsiveness is a type of validity, however for simplicity this thesis will review 
responsiveness as a separate concept.10,19 Responsiveness is broadly defined as the ability 
of an outcome measure to accurately detect change,15,24-26 and must be contextualized by 
the type of change being assessed.24,26 This contextualization may occur according to the 
taxonomy of responsiveness developed by Beaton et al. (2001), which includes three axes 
of classification:  
1) The “Who” axis differentiates between individual level and group level of 
analysis and interpretation.26 
2) The “Which” axis describes whether the scores being contrasted are measuring 
between-person differences at one point in time, within-person changes over time, 
or between-person differences of within-person change over time.26 
3) The “What” axis specifies the type of change being quantified in the study, such 
as minimum potentially detectable change by the instrument, observed change 
measured by an instrument in a population, or observed change in a population 
deemed to have improved by a clinician.26 
The three conceptualizations of change most relevant for this thesis, and examples of 
methods for assessing responsiveness for each, are presented below. Please note that the 
group-level analysis and interpretation of change is often used for research studies, but 
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outcome measures will require adequate levels of responsiveness to individual-level 
change if they are intended to also be used for one-on-one assessments, such as in a 
clinical setting.  
Baseline Discrimination: Responsiveness to group-level between-person differences in 
stage of disease progression at one point in time. The health condition of interest for this 
thesis can be viewed as a continuum of severity which includes the key stages of Normal 
Cognition (NC), Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment 
(MCI), and dementia.27-33 At any arbitrary baseline point, subjects at the different stages 
of disease progression beyond NC have already changed in terms of their underlying 
disease pathology and phenotypic expressions of such. And, if the natural history of the 
disease has predictable stages, then all subjects are expected to go through similar 
changes in phenotypic expression as they progress from NC to severe dementia. Just 
because the changes did not occur within the observation window of the study does not 
mean it is not change we are measuring – it means the change has occurred 
retrospectively. Therefore, the ability of a measurement tool to discriminate between 
subjects with NC, SCI, MCI, dementia, or even more refined categories at one point in 
time, can be interpreted as a type of responsiveness. This separation of subjects into 
distinct diagnostic categories is adopting a categorical latent trait conceptualization of the 
dementing process.  
A simple way to assess baseline discrimination is to compare the mean scores of the 
outcome measure in each of the predefined diagnostic categories. These scores may be 
tested for statistically significant differences with a t-test or Analysis of Variance, 
depending on the number of groups to be compared.13 Non-parametric counterparts to 
these tests, Mann Whitney U and Kruskal-Wallis, are also suitable options.13 
It is important to note that if the health condition of interest did not progress continuously 
through stages of severity in its natural history, it would not be appropriate to refer to 
baseline discrimination as a type of responsiveness. For example, if we were trying to 
identify children with different allergies, a child with a peanut allergy is not expected to 
have previously been in a citrus allergy category, nor are they expected to progress 
towards a fish allergy category. For these types of health conditions defined with nominal 
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categories, baseline discrimination is more similar to sensitivity, with the caveat that 
discriminative ability is often quantified in relation to other measures while sensitivity is 
compared to pre-specified criteria of presence versus absence.10 Sensitivity is further 
described in Section 2.2.8. 
Disease progression: Responsiveness to group-level within-person observed change 
measured by an outcome measure in a given population. This may include progression 
(i.e. increasing severity) within or between the above-mentioned stages of dementia 
progression.26 It is not limited by those diagnostic categories, and therefore is adopting a 
dimensional latent trait conceptualization of the entire dementing process.  
The main statistical tests used to assess this type of responsiveness include paired t-tests, 
which test the null hypothesis that there is no change in the individual outcome scores for 
the same group across two time points, standardized effect sizes, which express the 
magnitude of change in outcome measure scores across two time points by comparing the 
average amount of within-person change to the variability of baseline scores, and the 
standardized response mean (SRM; also known as the signal-to-noise ratio, 
responsiveness-treatment coefficient, efficiency index, or standardized change), which 
expresses the magnitude of change in the observed outcome measure scores relative to the 
variability of those change scores.24 A key advantage of the SRM is that it allows direct 
comparison between different outcome measures because it takes into account the fact 
that different measures have different score ranges and variability in change from 
baseline.34 
Treatment Effect: Responsiveness to group-level between-person differences of within-
person observed change over time. Sample statistical tests that may be used to assess this 
type of responsiveness are a two-way Analysis of Variance including a treatment group by 
time factor, an Analysis of Covariance with terms for baseline score and treatment group, 
or regression models.13 The scores from an outcome measure designed to be responsive 
to a treatment effect can be used to calculate an effect size, which summarizes the 
magnitude and direction of differences between two or more groups which differ on at 
least one important characteristic (in this case, whether or not the group received active 
treatment).35 For example, a treatment effect in a clinical trial may be that the group 
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receiving active treatment improved their score on the outcome measure by 15% whereas 
the group receiving placebo remained stable. Effect sizes can also include different rates 
of deterioration, such as if the treatment group experienced average 5% worsening in 
scores compared to the placebo group’s average 15% worsening. Regardless of statistical 
significance, the clinical significance of a treatment effect size should always be 
interpreted within the context of what is being assessed and how much of a reduction (or 
increase) in the outcome is meaningful to patients, caregivers, or clinicians.35 Effect sizes 
can be adjusted for potential confounding factors. Confounders may increase or decrease 
the magnitude of effect, or change the direction of effect (qualitative confounding).35 This 
is important to keep in mind when comparing effect sizes from different studies.  
2.2.8 Sensitivity and Specificity 
Sensitivity and specificity are characteristics of outcome measures designed to classify a 
subject as having or not having a health condition.36-38 These outcome measures do not 
need to be based on CTT. Sensitivity and specificity are calculated from the perspective 
of a ‘gold standard’ or external criterion: 
Sensitivity, or true positive probability, is the ability to detect a specific health condition, 
when that health condition is truly present.10,36-38 
Sensitivity = # True Positives / (# True Positives + # False Negatives) 
Specificity, or true negative probability, is the ability to identify those without a specific 
health condition, when that health condition is truly absent.10,36-38 
Specificity = # True Negatives / (# True Negatives + # False Positives) 
Where True Positive = The test provides a positive result (disease present) when the 
subject really does have the health condition of interest, False Positive = The test provides 
a positive result when the subject does not really have the health condition of interest, 
True Negative = The test provides a negative result (disease absent) when the subject 
really does not have the health condition of interest, False Negative = The test provides a 
negative result when the subject really does have the health condition of interest. Overall 
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accuracy can be obtained by dividing the number of correct assessments (True Positives + 
True Negatives) by the total number of assessments.38 
When the health condition of interest exists on a continuum of severity that can be 
captured by increasing or decreasing scores on an outcome measure, cut-points can be 
used to decide what score corresponds to a positive test result indicating that a subject 
may have the health condition of interest.10 Choosing higher or lower cut-points will alter 
the sensitivity and specificity of the test. Usually when sensitivity increases, specificity 
decreases, and vice versa.10,37 The prevalence of the health condition in the population 
being tested does not affect the sensitivity and specificity.10,37 
Receiver Operating Characteristic (ROC) curves plot false positives (1-specificity) 
against true positives (sensitivity) for all possible cut-off values.38,39 The area under the 
curve (AUC) represents the probability that, given a random pair of people where one 
truly has the outcome and one does not, the person who has the outcome will score higher 
than the person who does not.10,39 The AUC ranges from 0.5 (random chance that the test 
will correctly classify a patient) to 1.0 (test perfectly classifies all patients).37,38 ROC 
curves can be used to assess responsiveness when responsiveness is described in terms of 
sensitivity and specificity for detecting change and no change in an external standard. The 
external standard score must be dichotomized at a cut-off for what constitutes meaningful 
change. 
2.3 Item Response Theory  
The above definitions of reliability, validity, and responsiveness are based on CTT.10 The 
second major measurement model used to assess outcome measures for latent traits is 
IRT.8,10 IRT is both a measurement model and a probability model.8,9 It estimates the 
probability of a subject selecting a particular test item response given their ability on a 
latent trait.8,10 So, unlike CTT which focuses on the total test score, IRT focuses on 
individual test items.9,10 Furthermore, IRT does not assume that all test items are 
equivalent.8,10 Rather, specific item properties can be built into the IRT model to try to 
obtain the best possible estimate of a subject’s level of latent trait ability.8,10  
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IRT models are usually described by the number of item parameters they contain. Three 
different item parameters have been defined, any number of which may be included in an 
IRT model.8,10 A multi-item outcome measure may contain items which have the same or 
different values for each of the item parameters.8 The three item parameters can be 
described visually with item characteristic curves (ICC) or item characteristic functions in 
plots of the latent trait ability against the probability of a particular response (Figure 
5).8,10 ICCs can be plotted for dichotomous or polytomous items, and each item response 
option may be given its own ICC on the plot.8 
 
Figure 5 Sample item characteristic curve. 
The first item parameter is an item difficulty parameter, and is situated at the point of 
inflection of the ICC, or the point at which the probability of selecting a particular 
response option is 0.5 (Figure 5, point A).8,10 The purpose of the item difficulty parameter 
is to locate each test item on the same continuum of latent trait ability that subjects are 
located on.8,10  
The second is an item discrimination parameter, and is reflected by the slope of the 
   23 
 
ICC (Figure 5, point B).5,8,10 The item discrimination parameter relates to how much 
information a test item holds about the underlying latent ability.8,10 An item with a steeper 
slope is better able to discriminate between levels of latent ability, for the levels of ability 
which it covers, because the probability of the response changes very quickly as one 
moves along the latent trait continuum.5,8,10 
The third is an item guessing parameter, identified by the lower asymptote of the ICC 
(Figure 5, point C).8 The item guessing parameter models the chance probability of 
responding to a test item in a certain way (e.g. how likely one is to choose a correct 
response by guessing).8,10 
Model-data fit analyses can be used to test whether an IRT model is a good description of 
the data, whereas with CTT the model is just assumed to be true.9 IRT also does not 
calculate reliability in the same was as CTT.10 IRT focuses on precision rather than 
reliability, whereby higher precision indicates a higher level of “information”.8,10 
Standard Error (latent trait) = 1 / √information (latent trait) 
Methods for calculating level of information differ among IRT models, but in general 
higher information corresponds to lower standard error of estimate for a person’s location 
on the latent trait continuum, and the higher the item discrimination parameter, the higher 
the item information.8,10 Item information is the cumulative sum of all information from 
all of that item’s response categories.8 Test information is the cumulative sum of the 
information from all test items.8 The information peak is located at the apex of an ICC, 
and corresponds to the level of latent trait ability for which the item (or response option, 
or test) holds the most information.8 
The simplest IRT model is the Rasch model, which is a particular type of one parameter 
logistic model.8,10 A one parameter logistic model provides the probability of a particular 
item response given the subject’s latent ability, the item difficulty, and the item 
discrimination.8,10  For a Rasch model the item discrimination parameter is set to 1, and 
for the one parameter logistic model it can be any number, but that number remains 
constant for all items.8,10 The two parameter logistic model builds on the one parameter 
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logistic model by allowing the parameter for test item discrimination to differ between 
items.8,10 The three parameter logistic model adds in the item guessing parameter.8,10 IRT 
models have three main assumptions: 
1) The dimensionality assumption states that test responses are due to one’s latent 
trait ability level.8,10 Although most often the latent trait is assumed to be 
unidimensional, modifications can be made for multidimensional cases. If 
different latent traits underlie different test items (between-item 
multidimensionality) then separate IRT models can be built for clusters of items 
relying on the same latent trait.8 If multiple latent traits underlie responses to a 
single item, then a multidimensional IRT model can be built.8 A multidimensional 
IRT model can be either compensatory or non-compensatory depending on 
whether one latent trait is able to compensate for deficiencies in the other latent 
trait.8,10 
2) The conditional or local independence assumption states that each individual 
item response is independent of any other item responses given the subject’s latent 
trait ability.8-10 In other words, test item responses are due completely to a specific 
latent trait ability, not due to other latent traits or knowledge or priming from 
other test items.8-10 
3) The functional form assumption includes whether the model correctly specifies 
the function that the data follow.8,10 
2.4 Approaches for Modifying Outcome Measures 
Two main approaches for modifying, or attempting to improve, a pre-existing outcome 
measure are changing the scoring methodology and adding additional test items.40 These 
approaches can be used individually or in combination.40 Regardless of the approach 
taken, it is recommended that the modified measure be backwards-compatible with the 
original measure. Backwards compatibility means the original measure can be recovered 
from the new or modified version, which preserves the ability to compare results between 
studies using the modified and original version.41 When the measure to be modified is 
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considered the current gold standard, backwards compatibility will also allow researchers 
to show regulators results from their study in terms of the original gold standard measure, 
while results from the modified version can be used for further research purposes 
including demonstration of improved measurement properties.  
2.4.1 Statistical Modification of Scoring Methodology  
The simplest scoring method for any outcome measure is a straight summation of points 
across all test items, whereby points gained from any test item contribute equally to the 
total score.2,42 This transparent method assumes that all test items are equally important 
and informative for assessing disease severity.43-45 Item weights can be altered so that a 
point on one test item would contribute more or less to the total score than a point on a 
different test item.2 Applying a weight of zero to a test item is effectively the same as 
removing the item from the scoring process, while maintaining the capacity for 
backwards compatibility. Values for the re-weighting process may be derived statistically 
or theoretically in accordance with the relative importance of each item for the health 
condition of interest. Psychometric methods, such as IRT, can also be used to modify 
scoring for any given outcome measure.43,45 
2.4.2 Adding Additional Item Content  
The second approach to improve a pre-existing outcome measure is to administer the 
original outcome measure along with additional test items.34,40,46 Often items are added 
because theoretical advancements in a field identified an important component of a health 
condition that is not effectively being assessed by the original outcome measure. 
Statistical approaches to adding test items may also be used. The total score range of the 
modified outcome measure can be derived by simply extending the scoring range of the 
original version to accommodate the additional items, or by some other scoring 
modification. The additional item content may change the latent trait(s) assessed by the 
outcome measure, warranting the need for further validation studies of the additional item 
content as well as the modified outcome measure as a whole.10 
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2.5 Key Cognitive Outcome Measures  
Three main cognitive outcome measures used today include the Mini-Mental State 
Examination (MMSE), the Montreal Cognitive Assessment (MoCA), and the Alzheimer 
Disease Assessment Scale – Cognitive Subscale (ADAS-Cog). 
The MMSE was developed in 1975 to address the need for an outcome measure to screen 
for possible cognitive impairment in several psychiatric conditions including but not 
limited to dementia.47 The MMSE contains 11 questions, can be administered in five to 
ten minutes, and is scored from 0 to 30 with higher scores reflecting better cognitive 
function.47 Domains of cognitive function assessed include orientation, memory, 
language, attention, and visuospatial abilities.47,48 Although not developed specifically for 
dementia, the MMSE is the most commonly used screening test for dementia, whereby a 
score of 23 or 24 is often selected as the cut-off to identify subjects with probable 
dementia.48 A meta-analysis of the diagnostic performance of the MMSE across 108 
cohort studies with different patient populations found that the overall summary 
sensitivity of the MMSE for detecting dementia was 0.81 (95% Confidence Interval (CI) 
0.78, 0.84), the specificity 0.89 (95% CI 0.87, 0.91), and the overall accuracy 92% (95% 
CI 90, 94).48 Twenty-one cohorts in the same meta-analysis assessed the ability of the 
MMSE to detect MCI, yielding a summary sensitivity of 0.62 (95% CI 0.52, 0.71), and 
specificity of 0.87 (95% CI 0.80, 0.92).48 This comparatively low performance for 
detecting MCI may be because many people meeting the clinical criteria for MCI score in 
the “normal” range on the MMSE (over 26 points).49   
The MoCA was developed in 2005 for the purpose of improving detection of MCI 
specifically.49 The MoCA contains 10 questions, can be administered in under 10 
minutes, and is scored from 0 to 30 with higher scores indicating better cognitive 
function.48,49 Cognitive domains assessed by the MoCA include memory, executive 
function, attention, language, and orientation.48,49 The meta-analysis described above 
assessed the diagnostic performance of the MoCA for detecting MCI across nine cohorts, 
and found a summary sensitivity of 0.89 (95% CI 0.84, 0.92) and specificity of 0.75 (95% 
CI 0.62, 0.85).48   
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While the MMSE and the MoCA were developed as screening tools to assist primary care 
physicians identify patients with cognitive difficulties, they are also used for group-level 
analyses in research studies. The ADAS-Cog is another commonly used cognitive 
outcome measure for studies of dementia and pre-dementia syndromes. In contrast to the 
MMSE and MoCA which were developed to identify people from a heterogeneous 
sample whom may have MCI or dementia, the ADAS-Cog was developed for the purpose 
of identifying severity of dysfunction in samples of subjects with known AD.50 The 
ADAS-Cog is the current ‘gold standard’ for clinical trials of treatments for dementia, 
and is often also used as such in studies of MCI and other pre-dementia syndromes. 
Unfortunately, several concerns about the use of the ADAS-Cog have emerged. These 
concerns will be a main focus of this thesis. Most notably, the ADAS-Cog appears to 
have poor responsiveness to important changes in subjects with pre-dementia syndromes, 
and has low content validity since advancements in the study of dementia and pre-
dementia syndromes have identified domains not covered by the ADAS-Cog which are 
emerging as important components of dementia and pre-dementia syndromes. Chapter 
three will provide a comprehensive literature review on the ADAS-Cog, including a 
description of individual scale tasks and scoring.   
2.6 Summary  
Latent traits are underlying dimensions, such as cognitive ability, which people possess 
but cannot be observed directly. Latent traits can be divided into categorical, dimensional, 
and factor mixed model structures. Cognition can be conceptualized using any of these 
structures, depending on the theoretical framework and measurement model being used. 
Two main measurement models used to develop outcome measures for latent traits 
include CTT and IRT. Three key cognitive outcome measures include the MMSE, 
MoCA, and ADAS-Cog. All three were developed using CTT. The ADAS-Cog is the 
current ‘gold standard’ outcome measure for clinical trials in dementia and pre-dementia 
syndromes, however there is some concern about its utility in studies of pre-dementia 
syndromes.  
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Chapter 3  
3 Literature Review  
The purpose of Chapter 3 is to explain how the Alzheimer’s Disease (AD) Assessment 
Scale (ADAS) was developed, briefly review measurement properties of the ADAS 
Cognitive Subscale (ADAS-Cog) in dementia and pre-dementia populations, and provide 
a comprehensive review of all modifications that have been made to the ADAS-Cog and 
any assessments of the responsiveness of these modified versions. Please note that only 
literature published in the English language, and English language versions of the ADAS-
Cog or modifications thereof, were examined.   
3.1 Development of the Alzheimer’s Disease Assessment 
Scale 
The ADAS was originally designed to fulfill the need for a rating scale specific to AD 
studies. Goals for the ADAS included being able to assess the severity of cognitive and 
non-cognitive dysfunction from mild to severe dementia, while maintaining reliability 
and brevity of administration for subjects in different environments.1  
3.1.1 Item Selection  
Item selection for the ADAS began with calculating the reliability and validity of forty 
candidate items in a development sample of 27 subjects with AD and 28 subjects with 
normal cognitive function (NC).1 Most of the forty items showed statistically significant 
inter-rater reliability and test-retest reliability as assessed by intraclass correlation 
coefficients (ICC) and Spearman rank-order correlations, respectively, in the AD and NC 
groups separately.1 Practice effects were detected only in the NC group.1 Results from the 
AD group alone were used to select the final 21 items, which can be divided into 
cognitive and non-cognitive subscales. The ADAS takes about 45 minutes to administer. 
It is scored from 0 to 150 by summing the number of errors made on each test item so that 
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higher scores indicate worse performance.1 The mean ADAS total score in the 27 subjects 
with AD was 37.0  (Standard Deviation (SD)=17.5).1 
The non-cognitive subscale (ADAS-Noncog) includes 10 assessments, scored from 0 to 
50, which consider mood and behavioural changes. The mean ADAS-Noncog score for 
the original 27 subjects with AD was 4.4 (SD=3.5).1 Specific items include: 
1. Tearful 
2. Appears/reports depressed mood 
3. Concentration and distractibility 
4. Uncooperative to testing 
5. Delusions 
6. Hallucinations 
7. Pacing 
8. Increased motor activity 
9. Tremors 
10. Increase or decrease in appetite  
The cognitive subscale (ADAS-Cog) includes 11 tasks that are either a test to be 
completed by a subject or an assessment made by the test administrator about the subject, 
and which broadly assess the cognitive domains of memory, language, and praxis. The 
ADAS-Cog is scored from 0 to 70, and the mean ADAS-Cog score for the initial 27 
subjects with AD was 19.3 (SD=12.1).1 Specific tasks include: 
1. Word Recall. A list of 10 words is read by the subject, and then the subject is 
asked to verbally recall as many of the words as possible. Three trials of reading 
and recalling are performed. The task score is the mean number of words not 
recalled across the three trials (range 0 to 10).1  
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2. Naming Objects and Fingers. The subject is asked to name the fingers of their 
dominant hand as well as twelve objects, including: flower (plastic), bed (doll 
house furniture), whistle, pencil, rattle, mask, scissors, comb, wallet, harmonica, 
stethoscope, and tongs. The task score is calculated based on the number of 
fingers and objects correctly named, and ranges from 0 to 4.1  
3. Commands. The subject is asked to perform one to five step commands. For 
example, the two step command is to “Point to the ceiling, then to the floor.” The 
task score is from 0 to 5, based on the largest number of steps that are correctly 
performed (score is 0 if five step command is correctly performed).1  
4. Constructional Praxis. The subject is shown four geometric forms (circle, two 
overlapping rectangles, rhombus, cube) and asked to copy them on a piece of 
paper. The task is scored from 0 to 5 based on the number of correctly drawn 
forms.1 
5. Ideational Praxis. The subject is asked to pretend to send a letter to themselves. 
Scoring is based on difficulty of performing the five components of: fold letter, 
put letter in envelope, seal envelope, address envelope, and putting a stamp on the 
envelope (range 0 to 5).1 
6. Orientation. The subject is asked the date, month, year, day of the week, season, 
time of day, place, and person. The number of correct responses is the task score 
(range 0 to 8).1 
7. Word Recognition. The subject reads twelve words aloud, and then these twelve 
words are randomly shuffled with twelve new words, and the subject is asked 
whether they have previously seen each of the twenty-four words. Three trials are 
performed, and the task score is the mean number of correct responses across the 
three trials (range 0 to 12).1 
8. Language. After the administration of the Word Recall task (Q1) ten minutes of 
open-ended conversation occur between the test administrator and subject, before 
the remainder of the tasks are presented. These ten minutes of conversation are 
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used to assess language ability. Quality of speech is given a global rating by the 
administrator that ranges from 0 to 5.1 
9. Comprehension of Spoken Language. This task also relies on the ten minutes of 
open-ended conversation. The administrator provides an assessment of how well 
the subject can understand speech that ranges from 0 to 5.1 
10. Word Finding Difficulty. This task is also rated by the administrator during 
spontaneous speech to assess how much difficulty the subject has in finding 
desired words from 0 to 5.1 
11. Remembering Test Instructions. This task is a rating by the administrator from 1 
to 5 according to the number of times that the subject needed to be reminded of 
instructions for the Word Recognition task.1  
Initially the two memory tasks (numbers 1 and 7) were viewed as a separate memory 
subscale and scored out of 22 points, with the remainder of the cognitive tasks scored out 
of 48 points (ADAS-Cog 9).1 From here on “ADAS-Cog 11” refers to the full 11-item 
version of the ADAS-Cog. 
3.1.2 Validation of the Alzheimer’s Disease Assessment Scale 
Concurrent criterion validation was assessed in the original sample by correlating ADAS 
scores with previously well-established measures used to help assess disease severity. 
There were statistically significant correlations between the Sandoz Clinical Assessment-
Geriatric and the full ADAS (r=0.52, P<0.02) as well as the ADAS-Cog 9 (r=0.67, 
P<0.01), but not the ADAS-Noncog (r=0.25, P>0.10).1 There were statistically 
significant correlations between the Memory-Information Test and the full ADAS (r=-
0.67, P<0.001), the ADAS-Cog (r=-0.78, P<0.001), and the ADAS-Noncog (r=-0.42, 
P<0.02).1 There were also statistically significant correlations between the Dementia 
Rating Scale and the full ADAS (r=0.64, P<0.001), the ADAS-Cog (r=0.48, P<0.01), and 
the ADAS-Noncog (r=0.46, P<0.01).1 
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Further concurrent criterion validation was performed in a separate study of 61 subjects 
with very mild, mild, moderate, or severe AD, and 52 subjects with NC.2 The ADAS-Cog 
11 and a modified ADAS-Noncog (nine items: tearfulness, depression, concentration, 
uncooperativeness, delusions, pacing, increased motor activity, tremors, appetite) were 
administered. The ADAS-Cog 11 correlated strongly with the Mini-Mental State 
Examination (MMSE; r=-0.76, P<0.0001), but there was a weaker correlation between 
the modified ADAS-Noncog and MMSE (r=-0.39, P=0.0019).2  
3.1.3 Responsiveness to Baseline Discrimination  
In the original ADAS development sample, point-biserial correlations were used to show 
that the group of subjects with AD had significantly higher scores on the ADAS-Cog 11 
(r=0.754, P<0.0001) as well as on all individual ADAS-Cog 11 tasks (all P<0.0001) than 
the group of subjects with NC.1 Subjects with AD also scored significantly worse on the 
ADAS-Noncog (r=0.487, P<0.003), and three individual ADAS-Noncog items.1 Since 
then, several other studies with larger samples have also shown that the ADAS-Cog 11 is 
able to discriminate between the diagnostic categories of NC, Mild Cognitive Impairment 
(MCI), and AD at one point in time, and that the scores for subjects with NC are 
appropriately lower than those with MCI and subsequently AD.2-8 ADAS-Cog 11 scores 
have also been shown to discriminate between mild, moderate, and severe AD, but not 
between very mild and mild AD.2 This remained true after removing the language tasks 
(Language, Comprehension of Spoken Language, Word Finding Difficulty) from the 
ADAS-Cog 11.2 Another study including 485 subjects found statistically significant 
differences between ADAS-Cog 11 scores from subject groups with Clinical Dementia 
Rating (CDR) Scale scores of 0, 0.5, and 1.9  
The ability of the ADAS-Cog 11 to act as a diagnostic instrument to classify subjects as 
having AD or not was tested by Zec et al. (1992), whereby two SD above the NC group 
mean was used as a cut-off for abnormal cognition.2 Only two subjects with AD and one 
subject with NC were misclassified.2 Good classification remained after removing the 
language tasks from the ADAS-Cog 11.2  
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3.1.4 Responsiveness to Disease Progression  
Rosen et al. (1984) found a statistically significant worsening on total ADAS (P=0.02), 
ADAS-Cog 11 (P=0.01), and ADAS-Noncog (P=0.03) scores over a twelve-month 
period for ten subjects with AD, but not for ten of the subjects with NC (all P>0.05) that 
were used to develop the ADAS.1 Eight of the subjects with AD showed a worsening on 
each individual task.1  
Evans et al. (2010) found statistically significant differences (P<0.0005 for all) between 
the magnitude of mean 12 month ADAS-Cog 11 change scores for subjects in different 
diagnostic categories, adjusted for baseline score, age, and gender, whereby the 99 
subjects with AD changed the most (mean change=3.53 points, SD=5.42) compared to 
the 231 subjects with MCI (mean change=1.16 points, SD=4.31) and the 131 subjects 
with NC (mean change=-0.53 points, SD=2.70).10 Petersen et al. (2010) found statistically 
significant differences (P<0.001 for all) between mean ADAS-Cog 11 12 month change 
scores for 210 subjects with NC (mean change=-0.5 points, SD=3.0), 357 subjects with 
MCI (mean change=1.1 points, SD=4.4), and 161 subjects with AD (mean change=4.3 
points, SD=6.6).4 It is important to note that the magnitudes of these changes are small, 
especially in MCI and NC groups. Other studies have found similar results. Steenland et 
al. (2014) found that ADAS-Cog 11 scores of 191 subjects with NC worsened by an 
average 7.5% over 3 years (P=0.0007) after adjusting for age, gender, race, education, 
and Apolipoprotein E (APOE) e4 allele presence.11 Podhorna et al. (2016) did not 
perform statistical tests, but reported almost no change on the ADAS-Cog 11 in 382 
subjects with MCI over 24 months (mean change=0.9 points, SD=4.45) and in 169 
subjects with MCI over 36 months (mean change=1.9 points, SD=5.45).12 For an 
‘enriched’ subgroup of subjects with MCI who had cerebrospinal fluid (CSF) or APOEe4 
allele biomarkers indicative of AD pathology, there was still only a 1.9 mean point 
change (SD=4.92) over 24 months (n=206) and 3.7 mean point change (SD=6.21) over 36 
months (n=89).12 In 97 subjects with mild AD there was a clinically relevant change over 
12 months (mean change=3.5 points, SD=5.59) and for 40 subjects with mild AD over 24 
months (mean change=8.3 points, SD=8.96).12  
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3.1.5 Minimum Clinically Relevant Change 
Schrag et al. (2011) divided the scores of 358 subjects with mild AD into those who were 
rated by clinicians as having versus not having experienced clinically relevant worsening 
in the domains of memory, non-memory, general cognitive function, and functionality as 
assessed by the Functional Activities Questionnaire (FAQ) and CDR Scale.13 The range 
of ADAS-Cog score change corresponding to clinically relevant change separated by the 
four domains was 2.7 to 3.8 point increase over 6 months.13 For those judged not to have 
changed it was a mean 1.2 to 2.0 point increase over 6 months.13 All change scores were 
statistically significant (P<0.05).13 Based on these comparisons they determined that a 3 
point or larger increase (worsening) on the ADAS-Cog 11 is a clinically relevant 
change.13 
3.1.6 Summary  
The ADAS was developed to assess the severity of cognitive and non-cognitive 
dysfunction in people with AD. The ADAS-Cog 11 and ADAS-Noncog are able to 
discriminate between groups of subjects with NC and AD, and the ADAS-Cog 11 can 
also discriminate MCI from NC and AD. The ADAS-Cog 11 has also been shown to be 
able to detect change over time in dementia and pre-dementia samples; however, the 
magnitude of the change detected in MCI and NC samples is very small. The ADAS-
Noncog is not widely used and will not be reviewed further.  
3.2 Assessment of the ADAS-Cog 11 in Pre-
Dementia Populations  
3.2.1 Ceiling Effects  
Seven of the eleven ADAS-Cog 11 tasks demonstrate severe ceiling effects in MCI and 
NC samples (Table 1), whereby all or most subjects make zero errors on those tasks.5,14-19 
A further two tasks show milder ceiling effects.14,15,17-19 Accordingly, 84% of errors made 
by subjects with NC and 71% of errors made by subjects with MCI occur on the two 
ADAS-Cog 11 tasks which do not demonstrate ceiling effects, Word Recall and Word 
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Recognition.5 Item Response Theory (IRT) analyses have also found that those two tasks 
have the most difficult ranking among all ADAS-Cog 11 tasks (please consult Section 2.3 
for an overview of IRT).20  
Table 1 ADAS-Cog 11 Ceiling Effects. 
Study data SIU-
NAS5 
Italian 
clinical 
trial14 
Multiple 
pooled 
studies15 
BCM-
ADC16 
ADCS17 ADNI18  ADNI19 ADNI21 ADNI10 
Q1         N/A 
Q2        N/A N/A 
Q3        N/A N/A 
Q4        N/A N/A 
Q5        N/A N/A 
Q6        N/A N/A 
Q7        N/A N/A 
Q8         N/A N/A 
Q9        N/A N/A 
Q10        N/A N/A 
Q11        N/A N/A 
Total Score    N/A    N/A  
Legend: Green=No ceiling effect, Orange=Mild ceiling effect, Red=Severe ceiling effect; 
ADCS=Alzheimer's Disease Cooperative Study, ADNI=Alzheimer’s Disease 
Neuroimaging Initiative, BCM-ADC=Baylor College of Medicine Alzheimer's Disease 
Study, N/A=Not Available, Q1=Word Recall, Q2=Naming Objects and Fingers, 
Q3=Commands, Q4=Constructional Praxis, Q5=Ideational Praxis, Q6=Orientation, 
Q7=Word Recognition, Q8=Language, Q9=Comprehension of Spoken Language, 
Q10=Word Finding Difficulty, Q11=Remembering Test Instructions, SIU-
NAS=Southern Illinois University Normal Aging Study. All studies included participants 
with Mild Cognitive Impairment except BCM-ADC, which included exclusively 
cognitively normal controls. 
 
3.2.2 Information Content  
An ideal outcome measure for MCI would have the information peaks of all item 
information curves generated by an IRT analysis of all individual outcome measure items 
in the range of cognitive ability expected to be seen in subjects with MCI. Ueckert et al. 
(2014) found that all but three ADAS-Cog 11 tasks have their information peak in a range 
that corresponds to levels of cognitive dysfunction more severe than would be expected in 
MCI, indicating that they are not optimally sensitive for use with MCI populations.15 
Through summation of the information available for each subtask item (individual 
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response options), Ueckert et al. (2014) found that the most informative ADAS-Cog 11 
tasks for assessing MCI levels of cognitive dysfunction were Word Recall, Orientation, 
Word Recognition, and Naming Objects and Fingers.15 Furthermore, an in-depth 
evaluation of the Word Recall Task has shown that the Pole response item has a higher 
recall probability than other response items for NC, MCI, and AD groups, suggesting that 
it is an abnormally easy item on the ADAS-Cog 11.21 These types of in-depth analyses for 
other individual ADAS-Cog 11 tasks have not been published.  
3.2.3 Invariances  
All individual ADAS-Cog 11 tasks as well as the total score have shown measurement 
invariance with respect to education and age in MCI samples.5 Measurement invariance 
to sex has also been found for the total ADAS-Cog 11 score in MCI samples.5 In samples 
with NC, the ADAS-Cog 11 total score also showed measurement invariance with respect 
to sex and education, but not for age.2,5,16 Age was significantly correlated with total 
ADAS-Cog 11 score as well as the Word Recall task in NC samples.2,5,16 For example, 
the ADAS-Cog 11 validation study that included 61 subjects with very mild, mild, 
moderate, or severe AD, and 52 subjects with NC recruited an additional 80 subjects with 
NC to assess whether age and education correlated with ADAS-Cog 11 scores.2 They 
found ADAS-Cog 11 scores from subjects with NC were moderately correlated with age 
(r=0.42, P=0.0018), but non-significantly correlated with education (r=-0.21, P=0.13).2 
When categorized, age remained significantly correlated and education did not, 
suggesting that age but not education may influence ADAS-Cog 11 scores in NC 
samples.2 Specifically, among the subjects with NC, those aged 7 to 13 or 60 to 89 years 
old performed significantly worse than those aged 14 to 59 years old, although the size of 
these differences was small.2 In contrast, among subjects with AD correlations with age 
(r=-0.08, P=0.56) and education (r=-0.06, P=0.66) were both small and non-significant.2 
Altogether these results suggest that the only threat to measurement invariance is the age 
of subjects with NC.   
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3.2.4 Reliability  
Significant variance in administration procedures and materials used for the ADAS-Cog 
11 across clinical trials has been found, which threatens inter-observer, intra-observer, 
and test-retest reliability.22 Learning effects may also be a concern as Herholz et al. 
(2011) found a statistically significant decline in ADAS-Cog 11 scores in sample of 
subjects whom otherwise did not appear to be progressing in symptoms (stable NC) 
(ICC=0.47, 95%CI 0.32, 0.63).23  
3.2.5 Concurrent Criterion Validation  
One study found ADAS-Cog 11 scores significantly correlated with MMSE scores in 
both NC (Spearman rho=-0.29, P<0.001) and MCI (Spearman rho=-0.66, P<0.001) 
samples, indicating agreement with another well-established assessment of overall 
cognitive ability.5 However, the only individual ADAS-Cog 11 tasks significantly 
correlated with the MMSE were Word Recognition in subjects with NC (Spearman rho=-
0.26, P<0.001) and Word Recognition and Word Recall in subjects with MCI (Spearman 
rho range -0.36 to -0.49, P<0.001).5 Another study in 124 subjects with NC found the 
ADAS-Cog 11 was not significantly correlated with MMSE scores (r=-0.13, P=0.16).16 
3.2.6 Responsiveness at the Item Level 
Baseline discrimination. All ADAS-Cog 11 tasks have shown statistically significant 
differences between NC and MCI subgroups,4,5,17 and all but three tasks (Commands, 
Ideational Praxis, Language) have demonstrated significantly higher scores in AD than 
MCI subgroups.5 Furthermore, three of the ADAS-Cog 11 tasks (Word Recall, Word 
Recognition, Orientation) were found to detect a statistically significant difference 
between subjects with MCI and none versus one versus two APOEe4 alleles.24 
Disease progression. All individual ADAS-Cog 11 tasks have been found to have 
smaller Standardized Response Means (SRM)s than the ADAS-Cog 11 total score, where 
the three tasks demonstrating the largest SRM were Word Recall, Orientation, and Word 
Recognition.19 Groups of subjects with NC compared to MCI have been found to have 
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statistically significant different 12 month change scores on the Word Recall and Word 
Recognition tasks.4 The magnitude of 12 month and 24 month change scores for five 
ADAS-Cog 11 tasks were similar when comparing MCI and AD groups, while the six 
other tasks produced smaller change scores for the MCI group compared to the AD 
group.19  
3.2.7 Performance of the ADAS-Cog 11 as an Outcome Measure 
in Pre-Dementia Studies  
Forty-six studies were found which use the ADAS-Cog 11 as an outcome measure to 
assess whether there is an association between an exposure or intervention and cognitive 
ability. This thesis takes a very rudimentary approach to assessing the performance of the 
ADAS-Cog 11 in these studies, and merely examined whether or not the ADAS-Cog 11 
produced statistically significant results for these associations. It is assumed that all 
studies in this portion of the literature review have an adequately developed theoretical 
framework to reasonably expect that a difference in cognitive ability between exposure 
groups should exist, either at baseline or over time, even though some of the exposures 
may actually be ineffectual towards cognitive ability. Results from other outcome 
measures used to assess the same association as the ADAS-Cog 11 in each study may be 
used as a sort of proxy for whether the ADAS-Cog 11 is capturing associations which 
truly do exist (other measures statistically significant). Please note that due to publication 
bias towards positive results, the results presented here may overestimate the proportion 
of statistically significant associations detected by the ADAS-Cog 11 in pre-dementia 
study samples. 
Responsiveness to group-level between-person differences in observed level of 
disease severity based on exposure status. Twenty-two studies assessed cross-sectional 
associations between exposure status and ADAS-Cog 11 scores in older adults with pre-
dementia levels of impairment, as summarized below in Table 2 for NC, Table 3 for MCI, 
and Table 4 for mixed NC and MCI samples.4,11,25-44 Within these studies there were 
twenty statistically significant associations between exposure status and ADAS-Cog 11 
scores (green highlight). There were sixteen non-statistically significant associations 
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found between the ADAS-Cog 11 and an exposure, where any other cognitive or brain 
imaging outcome measures used to assess the same association also produced non-
statistically significant results (orange highlight). The ADAS-Cog 11 failed to produce a 
statistically significant result for eight associations which were statistically significant for 
at least one other cognitive or brain imaging outcome measure (red highlight).   
Table 2 Normal Cognition Samples: ADAS-Cog 11 responsiveness to group-level 
between-person differences in observed level of disease severity based on exposure 
status. 
First 
Author & 
Publication 
Year 
Exposure  
 
(continuous 
variable unless 
otherwise 
specified) 
Association 
between 
exposure 
and ADAS-
Cog 11 
[Effect 
estimate, 
 P-Value, 
 (n)] 
Other 
statistically 
significant 
outcome 
measures 
Other 
statistically non-
significant 
outcome 
measures 
Factors controlled 
for 
 (None if blank) 
Crane 
201225 
Hippocampal 
Volume  
β=1.03, 
P>0.05, 
(225) 
 
ADNI-Mem, 
RAVLT, ADAS-
Cog13, ADAS-
Rasch, ADAS-
Tree, MMSE, 
CDR-SB 
Age, education, 
gender, APOEe4 
allele, intracranial 
volume  
Crane 
201225 
Parahippocampal 
Thickness 
β=1.30, 
P>0.05, 
(225) 
 
ADNI-Mem, 
RAVLT, ADAS-
Cog13, ADAS-
Rasch, ADAS-
Tree, MMSE, 
CDR-SB 
Age, education, 
gender, APOEe4 
allele, intracranial 
volume  
Crane 
201225 
Entorhinal 
Thickness 
β=0.27, 
P>0.05, 
(225) 
 
ADNI-Mem, 
RAVLT, ADAS-
Cog13, ADAS-
Rasch, ADAS-
Tree, MMSE, 
CDR-SB 
Age, education, 
gender, APOEe4 
allele, intracranial 
volume  
Crane 
201225 
Fusiform 
Thickness 
β=-0.17, 
P>0.05, 
(225) 
ADNI-Mem, 
RAVLT  
ADAS-Cog13, 
ADAS-Rasch, 
ADAS-Tree, 
MMSE, CDR-SB 
Age, education, 
gender, APOEe4 
allele, intracranial 
volume  
Daiello 
201526 
Fish Oil 
Supplement vs. 
None 
β=-7.01, 
P<0.01, 
(229) 
MMSE  Age, gender, 
education, race, CVD 
risk score, APOEe4 
allele, ChEI use 
Doraiswamy 
201227 
Aβ positive vs. 
negative 
P=0.17, 
(69) 
DSS, WMS 
immediate & 
delayed 
recall 
MMSE, CDR-SB, 
verbal fluency 
(animals & 
vegetables) 
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Doraiswamy 
201428 
Aβ positive vs. 
negative 
P=0.20,  
(67) 
DSS, WMS 
immediate 
recall 
MMSE, WMS 
delayed recall, 
CDR-SB, verbal 
fluency (animals 
& vegetables) 
 
Landau 
201229 
Brain Glucose 
Metabolism  
P>0.05,  
(126)  
   
Landau 
201229 
Aβ rho=0.17, 
P=0.06, 
(126)  
   
Petersen 
20104 
Aβ r=-0.21, 
P<0.05,  
(229) 
   
Steenland 
201411 
Future 
Conversion to 
MCI or AD vs. 
No Future 
Conversion 
P=0.09, 
(191) 
RAVLT trial 
5 & short 
recall, WMS 
immediate & 
delayed 
logical 
memory, 
BNT 
Mini-Cog, 
MMSE, ANART, 
Category (animal) 
fluency, 
TMTA&B, brain 
volume measures 
(whole brain, 
ventricle, left 
hippocampus, 
right 
hippocampus). 
 
Legend: See List of Abbreviations (pages xii to xvi). Effect estimates include regression 
coefficients (β), Spearman rank correlation coefficients (rho), and Pearson correlation 
coefficients (r). If a statistical test was performed without an effect estimate reported, 
only the P-value is shown. Highlighting refers to results of associations tested using the 
ADAS-Cog as an outcome measure: Green=statistically significant result, suggesting 
responsiveness; Orange=non-statistically significant result where no other cognitive or 
neuroimaging outcome measure found a statistically significant association, suggesting 
unknown responsiveness; Red=non-statistically significant result where at least one other 
cognitive or neuroimaging outcome measure detected a statistically significant result, 
suggesting poor responsiveness of the ADAS-Cog.  
 
Table 3 Mild Cognitive Impairment Samples: ADAS-Cog 11 responsiveness to 
group-level between-person differences in observed level of disease severity based on 
exposure status 
First 
Author & 
Publication 
Year 
Exposure 
 
(continuous 
variable unless 
otherwise 
specified) 
Association 
between 
exposure 
and ADAS-
Cog 11 
[Effect 
estimate, 
 P-Value, 
 (n)] 
Other 
statistically 
significant 
outcome 
measures  
Other 
statistically 
non-significant 
outcome 
measures  
Factors controlled for 
(None if blank)  
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Crane 
201225 
Hippocampal 
Volume  
β=6.32, 
P<0.05, 
(394) 
ADNI-
Mem, 
RAVLT, 
ADAS-
Cog13, 
ADAS-
Rasch, 
ADAS-Tree, 
MMSE, 
CDR-SB 
 
Age, education, gender, 
APOEe4 allele, 
intracranial volume  
Crane 
201225 
Parahippocampa
l Thickness 
β=1.63, 
P>0.05, 
(394) 
ADNI-
Mem, 
RAVLT, 
ADAS-Tree, 
CDR-SB 
ADAS-13, 
ADAS-Rasch, 
MMSE 
Age, education, gender, 
APOEe4 allele, 
intracranial volume 
Crane 
201225 
Entorhinal 
Thickness 
β= 7.68, 
P<0.05, 
(394) 
ADNI-
Mem, 
RAVLT, 
ADAS-
Cog13, 
ADAS-
Rasch, 
ADAS-Tree, 
MMSE, 
CDR-SB 
 
Age, education, gender, 
APOEe4 allele, 
intracranial volume  
Crane 
201225 
Fusiform 
Thickness 
β= 4.46, 
P<0.05, 
(394) 
ADNI-
Mem, 
RAVLT, 
ADAS-
Cog13, 
ADAS-
Rasch, 
ADAS-Tree, 
MMSE, 
CDR-SB 
 
Age, education, gender, 
APOEe4 allele, 
intracranial volume  
Cronk 
201030 
Body Mass 
Index 
No statistical 
test, (286) 
 
MMSE, global 
cognition score 
Age, sex, education  
Daiello 
201526 
Fish Oil 
Supplement vs. 
None 
β=-3.29, 
P=0.20, 
(397) 
 
MMSE Age, gender, education, 
race, CVD risk score, 
APOEe4 allele, ChEI 
Doraiswamy 
201227 
Aβ positive vs. 
negative 
P=0.06, 
(51) 
 MMSE, CDR-SB, 
DSS, verbal 
fluency 
(vegetables & 
animals), WMS 
immediate & 
delayed recall 
 
Doraiswamy 
201428 
Aβ positive vs. 
negative 
P=0.10, 
(47) 
 MMSE, CDR-SB, 
DSS, verbal 
fluency (animal & 
vegetable), WMS 
immediate & 
delayed recall 
 
Irizarry 
200931  
Urate Quintiles  P=0.65, 
(747) 
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Kennedy 
201232 
Aβ <  vs. > 192 
pG/mL 
P=0.002, 
(198) 
WMS 
delayed 
logical 
memory, 
RAVLT 
delayed 
MMSE, CDR-SB 
 
Kennedy 
201232 
t-Tau/Aβ > vs. < 
0.39  
P<0.001, 
(198) 
WMS 
delayed 
logical 
memory 
delay, 
RAVLT 
delay 
MMSE, CDR-SB 
 
Kennedy 
201433 
APOEe4 allele 
Carrier vs. Non-
Carrier  
P<0.001, 
(1192) 
CDR-SB, 
MMSE 
  
Kennedy 
201634 
APOEe4 allele 
Carrier vs. Non-
Carrier  
P<0.001, 
(1171) 
   
Landau 
201229 
Aβ rho=0.24, 
P=0.002, 
(162 early) 
   
Landau 
201229 
Aβ rho=0.29, 
P=0.007,  
(85 late) 
   
Landau 
201229 
Brain Glucose 
Metabolism 
rho=-0.25, 
P=0.001, 
(162 early) 
   
Landau 
201229 
Brain Glucose 
Metabolism 
rho=-0.32, 
P=0.003,  
(85 late) 
   
Mackin 
201335 
Subsyndromal 
Symptoms of 
Depression vs. 
None 
P=0.10, 
(405) 
White 
matter 
lesion 
MMSE 
 
McGough 
201336 
Gait Velocity β=-0.19, 
P=0.008, 
(201) 
TMT A&B, 
WMS 
logical 
memory, 
word recall 
 
Age, sex, 
musculoskeletal 
comorbidity, 
depression symptoms 
McGough 
201336 
Physical 
Activity 
β=-0.10, 
P=0.18, 
(201) 
TMT B, 
Word recall 
TMT A, WMS 
logical memory I 
Age, sex, depressive 
symptoms, 
musculoskeletal 
comorbidity  
McGough 
201336 
Grip Strength β=-0.05, 
P=0.40, 
(201) 
TMT A TMT B, Word 
Recall, WMS 
logical memory I 
Age, sex, BMI, 
depressive symptoms, 
musculoskeletal 
comorbidity  
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Petersen 
20104 
Future 
Progression to 
AD at 1 year vs. 
No Progression 
to AD 
P<0.001, 
(398) 
CDR-SB, 
MMSE, 
ADAS-Cog 
without 
word list, 
recall, and 
recognition 
items, 
RAVLT, 
TMT A&B, 
Category 
fluency 
(animal & 
vegetable), 
Number 
cancellation, 
BNT, Digit 
backwards, 
Clock 
drawing  
CDR 
 
Petersen 
20104 
Aβ r=-0.22, 
P<0.05, 
(398) 
   
Portelius 
201537 
CSF 
Neurogranin 
Quartiles 
No statistical 
test, (173) 
 
MMSE 
 
Rozzini 
200638 
Progressive vs. 
Stable MCI  
P=0.05,  
(74) 
   
Rozzini 
200839 
Extrapyramidal 
Signs vs. None 
P=0.03, 
(160) 
ADAS-Cog 
without 
memory 
tasks 
MMSE, CDR, 
ADAS-Cog 
memory tasks, 
Short Story 
(Novelli), Rey's 
figure copy, 
Phonologic verbal 
fluency, Semantic 
verbal fluency 
 
Schneider 
201140 
ChEI vs. ChEI 
and Memantine 
Hydrochloride 
vs. Neither 
P<0.001, 
(392) 
CDR-SB MMSE 
 
Toledo 
201441 
CSF levels 
Complement 3  
β=-0.061, 
P=1.0,  
(187) 
 
MMSE, memory 
& EF summary 
scores 
Age, gender, education, 
APOEe4 allele, t-
Tau/Aβ 
Toledo 
201441 
CSF levels 
Factor H  
β=-0.077, 
P=1.0,  
(187) 
 
MMSE, memory 
& EF summary 
scores 
Age, gender, education, 
APOEe4 allele, t-
Tau/Aβ 
Toledo 
201441 
Complement 
3/Factor H 
β=0.076, 
P=1.0,  
(187) 
 
MMSE, memory 
& EF summary 
scores 
Age, gender, education, 
APOEe4 allele, t-
Tau/Aβ 
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Whitehair 
201042 
APOEe4 allele 
Carriers vs. 
Non-Carriers  
P<0.001, 
(516) 
ADAS-
Cog13, 
NYU 
paragraph 
recall 
immediate 
and delayed 
recall, 
MMSE, 
CDR-SB, 
Clock 
drawing, 
Category 
fluency, 
Number 
cancellation 
target hits, 
SDMT 
Digit backwards 
task, BNT, 
Number 
cancellation target 
errors, Maze 
tracing 
 
Legend: See List of Abbreviations (pages xii to xvi). Effect estimates include regression 
coefficients (β), Spearman rank correlation coefficients (rho), and Pearson correlation 
coefficients (r). If a statistical test was performed without an effect estimate reported, 
only the P-value is shown. Highlighting refers to results of associations tested using the 
ADAS-Cog as an outcome measure: Green=statistically significant result, suggesting 
responsiveness; Orange=non-statistically significant result where no other cognitive or 
neuroimaging outcome measure found a statistically significant association, suggesting 
unknown responsiveness; Red=non-statistically significant result where at least one other 
cognitive or neuroimaging outcome measure detected a statistically significant result, 
suggesting poor responsiveness of the ADAS-Cog. 
 
Table 4 Mixed Normal Cognition and Mild Cognitive Impairment Samples: ADAS-
Cog 11 responsiveness to group-level between-person differences in observed level of 
disease severity based on exposure status. 
First 
Author & 
Publication 
Year 
Exposure 
 
(continuous 
variable unless 
otherwise 
specified) 
Association 
between 
exposure 
and ADAS-
Cog 11  
[Effect 
Estimate, P-
Value, (n)] 
Other 
statistically 
significant 
outcome 
measures 
Other 
statistically  
non-significant 
outcome 
measures 
Factors controlled for 
(None if blank) 
Betterman 
201243 
Lipid Lowering 
Medication vs. 
None 
P=0.81, 
(3069)  
  3MSE 
 
Perneczky 
200644 
Activities of 
Daily Living 
r=-0.46, 
P<0.01 (75) 
      
 Legend: See List of Abbreviations (pages xii to xvi). Effect estimates include a Pearson 
correlation coefficient (r). If a statistical test was performed without an effect estimate 
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reported, only the P-value is shown. Highlighting refers to results of associations tested 
using the ADAS-Cog as an outcome measure: Green=statistically significant result, 
suggesting responsiveness; Orange=non-statistically significant result where no other 
cognitive or neuroimaging outcome measure found a statistically significant association, 
suggesting unknown responsiveness; Red=non-statistically significant result where at 
least one other cognitive or neuroimaging outcome measure detected a statistically 
significant result, suggesting poor responsiveness of the ADAS-Cog. 
Responsiveness to group-level between-person differences of within-person observed 
change in those estimated to be different based on baseline exposure status. Twenty-
two studies were found which tested for an association between baseline exposure status 
and change in ADAS-Cog 11 scores over a follow-up period, as summarized below in 
Table 5 for NC and Table 6 for MCI samples.4,10,11,14,23,25,27-29,32,33,35,38-41,43-48 Among these 
studies there were forty-three statistically significant associations between baseline 
exposure status and ADAS-Cog 11 scores over time (green highlight). There were 
twenty-one non-statistically significant associations between baseline exposure and 
ADAS-Cog 11 scores over time, whereby any other cognitive or brain imaging outcome 
measures also produced non-statistically significant results (orange highlight). The 
ADAS-Cog 11 produced a further three non-statistically significant results for 
associations found to be statistically significant by at least one other cognitive or brain 
imaging outcome measure (red highlight).  
 
Table 5 Normal Cognition Samples: Responsiveness to group-level between-person 
differences of within-person observed change in those estimated to be different 
based on baseline exposure status. 
First 
Author & 
Publication 
Year 
Exposure 
 
(continuous 
variable 
unless 
otherwise 
specified) 
Association 
between 
exposure 
and change 
in ADAS-
Cog 11 
[Effect 
Estimate, P-
Value, (n, 
years of 
follow-up)] 
Other 
statistically 
significant 
outcome 
measures 
Other 
statistically  
non-significant 
outcome 
measures 
Factors controlled for 
(None if blank) 
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Bettermann 
201243 
Lipid 
Lowering 
Medications 
vs. None 
P=0.04, 
(2578, 3) 
3MSE 
 
Age, sex, race, 
education, clinic, 
treatment group, MCI, 
APOEe4 allele, CHD, 
stroke 
Crane 201225 AD CSF 
Signature vs. 
No Signature 
Z=-1.96 
(reversed score), 
P<0.05, 
(112, 3) 
ADAS-Cog 
13, CDR-SB 
ADNI-Mem, 
RAVLT, ADAS-
Rasch, ADAS-
Tree, MMSE 
Age, education, sex, 
APOEe4 allele 
Doraiswamy 
201227  
Aβ Positive 
vs. Negative 
P=0.005, 
(67, 1.5) 
CDR-SB MMSE, DSS, 
Verbal Fluency 
(animals & 
vegetables), 
WMS delayed & 
immediate recall  
Age, psychometric 
assessment 
Doraiswamy 
201227  
Florbetapir 
SUVr 
P=0.095, 
(67, 1.5) 
 
MMSE, CDR-SB, 
DSS, Verbal 
fluency (animals 
& vegetables), 
WMS delayed & 
immediate recall 
Age, psychometric 
assessment  
Doraiswamy 
201428 
Aβ Positive 
vs. Negative 
P=0.001, 
(67, 3) 
CDR-SB, 
DSS, Verbal 
fluency 
(vegetable)  
Verbal fluency 
(animal), WMS 
logical & 
immediate recall, 
MMSE 
Age, cognitive function 
assessment 
Landau 
201229 
Aβ Positive 
vs. Negative 
β=0.43, 
P<0.001,  
(76, 4) 
  
Age, sex, education 
Landau 
201229 
Brain 
Hypometaboli
sm 
P>0.05,  
(76, 4) 
  
Age, sex, education 
Lo 201145 Aβ P>0.05,  
(36, 3) 
  
Age, baseline 
biomarker 
Lo 201145 Brain Glucose 
Metabolism 
P>0.05, 
(104, 3) 
  
Age, baseline 
biomarker value 
Lo 201145 Hippocampal 
Volume  
P>0.05, 
(228, 3) 
  
Age, baseline 
biomarker value 
Petersen 
20104 
Aβ r=-0.23, 
P<0.05, 
(229, 1) 
   
Steenland 
201411 
Age β=0.15 
(log[ADAS-Cog]), 
P=0.003, 
(191, 3.1) 
  
Gender, race, 
education, APOEe4 
allele, time  
Steenland 
201411 
Male β=0.19 
(log[ADAS-Cog]),  
P=0.0009, 
(191, 3.1) 
  
Age, race, education, 
APOEe4 allele, time 
Steenland 
201411 
Race, white  β=0.05 
(log[ADAS-Cog]),  
P=0.65, 
(191, 3.1) 
  
Age, gender, education, 
APOEe4 allele, time 
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Steenland 
201411 
Education β=-0.03 
(log[ADAS-Cog]),  
P=0.002, 
(191, 3.1) 
  
Age, gender, race, 
APOEe4 allele, time 
Steenland 
201411 
APOEe4 
allele 
β=0.14 
(log[ADAS-Cog]),  
P=0.03, 
(191, 3.1) 
  
Age, gender, race, 
education, time 
Steenland 
201411 
Category 
(Animal) 
Fluency 
P=0.05, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
Whole Brain 
Volume 
P=0.02, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
Hippocampal 
Volume 
P=0.02 (left) 
P=0.008 
(right),  
(186, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
t-Tau P=0.04, 
(188, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
p-Tau P=0.006, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
Aβ P=0.0007, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
t-Tau/Aβ P=0.01, 
(188, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
p-Tau/Aβ P=0.003, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
Mini-cog P>0.05, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
MMSE P>0.05, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
ANART P>0.05, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
RAVLT trial 
5 
P>0.05, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
RAVLT short 
recall 
P>0.05, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
TMT A or B P>0.05, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
WMS Logical 
Memory 
(immediate or 
delayed) 
P>0.05, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
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Steenland 
201411 
Boston 
Naming Test 
P>0.05, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Steenland 
201411 
Ventricle 
Volume  
P>0.05, 
(191, 3.1) 
  
Age, gender, race, 
education, APOEe4 
allele, time 
Ye 201646 Serum Uric 
Acid 
(Females) 
β=0.10, 
P=0.02, 
(137, 2.9) 
 
 MMSE   Age, sex, education, 
BMI, race, APOEe4 
allele, cardiovascular 
risk factors, study site 
Ye 201646 Serum Uric 
Acid (Males) 
β=0.01, 
P=0.88, 
(134, 2.9) 
 
MMSE Age, sex, education, 
BMI, race, APOEe4 
allele, CVD risk 
factors, study site 
 Legend: See List of Abbreviations (pages xii to xvi). Effect estimates include regression 
coefficients (β), Z-scores from mixed effects models (Z), and Pearson correlation 
coefficients (r). If a statistical test was performed without an effect estimate reported, 
only the P-value is shown. Highlighting refers to results of associations tested using the 
ADAS-Cog as an outcome measure: Green=statistically significant result, suggesting 
responsiveness; Orange=non-statistically significant result where no other cognitive or 
neuroimaging outcome measure found a statistically significant association, suggesting 
unknown responsiveness; Red=non-statistically significant result where at least one other 
cognitive or neuroimaging outcome measure detected a statistically significant result, 
suggesting poor responsiveness of the ADAS-Cog. 
 
 
Table 6 Mild Cognitive Impairment Samples: Responsiveness to group-level 
between-person differences of within-person observed change in those estimated to 
be different based on baseline exposure status. 
First Author 
& 
Publication 
Year 
Exposure 
 
(continuous 
variable unless 
otherwise 
specified) 
Association 
between 
exposure 
and change 
in ADAS-
Cog 11 
 
[ Effect 
Estimate, P-
Value, (n, 
years of 
follow-up)] 
Other 
statistically 
significant 
outcome 
measures  
Other 
statistically non-
significant 
outcome 
measures  
Factors controlled 
for  
(None if blank) 
Bettermann 
201243 
Lipid 
Lowering 
Medications 
vs. None 
P>0.05,  
(491, 3) 
 
3MSE Age, sex, race, 
education, clinic, 
treatment group, 
MCI, APOEe4 
allele, CHD, stroke 
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Cardinali 
201247 
Melatonin vs. 
None 
ZMW=-5.73, 
P<0.001,  
(96, 5) 
MMSE, 
Mattis' 
score, DSS, 
TMT A&B, 
RAVLT 
  
Crane 201225 AD CSF 
Signature vs. 
No Signature 
Z=-4.39, 
P<0.05,  
(193, 3) 
ADNI-Mem, 
RAVLT, 
ADAS-
Cog13, 
ADAS-
Rasch, 
ADAS-Tree, 
MMSE, 
CDR-SB 
 
Age, education, 
sex, APOEe4 allele 
Cronk 201030 BMI Wald 
X2=6.7, 
P=0.02.  
(286, 1) 
MMSE, 
Global 
composite 
CDR-SB Age, education, sex  
Doraiswamy 
201227 
Aβ positive 
vs. negative 
P=0.001,  
(46, 1.5) 
MMSE, 
CDR-SB, 
DSS, Verbal 
fluency 
(vegetables), 
WMS 
delayed & 
immediate 
recall 
Verbal fluency 
(animals) 
Age, baseline 
psychometric score  
Doraiswamy 
201227 
Florbetapir 
SUVr  
r=0.41, 
P=0.006,  
(46, 1.5) 
MMSE, 
CDR-SB, 
DSS, WMS 
immediate 
recall  
Verbal fluency 
(animal & 
vegetable), WMS 
delayed recall 
Age, baseline 
psychometric score 
Doraiswamy 
201428 
Aβ positive 
vs. negative 
P=0.001,  
(46, 3) 
CDR-SB, 
DSS, verbal 
fluency 
(vegetable), 
MMSE 
Verbal fluency 
(animal), WMS 
logical & 
immediate 
memory 
Age, baseline 
cognitive function 
scores  
Evans 201010 Brain Atrophy 
Rates  
P<0.0001, 
(231, 1) 
MMSE, 
TMT B 
TMT A Baseline brain 
volume, 
neuropsychological 
score, age, gender 
Evans 201010 Ventricular 
Expansion  
P<0.0005, 
(231, 1) 
MMSE, 
TMT B 
TMT A Baseline brain 
volume, 
neuropsychological 
score, age, gender 
Furio 200748 Melatonin vs. 
None 
ZMW=-5.55, 
P=0.001,  
(50, 1.5) 
MMSE, 
Mattis' 
score, TMT 
A&B, 
RAVLT 
DSS  
Herholz 
201123 
Progressive 
vs. Non-
Progressive 
MCI 
Cohen 
D=0.30, 
P>0.05,  
(94, 1) 
PET 
measure 
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Herholz 
201123 
Progressive 
vs. Non-
Progressive 
MCI 
Cohen 
D=0.60, 
P=0.006  
(94, 2) 
PET 
measure 
  
Irizarry 
200929 
Plasma Urate P>0.05,  
(747, 3) 
  
Age, sex, BMI, 
APOEe4 allele, 
current smoking, 
history of alcohol 
abuse, CVD, 
hypertension, use 
of nonsteroidal 
anti-inflammatory 
drugs and thiazide 
diuretics 
Kennedy 
201634 
APOEe4 allele 
Present vs. 
Absent  
P<0.001, 
(1171, 3) 
   
Landau 
201229 
Aβ Positive 
vs. Negative 
β=0.83, 
P=0.004,  
(81, 4) 
  
Age, sex, education 
Landau 
201229 
Brain Glucose 
Hypometaboli
sm Positive 
vs. Negative 
β=1.48, 
P<0.001,  
(81, 4) 
  
Age, sex, education 
Lo 201145 Aβ  P<0.05,  
(54, 3) 
  
Age, baseline 
biomarker value 
Lo 201145 Brain Glucose 
Metabolism  
P<0.001,  
(203, 3) 
  
Age, baseline 
biomarker value 
Lo 201145 Hippocampal 
Volume  
P<0.001,  
(390, 3) 
  
Age, baseline 
biomarker value 
Mackin 
201335 
Subsyndromal 
Symptoms of 
Depression vs. 
None 
βGEE=0.51, 
P=0.28,  
(405, 2) 
  
APOEe4 allele 
Petersen 
20104 
Aβ r=-0.29, 
P<0.05,  
(398, 1) 
   
Portelius 
201537 
CSF 
Neurogranin 
Quartiles 
β=0.002, 
P=0.0002, 
(173, 9) 
MMSE, 
hippocampal 
volume, 
cortical 
glucose 
metabolism 
 
Age, sex, education 
Schneider 
201140 
ChEIs vs. 
None 
β=0.78, 
P=0.03,  
(392, 2) 
MMSE, 
CDR-SB 
 
Age, APOEe4 
allele, education, 
baseline ADAS-
Cog or CDR-SB 
Schneider 
201140 
ChEI and 
Memantine 
Hydrochloride 
vs. None 
β=0.86, 
P=0.14,  
(251, 2) 
MMSE, 
CDR-SB 
 
Age, APOEe4 
allele, education, 
baseline ADAS-
Cog or CDR-SB 
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Schneider 
201140 
ChEIs and 
Memantine 
Hydrochloride 
vs. ChEIs only  
P>0.05,  
(177, 1.5) 
MMSE, 
CDR-SB 
  
Toledo 
201441 
CSF levels 
Complement 3 
β=-0.12, 
P=0.04, 
(160, 1.5) 
 
MMSE, Memory 
assessment, EF 
assessment 
Age, gender, 
APOEe4 allele, 
education, t-
Tau/Aβ 
Toledo 
201441 
CSF levels 
Factor H 
β=-0.08, 
P=0.04,  
(160, 1.5) 
 
MMSE, Memory 
assessment, EF 
assessment  
Age, gender, 
APOEe4 allele, 
education, t-
Tau/Aβ 
Toledo 
201441 
Complement 
3/Factor H 
β=-0.18, 
P=0.06,  
(160, 1.5) 
 
MMSE, memory 
assessment, EF 
assessment 
Age, gender, 
APOEe4 allele, 
education, t-
Tau/Aβ 
Whitehair 
201042 
APOEe4 
Allele Present 
vs. Absent 
P<0.001, 
(516, 3) 
ADAS-
Cog13, 
Delayed 
work list 
recall, 
MMSE, 
Digit 
backwards, 
BNT, Clock 
drawing, 
Category 
fluency, 
New York 
University 
immediate & 
delayed 
paragraph 
recall, 
Number 
cancellation 
target hits, 
SDMT, 
CDR-SB 
Number 
cancellation task 
target errors, maze 
tracing 
Age, sex, 
education, baseline 
CDR-SB 
Ye 201646 Serum Uric 
Acid  
β=-0.5, 
P<0.001, 
(244, 2.9) 
MMSE 
 
Age, sex, 
education, BMI, 
race, APOEe4 
allele, CVD risk 
factors, study site 
Ye 201646 Serum Uric 
Acid  
β=-0.001, 
P=0.99,  
(352, 2.9) 
 
MMSE Age, sex, 
education, BMI, 
race, APOEe4 
allele, CVD risk 
factors, study site 
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Zanotta 
201414 
Phytotherapeu
tic Compound 
plus 
PhosphatidylS
erine and 
Vitamin E vs. 
Placebo  
P<0.001, 
(102, 0.16) 
Clock 
drawing test, 
MMSE 
  
Legend: See List of Abbreviations (pages xii to xvi). Effect estimates include regression 
coefficients (β), parameters from generalized estimating equations (βGEE), Pearson 
correlation coefficients (r), and Z-scores from mixed effects models (Z) or Mann-Whitney 
U tests (ZMW). If a statistical test was performed without an effect estimate reported, only 
the P-value is shown. Highlighting refers to results of associations tested using the 
ADAS-Cog as an outcome measure: Green=statistically significant result, suggesting 
responsiveness; Orange=non-statistically significant result where no other cognitive or 
neuroimaging outcome measure found a statistically significant association, suggesting 
unknown responsiveness; Red=non-statistically significant result where at least one other 
cognitive or neuroimaging outcome measure detected a statistically significant result, 
suggesting poor responsiveness of the ADAS-Cog. 
 
Responsiveness to treatment effects.  Seventeen clinical trials using the ADAS-Cog 11 
as an outcome measure in pre-dementia samples were found, and are summarized in 
Table 7, below.49-65 The ADAS-Cog 11 was able to detect seven statistically significant 
treatment effects (green highlight). The ADAS-Cog 11 did not find a significant effect for 
eleven interventions (orange or red highlight), four of which demonstrated a treatment 
effect for at least one other outcome measure (red highlight). Note that only results from 
the final time point of each study are presented, and subgroup analyses are only presented 
when the primary analyses did not include the ADAS-Cog 11 in a sample composed 
completely of older adults with pre-dementia levels of disease severity. 
 
Table 7 ADAS-Cog 11 Responsiveness to Treatment Effects in Pre-Dementia 
Clinical Trials 
First 
Author & 
Publication 
Year 
Treatment vs. Placebo  
 
(unless otherwise 
specified)  
Treatment 
effect  
[P-Value, 
(n, years of 
follow-up)] 
Other outcome 
measures  
(* if sig effect) 
ADAS-Cog 
as primary 
outcome? 
Factors 
controlled 
for 
(None if 
blank) 
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De 
Beaumont 
201649 
Donepezil  Stratified by 
genotype 
BCHE-K*: 
P<0.01; 
BCHE-K 
wild type: 
P>0.05;  
APOEe4+: 
P>0.05; 
APOEe4-: 
P>0.05,  
(408, 3) 
 
Yes Age, sex, 
baseline 
ADAS-Cog  
Buschert 
201150 
Multicomponent 
Cognitive Group 
Intervention 
P=0.02,  
(22, 0.5) 
MMSE, RBANS 
(story memory, 
recall*), TMT A&B, 
MADRS*, QoL-AD 
Yes Age, 
education 
Buschert 
201251 
Multicomponent 
Cognitive Group 
Intervention 
P=0.04,  
(24, 2.3) 
RBANS (immediate*, 
delayed), TMT A&B, 
MMSE, MADRS, 
QoL-AD 
Yes 
 
Chiu 200852 Omega-3 
Polyunsaturated Fatty 
Acids 
P=0.03,  
(23, 0.5) 
CIBIC-Plus Yes Age, gender, 
education 
Dubois 
201253 
Pro-Cholinergic Drug P=0.37, 
(241, 0.46) 
CDR-SB, CVLT(free 
immediate recall 
Monday list & 
Tuesday list*, short 
delay free and cued 
recall, long delay free 
and cued recall), 
Fluency test, TMT 
A&B, DSST, Global 
improvement 
evaluated by 
investigator & 
patient, ADL, AI 
Yes Country 
Forster 
201154 
Cognitive Intervention P=0.045, 
(21, 0.5) 
MMSE* Yes Education, 
age 
Kile 201555 Immunoglobulin P=0.03,  
(49, 2) 
Annualized percent 
change in ventricular 
volume, MMSE*, 
CDR-SB 
No 
 
Lin 201456 Sodium Benzoate P=0.23,  
(31, 0.46) 
CIBIC-Plus, 
Cognitive composite 
Yes 
 
Luchsinger 
201657 
Metaformin P=0.34,  
(80, 1) 
SRT*, Glucose 
uptake in posterior 
cingulate-precuneus, 
Aβ 
Yes 
 
Miao 201258 Chinese Herbal 
Medicine vs. Donepezil  
P=0.11,  
(72, 1) 
MMSE, ADL, 
Syndrome 
Differentiation Scale 
Yes 
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Petersen 
200559 
Donepezil and Vitamin E P>0.05, 
(769, 3) 
MMSE, CDR, CDR-
SB, ADL, Global 
deterioration scale, 
Neuropsychological 
battery, Time to 
development of AD 
No 
 
De Gobbi 
Porto 201560 
Aerobic Training P<0.001, 
(40, 0.46) 
Neuropsychological 
battery* 
Yes 
 
Reuter 
201261 
Cognitive 
Training+Transfer 
Training+Psychomotor 
Training vs. CT+TT vs. 
CT 
P<0.001, 
(223, 0.58) 
SCOPA-Cog*, BADS 
(zoo*, instruction*, 6 
elements*), Paced 
auditory serial 
addition test* 
Yes Age, sex, 
education 
Singh 201462 Computerized 
Multidomain Cognitive 
Training 
P=0.69,  
(51, 1.5) 
Standardized global 
cognition score, 
WAIS-III similarities 
& matrices, Category 
fluency, COWAT, 
Memory function, 
BVRT, Immediate & 
Delayed & Domain 
memory scores, 
SDMT, ADL 
Yes 
 
Singh 201462 High Intensity 
Progressive Resistance 
Training 
P=0.08, 
(49, 1.5) 
Standardized global 
cognition score, 
WAIS-III Similarities 
& matrices*, 
Category fluency, 
COWAT, Memory 
function, BVRT, 
Immediate & Delayed 
& Domain Memory 
scores, SDMT, ADL 
Yes 
 
Snitz 200963 G Biloba Extract P=0.97, 
(3069, 7.3) 
3MSE, Tests of 
memory, attention, 
visual-spatial 
construction, 
language, and EF 
Yes 
 
Suzuki 
201364 
Multicomponent 
Exercise with Multitask 
Conditions vs. 
Educational Classes 
P=0.16, 
(100, 0.5) 
MMSE, WMS-logical 
memory I & II, 
Volume of medial 
temporal areas 
including the 
entorhinal cortex, 
Whole brain cortices 
No 
 
Thal 200565 Rofecoxib P>0.05, 
(1457, 4) 
% patients convert to 
AD*, CDR-SB, SRT, 
MMSE 
No 
 
Legend: See List of Abbreviations (pages xii to xvi). P-values refer to statistical tests 
performed to assess whether a treatment effect was present. Highlighting refers to results 
of associations tested using the ADAS-Cog as an outcome measure: Green=statistically 
significant result, suggesting responsiveness; Orange=non-statistically significant result 
where no other outcome measure found a statistically significant association, suggesting 
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unknown responsiveness; Red=non-statistically significant result where at least one other 
outcome measure detected a statistically significant result, suggesting poor 
responsiveness of the ADAS-Cog. 
 
Sample size estimates from simulation studies. Four studies estimated the sample size 
needed to detect a treatment effect using the ADAS-Cog 11 in a clinical trial of pre-
dementia syndromes, and as summarized in Table 8 below, the ADAS-Cog 11 was never 
the outcome measure requiring the smallest sample size.66-69 A separate study found that 
increasing the proportion of APOEe4 allele carriers in clinical trial simulations, a method 
employed to try and increase the level of impairment of a sample, did not lead to 
meaningful increases in power to detect a treatment effect with the ADAS-Cog 11.31 
Furthermore, the ADAS-Cog 11 failed to produce statistically significant treatment 
effects in several situations where one was hypothesized to be present based on other 
indicators of disease progression.32  
 
Table 8 Sample Size Estimates to Detect Treatment Effects in Pre-Dementia Clinical 
Trials 
First 
Author & 
Publication 
Year 
Study Details  ADAS-Cog 11 rank versus other outcome 
measures  
Caroli 
201566 
Estimate n per treatment arm 
needed to detect 20% reduction in 
disease progression over 24 
months, with beta=0.20, and 
alpha=0.05.  
  
 MCI with Aβ 6th (n=568) of 6; best=brain atrophy rate (n=46) 
MCI with Hippocampal Atrophy 6th (n >1000) of 6; best=brain atrophy rate 
(n=77) 
Grill 201367 Estimate n per treatment arm 
required to detect 25% treatment 
effect in cognitive measures over 
24 and 36 months with beta=0.20 
and alpha=0.05. Assessed 
different sample enrichment 
strategies.  
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 NC with APOEe4 allele, 36 
months 
6th (No decline) of 6; best=RAVLT (n=499) 
MCI with APOEe4 allele, 24 
months 
5th (n=908) of 6; best=CDR-SB (n=329) 
NC with Aβ, 36 months 6th (n=420495) of 6; best=RAVLT (n=1090) 
MCI with Aβ, 36 months 3rd (n=639) of 6; best=CDR-SB (n=292) 
NC with Total CSF Tau, 36 
months 
6th (no decline) of 6; best=RAVLT (n=817) 
MCI with Total CSF Tau, 24 
months 
4th (n=537) of 6; best=CDR-SB (n=292)  
NC with CSF Tau phosphorylated 
at threonine 181, 36 months 
6th (n=2200678) of 6; best=RAVLT total score 
(n=559) 
NC with CSF Tau phosphorylated 
at threonine 181, 24 months 
3rd (n=714) of 6; best=CDR-SB (n=296) 
NC with CSF Total Tau/Aβ, 36 
months  
6th (no decline) of 6; best=RAVLT (n=559) 
MCI with CSF Total Tau/Aβ, 24 
months 
4th (n=676) of 6; best=CDR-SB (n=258) 
NC with CSF pTau/Aβ, 36 
months 
6th (n=214455) of 6; best=RAVLT (n=552) 
MCI with CSF pTau/Aβ, 24 
months  
3rd (n=696) of 6; best=CDR-SB (n=313) 
NC with Brain Glucose 
Hypometabolism, 36 months 
6th (n=13136) of 6; best=CDR-SB (n=1039) 
MCI with Brain Glucose 
Hypometabolism, 24 months 
3rd (n=357) of 6; best=MMSE (n=314) 
NC with Hippocampal Volume, 
36 months 
6th (n=21359) of 6; best=CDR-SB (n=1057) 
MCI with Hippocampal Volume, 
24 months 
5th (n=754) of six; best=CDR-SB (n=300) 
NC with Lateral Ventricle 
Volume, 36 months  
Tied for 6th (no decline) of 6; best=RAVLT 
delayed recall (n=1039) 
MCI with Lateral Ventricle 
Volume, 24 months  
3rd (n=666) of 6; best=CDR-SB (n=381) 
Ho 201068 Estimate n per treatment arm to 
measure 25% reduction in rate of 
change over 12 months, 
beta=0.20 and alpha=0.05. 
  
 
MCI 4th (n=1183) of 5; best=Rate of Annual Brain 
Volume Loss (n=108) 
   60 
 
Hua 200969  Estimate n required to detect 25% 
reduction in rate of decline over 
12 months with beta=0.20 or 0.10 
and alpha=0.05. 
  
 
MCI, 80% power 6th (n=6797) of 6; best=Atrophy using 
symmetric Kullback-Leibler S9L5 distance 
(n=85)   
MCI, 90% power 6th (n=9092) of 6; best=Atrophy using 
symmetric Kullback-Leibler S9L5 distance 
(n=114)  
Legend: See List of Abbreviations (pages xii to xvi). 
 
3.2.8 Summary of ADAS-Cog 11 Performance in Pre-Dementia 
Studies  
ADAS-Cog 11 scores in pre-dementia populations are driven primarily by the Word 
Recall and Word Recognition tasks, and age may influence scores for older adults with 
NC. Despite this, ADAS-Cog 11 scores do generally appear able to detect differences in 
cognitive ability in groups separated by an exposure that is expected to be associated with 
cognitive ability, although the magnitude of the differences detected tends to be small and 
are possibly attenuated by the nine tasks that demonstrated ceiling effects in pre-dementia 
populations. Responsiveness of the ADAS-Cog 11 to treatment effects appears low 
compared to other global outcome measures, and compared to outcome measures 
designed to assess subdomains of cognition or other aspects of dementia and pre-
dementia syndromes. Nonetheless, caution must be maintained when interpreting these 
findings because an in-depth exploration of whether there truly should be an association 
between cognition or disease severity and any given exposure or treatment, and the 
potential magnitude and direction of these associations, was not explored. Overall, the 
ADAS-Cog 11 seems able to provide a measure of disease severity in pre-dementia 
syndromes, but there is room for improvement.  
3.3 Modifications of the ADAS-Cog 11 
This section reviews all modifications that have been made to the ADAS-Cog 11, as well 
as other outcome measures which have been combined with some or all of the individual 
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ADAS-Cog 11 tasks for the purpose of measuring disease severity in studies of dementia 
or pre-dementia syndromes. The organizational structure of this section is to introduce an 
outcome measure, review available information about responsiveness to baseline 
discrimination, disease progression, and treatment effects, and then summarize the 
performance of that outcome measure in comparison with the ADAS-Cog 11 (See Section 
2.2.7 for responsiveness definitions). A visual representation of the modification history 
of the ADAS-Cog 11 is presented below in Figure 6, and a summary of each measure 
including coefficient of variation (CV) calculations can be found in Appendix A.  
 
 
Figure 6 Timeline of ADAS-Cog 11 modifications. 
3.3.1 ADAS-Cog 13  
Mohs et al. (1997) identified several cognitive domains hypothesized to be important to 
detect treatment effects in clinical trials of antidementia drugs that are not assessed by the 
ADAS-Cog 11.70 Accordingly, tests of attention and concentration, planning and 
executive function, verbal memory, nonverbal memory, and praxis were considered for 
addition to the ADAS-Cog 11.70 Recommendations about which specific tests to add to 
the ADAS-Cog 11 were based on assessments of reliability, influence of age and 
education on change scores, learning effects (one month interval), ability to assess full 
range of dementia severity, floor and ceiling effects, and ability to measure 12 month 
longitudinal change in 64 subjects with NC, 50 subjects with mild AD, 47 subjects with 
moderate AD, and 46 subjects with moderately severe AD.70 In summary, the authors 
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recommended adding items such as a four-trial learning plus delayed word recall task, 
one or two simple mazes, or number cancellation tasks for clinical trials involving 
subjects with mild AD or pre-dementia.70 A commonly used adaptation of these 
suggestions is the ADAS-Cog 13 which includes all ADAS-Cog 11 items as well as a test 
of delayed word recall and a number cancellation or maze task. Errors on the additional 
task are summed together with scores from the original 11 tasks to give a final ADAS-
Cog 13 score from 0 to 85.  
Baseline discrimination. Skinner et al. (2012) found the mean score on the ADAS-Cog 
13 was lower for 229 subjects with NC (mean=9.5, SD=4.1) than 394 subjects with MCI 
(mean=18.6, SD=6.2) and 187 subjects with AD (mean=28.9, SD=7.6).3 In a separate 
analysis, Podhorna et al. (2016) found the mean ADAS-Cog 13 score for 382 subjects 
with MCI (mean=15.23, SD=6.68) was lower than that of 97 subjects with mild AD 
(mean=29.91, SD=7.44).12 Podhorna et al. (2016) further divided the 382 subjects with 
MCI into two groups depending on whether a CSF or APOEe4 allele biomarker of AD 
pathology was present.12 The 206 subjects with MCI and an indication of AD pathology 
(enriched subgroup) had worse scores at baseline (mean=17.52, SD=6.81) on the ADAS-
Cog 13 than the 176 subjects with MCI but no such AD biomarkers present (mean=12.55, 
SD=5.43).12 Statistical significance of the above differences was not tested.  
Disease progression. Hobart et al. (2009) used Rasch Analysis to compare the ADAS-
Cog 11 and ADAS-Cog 13 on scale performance and person measurements in 371 
subjects with MCI and 217 subjects with AD.71 Although they found that the ADAS-Cog 
13 evaluates more cognitive domains than the ADAS-Cog 11, it was not better at 
measuring clinically significant changes in subjects with MCI.71 Podhorna et al. (2016) 
had similar results. They found little change on the ADAS-Cog 13 for 382 subjects with 
MCI over 24 months (mean change=1.34 points) or for 168 subjects with MCI over 36 
months (mean change=2.59 points).12 There was slightly more change detected in the 
enriched MCI subgroup (mean 24 month change=2.63 points; mean 36 month 
change=5.02 points), and no meaningful change on the ADAS-Cog 13 in the non-
enriched MCI subgroup (mean 24 month change=-0.18 points, mean 36 month change=-
0.15 points).12 Among 97 subjects with mild AD there was a modest change in mean 
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ADAS-Cog 13 score over 12 months (mean change=4.35 points) and among 38 subjects 
with AD over 24 months (mean change=9.46 points).12 The SRM for change over 24 
months in 382 subjects with MCI, adjusting for baseline age, baseline MMSE score, sex, 
and APOEe4 allele, was 0.39 (95% CI 0.16, 0.60) for the ADAS-Cog 13 compared to 
0.37 (95% CI 0.15, 0.57) for the ADAS-Cog 11.12 The SRM for change over 12 months 
in 97 subjects with AD was 0.98 (95% CI 0.58, 1.26) for the ADAS-Cog 13 and 0.87 
(95% CI 0.46, 1.13) for the ADAS-Cog 11.12 Skinner et al. (2012) found the Z-statistic 
for change over time in 394 subjects with MCI was slightly larger for the ADAS-Cog 13 
(Z=10.70) than for the ADAS-Cog 11 (Z=9.44), adjusting for age, education, gender, and 
APOEe4 allele.3 Raghavan et al. (2013) also found the ADAS-Cog 13 had larger 
standardized two-year change than the ADAS-Cog 11 in an MCI sample.19 
Treatment effect. Skinner et al. (2012) found that the estimated sample size per group to 
detect a 25% decrease over 12 months in subjects with MCI with 80% power and an 
alpha of 0.05 was smaller for the ADAS-Cog 13 (n=900) than for the ADAS-Cog 11 
(n=1230).3 Raghavan et al. (2013) found the estimated sample size to detect a 
hypothetical 25% treatment effect over 2 years in subjects with MCI with 80% power was 
also smaller for the ADAS-Cog 13 (n=582) than for the ADAS-Cog 11 (n=772).19  
Summary. The ADAS-Cog 13 appeared able to discriminate between groups of subjects 
with MCI and mild AD at one point in time. For subjects with AD, the responsiveness of 
the ADAS-Cog 13 to disease progression was better than that of the ADAS-Cog 11. For 
subjects with pre-dementia syndromes, the ADAS-Cog 13 demonstrated similar or only 
slightly better responsiveness to disease progression than the ADAS-Cog 11. 
Responsiveness to treatment effects in MCI was better for the ADAS-Cog 13 than the 
ADAS-Cog 11.  
3.3.2 Vascular Dementia Assessment Scale  
To address the need for a primary outcome measure for clinical trials in Vascular 
Dementia (VaD), Ferris et al. (1999) suggested using the ADAS-Cog 11 as a starting 
point because many of the cognitive domains affected by VaD are also affected in AD.72 
Cognitive domains important for VaD include memory, attention, processing speed, 
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visuospatial function, language, executive function, and abstraction.72 The original 
VaDAS included items suggested by Mohs et al. (1997) for the ADAS-Cog 13.70,72 An 
updated version had additional items to further target frontal lobe functions.73 This 
updated VaDAS includes all tasks from the ADAS-Cog 11 as well as a delayed recall 
portion added to the Word Recall task (memory), two number cancellation tasks 
(attention), a maze (executive function), symbol digit modalities 
(attention/concentration), backwards digit span (working memory), and animal category 
retrieval (verbal fluency) tasks.73 At the time of development, evaluation of the VaDAS 
was left to be done in future clinical trials.73  
Disease Progression. The VaDAS showed improvement over 18 weeks for both placebo 
and donepezil groups in an 18 week randomized clinical trial of donepezil versus placebo 
for 168 subjects with cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy (least squares mean change from baseline: placebo=-0.81, 
donepezil group=-0.85).74 
Treatment effect. No statistically significant treatment effect was found using the 
VaDAS, which was congruent with a version of the ADAS-Cog 13 (ADAS-Cog 11, 
number cancellation, maze), ADAS-Cog 11, and MMSE.74  
Summary. Theoretically the VaDAS should be better than the ADAS-Cog 11 at 
detecting VaD dysfunction and assessing change in this dysfunction over time; however, 
further studies are needed to definitively evaluate whether this is true. Analyses of 
baseline discrimination have also not been performed.  
3.3.3 ADAS-Cog 12  
A common modification to the ADAS-Cog 11 is to add a Delayed Word Recall task 
which provides a subject three trials to recall as many of the ten words from the Word 
Recall task after a period of time (delay).17 The task is scored from 0 to 10 based on the 
number of words not recalled (errors), and added to the ADAS-Cog 11 score to give a 
total score of 0 to 80. 
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Lowe et al. (2015) used IRT methods with 788 subjects ranging from pre-dementia 
syndromes (Subjective Cognitive Impairment (SCI), MCI) to severe stages of AD to 
determine where along the continuum of disease progression the Delayed Word Recall 
task provides the most information about cognitive ability, and if it alters the 
measurement precision of the ADAS-Cog 11.75 ICCs from the IRT analysis showed that 
in general memory tasks of the ADAS-Cog 12 are the most sensitive to the earlier stages 
of disease progression, and the Delayed Word Recall task provides the most information 
in the mildest range of cognitive impairment.75 Area under the curve (AUC) analyses 
found statistically significant differences in the overall average distance between the ICC 
for the Delayed Word Recall task and for the Word Recall task.75 The Delayed Word 
Recall task does not however have much sensitivity for more severe cognitive 
dysfunction such as that seen with AD.75 Floor effects (10 errors) on the Delayed Word 
Recall task were seen for 9% of the MCI group and 52% of the AD group at baseline.75 
Baseline discrimination. Grundman et al. (2004) found statistically significant different 
mean scores in the ADAS-Cog 12 between groups of subjects with aMCI (n=769), NC 
(n=107), very mild AD (n=122), and mild AD (n=183). Furthermore, subjects with MCI 
performed an average 2.1 SD higher than subjects with NC on the Delayed Word Recall 
task compared to an average of 1.8 SD higher on the original immediate Word Recall 
task.17 Sano et al. (2011) showed that 111 subjects with AD had significantly higher mean 
scores (two samples t-test, t = 15.3, P<0.001) on the ADAS-Cog 12 (mean=33.27 points, 
SD=10.3) than 259 subjects with MCI (mean=17.22 points, SD=5.9).7 Test information 
curves for the ADAS-Cog 11 and ADAS-Cog 12 show that both scales are maximally 
precise around mild to moderate AD, but the ADAS-Cog 12 is more precise, or holds 
more information about underlying cognitive impairment, in earlier stages of disease 
progression than the ADAS-Cog 11.75 The ADAS-Cog 12 maintains similar precision to 
the ADAS-Cog 11 for more severe stages of cognitive impairment, namely AD.75 Labos 
et al. (2011) compared performance on the MMSE, ADAS-Cog 11, traditional memory 
ADAS-Cog 11 tasks (immediate Word Recall and Word Recognition), and an additional 
Delayed Word Recall task in 230 subjects divided into NC, SCI, amnestic MCI (aMCI), 
multidomain MCI, and dementia categories.76 The scores from all four tests or subtasks 
were able to distinguish the group of subjects with dementia from subjects with NC, SCI, 
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aMCI, and multidomain MCI.76 The MMSE did not significantly discriminate between 
any other groups. Scores on the ADAS-Cog 11 as well as the isolated memory tasks were 
similar for groups with NC and SCI, but NC group scores were significantly better than 
the two MCI subtype groups, which were not distinguishable.76 The Delayed Word Recall 
task score was comparable for groups with NC and SCI, but the group with NC scored 
significantly worse than both MCI subtype groups.76 Furthermore, the aMCI scores were 
significantly worse than those for multidomain MCI.76  
Disease progression. Sano et al. (2011) found that 12 month unadjusted change scores 
were significantly different between MCI and AD groups for the ADAS-Cog 11 (t=4.26, 
P<0.001) and ADAS-Cog 12 (t=3.89, P<0.001), but the Delayed Word Recall task on its 
own was not (t=-0.45, P=0.654).7 Among the MCI group, the 12 month SRM was lower 
for the ADAS-Cog 11 (0.142) than for the ADAS-Cog 12 (0.160).7 The ratio of the SRM 
for the ADAS-Cog 12 divided by the SRM for the ADAS-Cog 11 was used to show that 
including Delayed Word Recall with the ADAS-Cog 11 increased the SRM by 12% 
(more responsive).7 For the AD group, the 12 month SRM was similar between the 
ADAS-Cog 11 (0.589) and ADAS-Cog 12 (0.569).7  
Treatment effect. The estimated sample size required to detect a 33% treatment effect in 
MCI with 80% power was over 600 subjects lower for the ADAS-Cog 12 than the 
ADAS-Cog 11.7 In contrast, the ADAS-Cog 12 did not outperform the ADAS-Cog 11 for 
estimations of sample size needed for a trial of AD.7 
Summary. The ADAS-Cog 12 has demonstrated the ability to discriminate between 
groups of subjects with MCI and AD, as well as between MCI subtypes. The ADAS-Cog 
12 demonstrated more responsiveness to disease progression and treatment effects in MCI 
than the ADAS-Cog 11. Further along the disease continuum responsiveness to disease 
progression and treatment effects of the ADAS-Cog 11 and 12 were comparable.  
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3.3.4 Test for the Early Detection of Dementia from Depression – 
Cognitive  
The Test for the Early Detection of Dementia from Depression (TE4D) was initially 
developed in the German language to differentiate early dementia from depression.6 
Mahoney et al. (2005) modified the TE4D with the intention of using it as a screening 
tool to detect MCI in English-speaking populations with AD (TE4D-Cog).6 The TE4D-
Cog is scored from 0 to 45, and has eight items among seven subscales which assess 
immediate recall, semantic memory, clock drawing, category fluency, orientation, and 
following commands (from ADAS-Cog 11).6 The TE4D-Cog was tested in a sample of 
178 subjects with AD and 25 subjects with NC, where it was found to have good 
concurrent criterion validity with the ADAS-Cog 11 (r=-0.90, P<0.001) and MMSE 
(r=0.92, P<0.001), high inter-rater reliability, and good internal consistency.6 
Baseline discrimination. Twenty-five subjects with NC scored significantly better on the 
TE4D-Cog than 178 subjects with AD both in terms of overall score (Mann-Whitney U 
test (U)=24.0, P<0.001), and each of the seven subscales (P<0.001).6 The ability of the 
TE4D-Cog to serve as a screening tool for dementia was compared with the MMSE by 
assessing sensitivity and specificity at different cut-points and calculating the area under 
the receiver operating characteristic (ROC) curve.6 The cut-point giving maximum 
(100%) sensitivity for the TE4D-Cog (score > 35) corresponded to a specificity of 84.0%. 
Using a cut-point for maximum sensitivity of the MMSE (score > 29) corresponded to a 
specificity of 32.0%.6 When set at maximum specificity (100%), the sensitivity of the 
TE4D-Cog drops to 79.5% and the MMSE to 65.9%. The AUC for the TE4D-Cog was 
0.98, and 0.96 for the MMSE.6  
Disease progression. In a subsample of 148 subjects with AD, baseline (mean=16.2, 
SD=11.1) and six month follow-up scores (mean=14.2, SD=10.8) on the TE4D-Cog were 
correlated (r=0.90, P<0.001) and there was a statistically significant worsening in scores 
over time (Wilcoxon signed rank test; Z=-4.9, P<0.001).6  
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Summary. The TE4D-Cog demonstrated the ability to discriminate between NC and AD 
groups, and demonstrated responsiveness to disease progression in AD. Responsiveness 
to treatment effects and comparison with the ADAS-Cog 11 was not tested.  
3.3.5 Pooled Index  
Carusone et al. (2006) were the first to add measures of functionality rather than just 
measures of cognition to the ADAS-Cog 11. They used data from a clinical trial 
involving 101 subjects with mild to moderate AD, and combined the following six scales 
using a pooled index approach: ADAS-Cog 11, Geriatric Depression Scale, Dysfunctional 
Behaviour Rating Instrument (DBRI), MMSE, Activities of Daily Living (ADL), and 
DBRI frequency.77 
Treatment effect. Effect sizes were calculated for each individual subscale measure as 
well as the Pooled Index for 3, 6, and 12 months of follow-up (Effect size=linear 
regression coefficient/SE of linear regression coefficient). None of the individual subscale 
measures demonstrated a statistically significant treatment effect at more than one time 
point.77 The Pooled Index found a statistically significant treatment effect at the 3 month 
and 12 month, but not 6 month, follow-up assessments.77 
AUC analyses of individual scores plotted against time were performed for both the 
standardized ADAS-Cog 11 and the Pooled Index. The standardized ADAS-Cog 11 
showed a statistically significant difference between treatment and placebo groups at the 
finite time period of 6 months, but not when assessing the 12 month time period as a 
whole.77 The Pooled Index showed statistically significant difference between placebo 
and treatment groups over the entire 12 month period, and at the individual time points of 
3 and 12 months, but not at 6 months.77  
Summary. The Pooled Index was more responsive to treatment effects than the ADAS-
Cog 11 in a clinical trial for mild to moderate AD. Responsiveness to baseline 
discrimination and to disease progression was not explored.  
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3.3.6 ADAS-Rasch  
Wouters et al. (2008) identified three problematic aspects of the ADAS-Cog 11 scoring 
methodology, whereby the total score is arrived at by summing points across tasks 
without recognition of how these individual tasks or subtask item response options may 
differ.78 Specifically, they found ADAS-Cog 11 tasks do not have equal measurement 
precision, several subtask item response categories are disordered in terms of difficulty, 
and a difference of a certain number of points at the low end of the scoring range does not 
equal the same amount of difference in cognitive ability as a difference of the same 
number of points at the higher end of the scoring range.78 This last limitation suggests that 
summed ADAS-Cog scores should not be treated as an interval-ratio level measure and 
analyzed using parametric statistics such as t-tests and linear regression models.   
To address the first two limitations Wouters et al. (2008) developed an alternate scoring 
method for the ADAS-Cog 11 using Rasch analysis. In brief, response categories with the 
same level of difficulty for each task on the ADAS-Cog 11 were collapsed so that the 
ADAS-Rasch has hierarchically ordered categories, and each task is weighted according 
to its measurement precision.78 The total possible score for each task of the ADAS-Rasch 
is the product of the number of different categories of difficulty present for the items of 
that task and the weight assigned to the task: Word Recall (total possible points for 
ADAS-Cog 11=10 versus total possible points for ADAS-Rasch=12), Naming (5 versus 
6), Commands (5 versus 8), Constructional Praxis (5 versus 4), Ideational Praxis (5 versus 
6), Orientation (8 versus 6), Word Recognition (12 versus 3), Remembering Test 
Instructions (5 versus 5), Language Ability (5 versus 5), Word-Finding Difficulty (5 
versus 4), Comprehension (5 versus 5), total score (70 versus 64).78 ADAS-Rasch scores 
are backwards-compatible to a Classical Test Theory-derived ADAS-Cog 11 sum score. 
The third scoring limitation (non-equal intervals) remains for both the ADAS-Cog 11 and 
the ADAS-Rasch. 
The ADAS-Rasch was developed from baseline data of the placebo arms of three clinical 
trials that included 706 subjects with mild to moderate dementia.78 External criterion 
validation was performed in 456 patients from a different trial with similar inclusion and 
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exclusion criteria.78 There was a high correlation between ADAS-Rasch and ADAS-Cog 
11 scores (r=0.93), and a moderate correlation between ADAS-Rasch and MMSE scores 
(r=-0.72).78  
Baseline discrimination. One-to-one correspondence between the ADAS-Rasch total 
score and level of cognitive impairment was demonstrated in both the development and 
external-validation samples.78 This one-to-one correspondence was not present for the 
ADAS-Cog 11, meaning two individuals with the same score may have different levels of 
cognitive impairment.78 In a later study, Skinner et al. (2012) found that mean scores on 
the ADAS-Rasch were lower for 229 subjects with NC (mean=4.8, SD=3.5) than for 394 
subjects with MCI (mean=11.8, SD=5.5), or 187 subjects with AD (mean=19.5, 
SD=7.4).3 Crane et al. (2012) found comparable results.25 Statistical tests of these 
differences were not performed. 
Disease progression. Skinner et al. (2012) found the Z-score for change over time in 394 
subjects with MCI, adjusted for age, education, gender, and APOEe4 allele, was smaller 
for the ADAS-Rasch (Z=8.50) than the ADAS-Cog 11 (Z=9.44).3 Similar analyses 
performed by Crane et al. (2012) found adjusted Z-scores for time were smaller for the 
ADAS-Rasch than ADAS-Cog 11 in NC (ADAS-Rasch=3.10, ADAS-Cog 11=3.20), 
MCI (ADAS-Rasch=-10.51, ADAS-Cog 11=-10.78), and AD (ADAS-Rasch=-11.28, 
ADAS-Cog 11=-12.25) samples.25  
Treatment effect. Skinner et al. (2012) found that the estimated sample size per group to 
detect a 25% decrease over 12 months in MCI with 80% power and an alpha of 0.05 was 
larger for the ADAS-Rasch (n=1409) than for the ADAS-Cog 11 (n=1230).3 Crane et al. 
(2012) found that the ADAS-Rasch required a larger estimated sample size than the 
ADAS-Cog 11 to detect a 25% decrease over 12 months, with 80% power and an alpha of 
0.05, for NC (41,295 versus 37,971), MCI (1692 versus 1651), and AD (346 versus 
242).25 
Summary. The ADAS-Rasch improved two of three problem areas with traditional 
ADAS-Cog 11 scoring methodology, and appeared to demonstrate better baseline 
discrimination than the ADAS-Cog 11. Responsiveness to disease progression and 
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treatment effects was worse for the ADAS-Rasch than the ADAS-Cog 11 in NC, MCI, 
and AD.   
3.3.7 ADAS-Tree 
Llano et al. (2011) developed an alternative weighting scheme for scoring the ADAS-Cog 
13 to identify subjects with MCI who have a high risk of converting to AD.18 The 
rationale for this was to increase the efficiency of a clinical trial by using conversion from 
MCI to AD as an outcome, and then enrolling subjects with a particularly high risk of this 
conversion.18 A second purpose of the ADAS-Tree is to discriminate between subjects 
with different levels of disease severity at the start of a clinical trial.18 Results for this 
baseline discriminative ability will be reviewed, but not results pertaining to the ability of 
the ADAS-Tree to predict conversion from MCI to AD as risk prediction is less relevant 
for this thesis.  
To develop the ADAS-Tree, the Random Forests (RF) tree-based algorithm was used to 
derive weights for each task of the ADAS-Cog 13 based on their ability to discriminate 
between subjects with NC, MCI, and AD. Briefly, ten thousand bootstrap datasets were 
taken from baseline data of 229 subjects with NC, 397 subjects with MCI, and 193 
subjects with AD.18 The RF algorithm was applied in each bootstrap dataset to develop a 
classification tree for NC, MCI, and AD diagnostic categories.18 Each bootstrap dataset 
was the same size as the original sample, but because datasets were obtained using 
random sampling with replacement, about one third of the original sample was not 
selected for any given bootstrap (some observations were sampled multiple times).18 
These left out samples were used to obtain an estimate of predictive accuracy by 
comparing diagnoses predicted by the majority of classification trees (RF model) with 
original diagnoses.18 Weights for each task of the ADAS-Cog 13 were derived by 
comparing the predictive accuracy of the RF model fit using the full ADAS-Cog 13 to the 
predictive accuracy of a RF model fit when one ADAS-Cog 13 task was replaced by 
noise, repeated for all tasks.18 Tasks that led to a large decrease in predictive accuracy 
when excluded were given the highest weights in the ADAS-Tree as this reflects a 
   72 
 
relatively large contribution to the ability of the ADAS-Cog 13 to discriminate between 
NC, MCI, and AD.18 
Item weights of the ADAS-Tree are: 1.05 Word Recall, 0.38 Commands, 0 Construction, 
1.17 Delayed Word Recall, 0.61 Naming, 0.13 Ideational Praxis, 1.13 Orientation, 0.41 
Word Recognition, 0.54 Recall Instructions, 0.49 Spoken Language, 0.69 Word Finding, 
0.39 Comprehension, 0.69 Number Cancellation.18  
Baseline discrimination. The ADAS-Tree was able to discriminate between NC, MCI, 
and AD diagnostic categories (P<0.0001).18 Furthermore, the Kruskal-Wallis test statistic 
used to assess the magnitude of difference between these categories was larger for the 
ADAS-Tree (401.1) than the ADAS-Cog 13 (393.3), ADAS-Cog 11 (378.9), and MMSE 
(368.8).18 A separate study found ADAS-Tree scores were lower for 229 subjects with 
NC (mean=7.9 points, SD=3.5) than 394 subjects with MCI (mean=15.9 points, SD=5.1), 
and 187 subjects with AD (mean=24.2 points, SD=5.6).3 A third study similar differences 
in scores between NC, MCI, and AD diagnostic categories.25 
Disease progression. Skinner et al. (2012) found that for 394 subjects with MCI the 
ADAS-Tree had a larger Z-score for time (Z=12.04) than the ADAS-Cog 11 (Z=9.44), 
adjusted for age, education, gender, and APOEe4 allele.3 Crane et al. (2012) also found 
that the ADAS-Tree had a larger adjusted Z-score for time than the ADAS-Cog 11 in 
MCI (ADAS-Tree: Z=-13.67, ADAS-Cog 11: Z=-10.78) and AD (ADAS-Tree: Z=-
14.05, ADAS-Cog 11: Z=-12.25), but not NC (ADAS-Tree: Z=0.73, ADAS-Cog 11: 
Z=3.20) samples.25  
Treatment effect. Skinner et al. (2012) found that the estimated sample size per group to 
detect a 25% decrease over 12 months in MCI with 80% power and an alpha of 0.05 was 
smaller for the ADAS-Tree (n=733) than for the ADAS-Cog 11 (n=1230).3 Crane et al. 
(2012) demonstrated that the ADAS-Tree required a larger estimated sample size than the 
ADAS-Cog 11 to detect a 25% decrease over 12 months, with 80% power and an alpha of 
0.05, for subjects with NC (573,996 versus 37,971), and a smaller estimated sample size 
than the ADAS-Cog 11 for subjects with MCI (981 versus 1651) or AD (214 versus 242) 
hypothetical clinical trials.25 
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Summary. The ADAS-Tree demonstrated greater baseline discrimination ability than the 
ADAS-Cog 11 for detecting a difference among NC, MCI, and AD diagnostic categories. 
Responsiveness to disease progression and treatment effects appears to be improved by 
the ADAS-Tree in MCI and AD, but not NC.  
3.3.8 Computerized ADAS-Cog  
The National Institute on Aging funded the development of a computerized version of the 
ADAS-Cog (cADAS-Cog) to try to increase consistency between and decrease errors 
made by administrators of the ADAS-Cog.79 The cADAS-Cog includes a computerized 
version of all ADAS-Cog 11 items plus Delayed Recall, Number Cancellation, and Maze 
tasks. It is administered using a Computerized Multiphasic Interactive Neurocognitive 
Dual Display System (CMINDS).79 The first step at any testing session is for the subject 
to practice using CMINDS via a Perception Response Evaluation (PRE) module.79 A 
secondary purpose of the PRE module is to ensure subjects have sufficient perceptual and 
response abilities to take the computerized test.79 Next, the cADAS-Cog is administered 
on one monitor display while the test administrator uses the second monitor to control the 
speed of the testing, request repeated test instructions, and receive information on the 
subject’s progress throughout the test.79 
A sample of 88 subjects with mild to moderate AD were administered both the 
computerized and paper ADAS-Cog versions three times, four months apart.79 Different 
versions were given on alternate time points, each one month apart.79 Both computerized 
and paper tests took approximately 44 minutes to administer.79 High concurrent criterion 
validity between the cADAS-Cog and paper version total scores, and all individual task 
scores was suggested by ICCs (all P<0.001), Pearson’s correlation coefficients (all 
P<0.01), and paired sample t-tests of differences between intra-subject scores (all 
P>0.10).79 High test-retest reliability was found over approximately five month (P<0.001) 
and ten month periods (P<0.001).79 Paired sample t-tests showed that the reliability 
across cADAS-Cog scores was significantly better than that of the paper administration 
method over five and ten month periods (5 month: mean cADAS-Cog ICC=0.87, mean 
paper ICC=0.80, t=2.88, P<0.02; 10 month: mean cADAS-Cog ICC=0.83, mean paper 
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ICC=0.77, t=2.54, P<0.03).79 Agreement was also demonstrated with a Bland-Altman 
plot of the differences between total scores.79 
Summary. The cADAS-Cog improved the reliability and standardization of an extended 
version of the ADAS-Cog 13, and may be considered as an alternative mode of 
administration especially when ADAS-Cog scores from multiple different administrators 
are going to be compared. Explicit tests of responsiveness were not conducted.  
3.3.9 Touch Panel-Type Dementia Assessment Scale  
Inoue et al. (2011) created a computerized version of a modified ADAS-Cog 11 that can 
be administered in 30 minutes.80 This Touch Panel-Type Dementia Assessment Scale 
(TDAS) has a 14” touch panel display and includes the seven tasks of the ADAS-Cog 11 
which they could computerize (Word Recognition, Following Commands, Orientation, 
visual-spatial perception (modified Constructional Praxis), Naming Fingers, object 
recognition (modified Naming Objects), accuracy of the order of a process (modified 
Ideational Praxis) as well as tests for money calculation and clock time recognition (non-
digital).80 The scoring range is 0 to 101, with lower scores indicating worse performance. 
A limitation of the TDAS is that people with severe AD or visual and/or hearing 
impairment require assistance or may not be able to finish the test.80  
Thirty-four subjects with AD were administered both the TDAS and a paper version for 
concurrent criterion validation analyses.80 Total scores from the two tests were 
significantly correlated (r=0.69, P<0.01).80 Kendall coefficients of concordance were 
calculated to assess agreement between six of the TDAS tasks and six of the paper 
ADAS-Cog 11 tasks.80 Three tasks showed acceptable concordance [Word Recognition 
(0.57), Orientation (0.41), and Naming Objects and Fingers (0.32)], while three showed 
poor concordance [Following Commands, Constructional Praxis, Ideational Praxis (all 
Kendall’s coefficients <0.3)].80 
Summary. The TDAS is a computerized test of cognitive ability which includes some 
modified items of the ADAS-Cog 11. Preliminary tests of agreement were mixed. Further 
tests would help to establish responsiveness of the TDAS.  
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3.3.10 Computerized Adaptive Testing of the Cambridge Cognitive 
Examination – Plus 
The Cambridge Cognition Examination (CAMCOG)-Plus is composed of a battery of 
neuropsychological tests including the ADAS-Cog 11.81 Wouters et al. (2011) used 
Computerized Adaptive Testing (CAT) to administer the CAMCOG and CAMCOG-Plus 
to 41 subjects with NC, 21 subjects with MCI, and 22 subjects with dementia to see 
whether the CAT version maintains diagnostic accuracy while decreasing length of 
administration.81 
The CAT procedure begins by asking subjects a series of standard questions which an 
internal algorithm uses to estimate cognitive ability.81 Each time a question is answered 
throughout the entirety of the testing procedure (i.e. during CAMCOG or CAMCOG-Plus 
administration) the algorithm updates the estimate of cognitive ability and uses the 
response to select the difficulty of the next question to be administered.81 Correct 
responses lead to the administration of more difficult questions while incorrect responses 
lead to the administration of easier ones.81 Difficulty levels of test items were initially 
estimated using a one parameter logistic model.81 The updating process is continued until 
25 items are administered or a standard error of measurement corresponding to 90% 
reliability for cognitive ability is reached.81  
In the original sample an estimate of cognitive ability was reached using the CAT 
CAMCOG-Plus after administering 53% fewer items than are included in the full test 
battery.81 Time to administer was reduced by 54%.81 The CAT CAMCOG-Plus had 
excellent agreement for estimating cognitive ability with the paper CAMCOG-Plus (ICC 
0.98, P<0.001) and the paper CAMCOG (ICC 0.99, P<0.001).81 Concurrent criterion 
validity was found between the CAMCOG-Plus and MMSE (Spearman’s rho=0.80, 
P<0.001) and Informant Questionnaire on Cognitive Decline in the Elderly (Spearman’s 
rho=-0.54, P<0.025).81 
Baseline Discrimination. The CAT CAMCOG-Plus but not CAT CAMCOG was better 
at discriminating between the diagnostic categories of NC, MCI, and dementia than the 
MMSE, as assessed by AUCs and optimal sensitivity and specificity values.81  
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Summary. The CAT CAMCOG-Plus demonstrated the ability to discriminate between 
NC, MCI, and dementia diagnostic categories. Direct comparisons with the ADAS-Cog 
11 were not performed, nor were assessments of responsiveness to disease progression 
and treatment effects.   
3.3.11 ADAS-Cog-5-Subset and ADAS-Cog-6-Subset  
Ihl et al. (2012) used a subsetting analysis approach to develop two separate subsets of 
ADAS-Cog 11 tasks based on the ability of individual tasks to detect a treatment effect in 
three 24 week randomized controlled trials of a total of 855 subjects with mild to 
moderate AD.82 The objective of the subsetting analysis was to remove tasks from the 
ADAS-Cog 11 that demonstrated low sensitivity for detecting a treatment response.82  
The first step of the subsetting analysis was to calculate the pre-post difference for all 
ADAS-Cog 11 tasks.82 If the pre-post difference on the task score was less than or equal 
to 0 (did not get worse over time; treatment responder) a binary variable for ‘response’ 
was given the value 1.82 If the pre-post difference was greater than 0 (subject got worse 
over the course of the study; treatment non-responder) the binary ‘response’ variable was 
coded as 0.82 Importantly, a “responder” was defined as a subject who showed no 
worsening on any task of a given subset of tasks over the course of the study.82 
Responders could be in the placebo or treatment group. A mathematical algorithm was 
then used to identify subsets of ADAS-Cog 11 tasks which could identify groups of 
responders, and Wilcoxon rank-sum tests were used to find subsets with statistically 
significant differences in the proportion of responders between treatment and placebo 
groups.82 The subset with the lowest P-value was selected as the collection of ADAS-Cog 
11 tasks with the most potential for detecting a treatment response.82 
The primary result of this analysis was the ADAS-Cog-5-Subset: Ideational Praxis, 
Remembering Test Instructions, Language, Comprehension, and Word Finding Difficulty 
tasks. Internal consistency of the ADAS-Cog-5-Subset (Chronbach’s alpha=0.81) was 
close to that of the ADAS-Cog 11 (Chronbach’s alpha=0.82).82  
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Tasks not selected for the primary subset were combined to create the ADAS-Cog 6-
Subset: Word Recall, Naming Objects and Fingers, Commands, Constructional Praxis, 
Orientation, and Word Recognition.82  
Treatment effect. The ADAS-Cog-5-Subset found statistically significant differences in 
the proportion of responders in the treatment compared to control groups for the overall 
study population (P=0.0001), as well as subgroups of subjects with mild AD (P=0.01), 
and moderate AD (P=0.01).82 The ADAS-Cog-6-Subset found statistically significant 
treatment effects for the overall study population (P=0.0016) and the moderate AD 
subgroup (P=0.0002), but not among the subgroup of mild AD subjects (P=0.53).82 The 
ADAS-Cog 11 found no statistically significant difference between the proportion of 
responders in the treatment versus control group.82  
Summary. Both the ADAS-Cog-5-Subset and the ADAS-Cog-6-Subset were more 
responsive than the ADAS-Cog 11 to treatment effects in AD. The ADAS-Cog-5-Subset 
was the most sensitive for detecting a memantine treatment response in mild AD. The 
ADAS-Cog-6-Subset was the most sensitive for detecting a memantine treatment 
response in moderate AD. Although subsetting analysis requires longitudinal data from a 
clinical trial, future studies may evaluate the ability of the Subsets to detect within-person 
change over time in observational studies. One limitation, common to other validation 
analyses, is that the Subsets were statistically optimized for sampling and measurement 
error of the test dataset and will not likely have the same performance characteristics in a 
new study.  
3.3.12 The ADAS-Cog-Plus (ADAS-Bifactor, ADAS-Plus-EF, ADAS-
Plus-EF&FA) 
Skinner et al. (2012) used two strategies to modify the ADAS-Cog 13 to try and improve 
responsiveness to changes in MCI.3 First, alternative weights to tasks of the ADAS-Cog 
13 were applied based on latent trait analysis with IRT. This resulted in a bi-factor model 
that accounted for correlations between Word Recognition and Word Recall tasks, and for 
correlations between the four examiner-rated tasks.3 The variance of the primary factor 
was fixed at one, and loadings were freely estimated.3 Scores for follow-up visits were 
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computed using item parameters from this baseline model transformed to a standard 
normal distribution (mean=0 and SD=1).3 Second, two other variants of the ADAS-Cog 
13 were created by adding tasks to assess Executive Functioning (EF) and informant 
reports of daily function (FA). The ADAS-Plus-EF consists of the ADAS-Cog 13 plus an 
additional task for category (vegetable) fluency.3 The ADAS-Plus-EF&FA consists of the 
ADAS-Cog 13 plus category (vegetable) fluency, Trail Making Tests (TMT) A and B, 
Digit Symbol Substitution (DSS) Test, and five Pfeffer FAQ items.3 These modifications 
were developed using data from 811 subjects with a range of cognitive abilities, validated 
in a subset of 394 subjects with MCI, and then compared to the ADAS-Cog 11, ADAS-
Cog 13, ADAS-Rasch (Section 3.3.6), and ADAS-Tree (Section 3.3.7).3  
Baseline discrimination. Plots of test information curves (Monte Carlo integrated test 
information versus cognitive ability) showed that the ADAS-Plus-EF&FA model had the 
highest test information over all levels of cognitive ability, followed by the ADAS-Plus-
EF, and then the ADAS-Bifactor.3 In general, the amount of information any of the three 
variants held about cognitive ability increased as cognitive ability worsened.3 
Disease progression. The Z-score for change over time in the validation sample adjusting 
for age, education, gender and APOEe4 allele was larger for the ADAS-Plus-EF&FA 
(Z=11.81) than the ADAS-Plus-EF (Z=10.61), ADAS-Bifactor (Z=10.26), and ADAS-
Cog 11 (Z=9.44).3  
Treatment effect. Estimated sample sizes to detect a 25% change in cognition over 12 
months with 80% power and alpha of 0.05 were calculated.3 The ADAS-Plus-EF&FA 
required a smaller sample size (n=547) than the ADAS-Plus EF (n=883), ADAS-Bifactor 
(n=1103), and ADAS-Cog 11 (n=1230).3  
Summary. The ADAS-bifactor, ADAS-Plus-EF, and ADAS-Plus EF&FA all 
demonstrated the ability to provide information about cognitive ability across various 
levels of cognitive impairment, suggesting they may be responsive to baseline 
discrimination. The ADAS-Bifactor, ADAS-Plus-EF, and ADAS-Plus EF&FA all 
showed superior responsiveness to disease progression in MCI than the ADAS-Cog 11, 
but were not better than the previously developed ADAS-Tree. Out of all measures 
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assessed, the ADAS-Plus EF&FA appeared to be the most responsive to treatment effects 
in MCI.  
3.3.13 Common Item Pooling  
Wouters et al. (2012) pooled data from 1863 subjects (585 NC, 66 MCI, 1012 AD, 133 
non-AD dementia, 67 unknown psychiatric diagnosis) across multiple data sets which 
each included some or all of the CAMCOG, modified ADAS-Cog (ADAS-Cog 12 plus a 
concentration task), and MMSE.20 Data pooling was performed using a method of 
“common item equating”, and Rasch measurement models were used to estimate the 
difficulty of each test item and the cognitive ability of each participant.20 The purpose 
was to locate an underlying dimension of cognitive ability common to all three outcome 
measures so that their scores could be compared (the score from any one test can be 
translated to the level of underlying cognitive ability, and then translated back into a score 
on one of the other tests).20 Items showing systematic differences in level of difficulty 
between data sets, or for which valid estimates of difficulty level could not be obtained, 
were excluded from common item pooling.20 
Rasch measurement theory was also applied to assess whether adding neuropsychological 
tests of episodic or semantic memory and executive function to the modified ADAS-Cog, 
CAMCOG, and MMSE increased precision for discriminating between levels of early 
cognitive decline and detecting mild dementia.20 Neuropsychological tests were found to 
be more difficult than the modified ADAS-Cog, MMSE, and CAMCOG items with 
difficulty levels compatible with NC to MCI and mild dementia.20 In contrast, the 
modified ADAS-Cog had only a few tasks with difficulty levels appropriate for pre-
dementia cognitive abilities.20 
Baseline discrimination. The measurement precision for assessing levels of latent 
cognitive ability varied between the individual outcome measures as well as between 
different combinations of the outcome measures. For subjects with below average levels 
of cognitive ability, adding the MMSE and modified ADAS-Cog together (T-score range 
50 to 60) improved precision for estimating underlying cognitive ability over either test 
alone.20 For subjects with above average cognitive ability, adding neuropsychological 
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tests to the MMSE was the best measurement combination (T-score range 50 to 60).20 
The estimated difficulty level of the neuropsychological tests (T-score range 50-65) was 
more comparable with NC and MCI or mild dementia levels of cognitive ability than 
from the estimated difficulty level of the CAMCOG, MMSE, or modified ADAS-Cog 
tasks.20 The neuropsychological tests were not however helpful for more severely 
impaired populations either alone, or when added to another measure.20  
Summary. The CAMCOG, MMSE, and modified ADAS-Cog estimate a common 
underlying dimension of cognitive ability. At mild levels of cognitive impairment, adding 
neuropsychological tests to the MMSE without the modified ADAS-Cog was 
recommended to maximize measurement precision, but for more severe levels of 
cognitive impairment adding the modified ADAS-Cog to the MMSE is advantageous 
over the modified ADAS-Cog alone. Formal assessments of responsiveness or 
comparisons to the ADAS-Cog 11 were not performed.  
3.3.14 Alzheimer’s Disease Neuroimaging Initiative Memory 
Composite  
Crane et al. (2012) used modern psychometric approaches to develop and test the validity 
of a composite score for memory (ADNI Memory Composite) made up of the Rey 
Auditory Verbal Learning Test (RAVLT), ADAS-Cog 13 Delayed Word Recall task, 
ADAS-Cog 11 Word Recognition task, MMSE three word memory task with distractors, 
and the Logical Memory test which involves attempting to recall facts from a passage.25 
Initial analyses of the ADNI Memory Composite involved 225 subjects with NC, 394 
subjects with MCI, and 184 subjects with AD.25 Psychometric approaches determined 
that a bi-factor model was not a substantially better fit than a single factor model for the 
ADNI Memory Composite, so a single factor model was maintained.25 Concurrent 
criterion validation found the ADNI Memory Composite performed at least as well as the 
RAVLT in all analyses.25 
Baseline discrimination. The ADNI Memory Composite score was slightly higher for 
subjects with NC (mean=1.0 points, SD=0.5) than subjects with MCI (mean=-0.1 points, 
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SD=0.6) and subjects with AD (mean=-0.8 points, SD=0.5).25 No statistical tests of these 
differences were performed. 
Disease progression. Ability of the ADNI Memory Composite to detect change over 
time in subjects with NC, MCI, and AD was evaluated using standardized regression 
coefficients for time, controlling for age, education, and sex, and presence of at least one 
APOEe4 allele.25 Coefficients for time were statistically significant for the ADNI 
Memory Composite in NC (3.02), MCI (-9.43), and AD (-11.59) subgroups (all 
P<0.05).25 In comparison, coefficients for the ADAS-Cog 11 were larger in the NC 
(3.20), MCI (-10.78), and AD (-12.25) subgroups (all P<0.05).25  
Treatment effect. Standardized coefficients and adjusted SD were used to estimate the 
sample size needed to detect a 25% reduction in rate of cognitive decline over 12 months 
with 80% power in a hypothetical two-arm clinical trial.25 The ADNI Memory Composite 
required a smaller sample size than the ADAS-Cog 11 for a hypothetical trial of NC 
(28,512 versus 37,971), but required a larger sample size than the ADAS-Cog 11 for MCI 
(2,167 versus 1,651) and AD trials (568 versus 242).25  
Summary. The ADNI Memory Composite appeared able to discriminate between NC, 
MCI, and AD diagnostic categories. Although it demonstrated responsiveness to disease 
progression in NC, MCI, and AD samples, this performance was not better than that of 
the ADAS-Cog 11. The ADNI Memory Composite was more responsive to treatment 
effects in subjects with NC than the ADAS-Cog 11, but not more responsive to treatment 
effects for MCI and AD levels of disease severity.   
3.3.15 ADAS-Cog IRT 
Balsis et al. (2012) developed an IRT scoring methodology for the ADAS-Cog 11 in 
1,240 subjects with varying levels of dementia severity.83 Although the primary focus was 
on identifying limitations to traditional ADAS-Cog 11 scoring methodology, they also 
showed how using IRT to model a subject’s score along with the difficulty of individual 
items can increase precision for estimating cognitive ability.83 
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Verma et al. (2015) found, using multidimensional IRT on data from three cohort studies, 
that the ADAS-Cog 11 is most appropriately modelled using three latent factors 
corresponding to the cognitive domains of memory, language, and praxis in a large 
sample of older adults with NC to AD.84 The memory domain includes the Word Recall, 
Orientation, and Word Recognition tasks.84 The Language domain includes the Naming 
Objects and Fingers, Language, Comprehension of Spoken Language, Word Finding 
Difficulty, and Remembering Test Instructions tasks.84 The praxis domain includes the 
Commands, Constructional Praxis, and Ideational Praxis tasks.84  
Verma et al. (2015) evaluated their multidimensional IRT scoring methodology for the 
ADAS-Cog 11 using data from the treatment arms of 11 clinical trials that enrolled older 
adults with AD. Their ADAS-Cog IRT uses ICCs from patient responses on the ADAS-
Cog 11 to provide an assessment of cognitive impairment based on maximum likelihood 
estimation.84 Differential Item Functioning (DIF) analyses were used to adjust item slopes 
and intercepts so that patient characteristics other than cognitive ability did not cause 
large variations in scores.84 To maintain non-negative integer final scores, the summary 
scores for memory, language, and praxis domains were linearly scaled by multiplying by 
a factor of 15 and adding 50.84 This ADAS-Cog IRT scoring methodology demonstrated 
good accuracy as assessed by root mean squared error of observed compared to predicted 
ADAS-Cog 11 scores (6.05 points).84 Precision was assessed using item information 
functions. Memory tasks showed good precision across the entire range of memory 
impairment, however precision for measuring language and praxis impairment was only 
good at lower levels of cognitive ability.84  
Baseline discrimination. The application of IRT scoring methodology to the ADAS-Cog 
11 provided the same score to all subjects with the same cognitive ability.83 In contrast, it 
was found that when using traditional ADAS-Cog 11 scoring methodology two subjects 
with the same cognitive ability may score differently, and two subjects with different 
scores on the ADAS-Cog 11 may have the same underlying cognitive ability.83  
Treatment effect. Verma et al. (2015) used clinical trial simulations to compare the 
ADAS-Cog 11 and ADAS-Cog IRT in terms of the power needed to detect a pre-
specified treatment effect for various sample sizes (n=200 to 1,000) over 24 months, and 
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for various lengths of follow-up with the sample size set at 400.84 Both ADAS-Cog IRT 
scoring methodology and original ADAS-Cog 11 scoring with an Analysis of Covariance 
test for a treatment effect showed low power (< 80%) for detecting a mild treatment effect 
regardless of the sample size or trial duration.84 For a moderate treatment effect, ADAS-
Cog IRT methodology reached 80% power with a smaller sample size and shorter trial 
duration compared to original ADAS-Cog 11 methods.84 Sensitivity analysis in a real 
clinical trial was also performed where the ADAS-Cog IRT scoring methodology 
detected a larger treatment effect than original ADAS-Cog 11 methods.84  
Summary. The ADAS-Cog IRT demonstrated more precise estimates of cognitive ability 
than original ADAS-Cog 11 scoring methodology, which is expected to improve 
responsiveness to baseline discrimination, and the ADAS-Cog IRT demonstrated greater 
responsiveness to moderately large treatment effects in AD. The finding that the ADAS-
Cog 11 was best modelled using multiple latent cognitive domains suggests that the 
unidimensional assumption used in CTT may not be appropriate for assessing the ADAS-
Cog 11. Responsiveness to disease progression was not evaluated.  
3.3.16 ADAS-3 
Raghavan et al. (2013) aimed to improve sensitivity to change and reduce variability of 
the ADAS-Cog 11 for MCI and early AD trials by removing uninformative items from 
the ADAS-Cog 11 and adding in more responsive measures of cognition or function.19 A 
total of six novel measures were derived based on analyses of cognitive and functional 
measures in 229 subjects with NC, 377 subjects with MCI, and 192 subjects with AD.19 
The criterion for an individual test item to be considered for inclusion in a novel 
composite was a standardized two-year change score of at least 0.4 for MCI 
participants.19 Three of the novel measures were composed solely of cognitive test items 
(Section 3.3.16 and 3.3.17), and three included cognitive items as well as measures of 
daily function (Section 3.3.18). Bootstrap validation was performed for the entire 
selection process. Performances of the six novel measures for detecting change over time 
were compared with each other as well as with other outcome measures, including the 
ADAS-Cog 11 and ADAS-Cog 13, using data from two-years of follow-up of 198 
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subjects with NC, 138 subjects with stable MCI, 139 subjects who converted from MCI to 
dementia, and 131 subjects with AD.19 
The first cognitive measure, the ADAS-3, includes ADAS-Cog 11 tasks which did not 
exhibit ceiling effects and surpassed the 0.4 threshold for standardized two-year change 
scores. ADAS-3 tasks include: Word Recall, Delayed Word Recall, and Orientation.19  
Disease progression. The standardized two-year change of the ADAS-3 was larger than 
that of the ADAS-Cog 11 and all individual tasks of the ADAS-Cog 11, but smaller than 
that of the other five novel composites.19  
Summary. The ADAS-3 was more responsive to disease progression than the ADAS-
Cog 11 among a sample of subjects with NC to AD levels of disease severity, but it was 
the worst performing novel composite developed by Raghavan et al (2013). 
Responsiveness to baseline discrimination and treatment effects was not evaluated.  
3.3.17 Cognitive Composites 1 and 2 
The second novel composite developed by Raghavan et al. (2013), the Cognitive 
Composite (CC) 1 (CC1), includes the same items as the ADAS-3 as well as the RAVLT 
immediate recall test, and the MMSE.19 
The third novel composite developed by Raghavan et al. (2013), the CC2, consists of the 
ADAS-3 and the cognitive portion of the Clinical Dementia Rating Scale – Sum of Boxes 
(CDR-SB).19  
Criterion validation was performed for both the CC1 and CC2 using Spearman’s 
correlations between two-year change scores for each of the composites and reference 
standards such as the ADAS-Cog 11 and CDR-SB, and factor analysis was used to assess 
the latent structure of each novel composite measure.19  
Baseline discrimination. For the CC1, subjects with MCI scored worse (mean=0.15 
points, SD=1.64) than subjects with AD (mean=3.15 points, SD=1.68), or subjects with 
MCI and Aβ pathology (mean=0.49 points, SD=1.55).19 The same was true for the CC2, 
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whereby subjects with MCI scored worse (mean=0.07 points, SD=0.94) than subjects 
with AD (mean=2.38 points, SD=1.28), or subjects with MCI and Aβ pathology 
(mean=0.22 points, SD=0.95).19 Statistical significance of these differences was not 
assessed. 
Disease progression. The CC1 and CC2 demonstrated greater standardized two-year 
mean change than the ADAS-Cog 11 and all individual items of the ADAS-Cog 11, and 
the ADAS-3.19 The CC2 was the most responsive purely cognitive measure developed by 
Ragavan et al. (2013), producing a standardized two-year change score only slightly 
smaller than the best performing composite incorporating items of cognition and 
functionality.19 Two-year change scores from the CC1 were more strongly correlated with 
ADAS-Cog 11 (Spearman’s rho=0.61) than CC2 with the ADAS-Cog 11 (Spearman’s 
rho=0.54).19  
Treatment effect. The estimated sample size required to detect a hypothetical 25% 
treatment effect with 80% power in a two-arm clinical trial of subjects with MCI was 
smaller for the CC2 (n=300) than the CC1 (n=477), the ADAS-Cog 11 (n=772), and the 
CDR-SB (n=375).19  
Summary. The CC1 and CC2 both appeared able to discriminate between groups of 
subjects with MCI and AD, and were more responsive than the ADAS-Cog 11 to disease 
progression in subjects with NC to AD. Results also suggest that both the CC1 and CC2 
are more responsive to treatment effects in subjects with MCI than the ADAS-Cog 11. 
The CC2 demonstrated similar responsiveness to the novel composites which include 
functional measures, while maintaining lower variability.  
3.3.18 Cognitive Functional Composites 1 and 2 
The fourth novel measure developed by Raghavan et al. (2013), the Cognitive Functional 
Composite (CFC) 1 (CFC1), was the first of their three novel composites which included 
measures to assess both cognition and daily functioning.19 The CFC1 is composed of the 
CC1 and the FAQ.19 
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The fifth composite derived by Raghavan et al. (2013), the CFC2, includes the CC2 and 
the FAQ.19  
The sixth composite was the only novel measure derived by Raghavan et al. (2013) which 
did not incorporate any ADAS-Cog 11 items (CFC3: CDR-SB and FAQ).19 For that 
reason, it will not be reviewed in the same manner as the other novel composites.  
Correlations between the cognitive portions of each of the CFCs with the FAQ were used 
to demonstrate that change scores on the CFCs were due to changes on both cognitive and 
functional sub-tasks rather than just being driven by one of the two domains.19 
Baseline discrimination. For the CFC1, subjects with MCI scored worse (mean=-0.11 
points, SD=1.02) than subjects with AD (mean=2.4 points, SD=1.42), or subjects with 
MCI and Aβ pathology (mean=0.06 points, SD=0.98).19 The same was true for the CFC2, 
whereby subjects with MCI scored worse (mean=-0.13 points, SD=1.0) than subjects with 
AD (mean=2.48 points, SD=1.51), or subjects with MCI and Aβ pathology (mean=0 
points, SD=1.01).19 Statistical significance of these differences was not assessed. 
Disease progression. Among MCI participants, the two-year standardized mean change 
of the CFC1 and CFC2 were larger than that of the ADAS-Cog 11, the CDR-SB, and all 
individual items of the ADAS-Cog 11.19 The CFC2 demonstrated the largest standardized 
mean change of all novel measures developed by Raghavan et al. (2013).19 Spearman’s 
correlation between two-year change scores on the CFC1 and on the ADAS-Cog 11 
(rho=0.54) was slightly higher than for the CFC2 and the ADAS-Cog 11 (rho=0.48).19  
Treatment effect. The estimated sample size required to detect a hypothetical 25% 
treatment effect with 80% power in a two-arm clinical trial of subjects with MCI was 
smaller for the CFC2 (n=302) than the CFC1 (n=348), the ADAS-Cog 11 (n=772), and 
the CDR-SB (n=375).19  
Summary. The CFC1 and CFC2 appeared able to discriminate between MCI and AD 
groups, and both were more responsive than the ADAS-Cog 11 to disease progression in 
subjects with NC to AD. It was also suggested that both the CFC1 and CFC2 would be 
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more responsive than the ADAS-Cog 11 to treatment effects in MCI. Overall, the CFC2 
was the most responsive measure developed by Raghavan et al. (2013).  
3.3.19 Item Response Theory and Pharmacometric ADAS-Cog 13 
Ueckert et al. (2014) used IRT and pharmacometric modelling to explore different 
methods for analyzing ADAS-Cog 13 scores.15  
First, an IRT model to estimate baseline cognitive ability was created using data from 
2,744 subjects with NC, MCI, or mild AD.15 The IRT baseline model models cognitive 
ability as a subject specific random effect following a standard normal distribution (Z-
score), with no limits on the upper or lower extremes of cognitive ability.15 The 
probability of a subject responding a certain way on an ADAS-Cog 13 task or task 
subitem, given their underlying cognitive ability, was described using four different test 
item specific models. First, tasks or subitems that are scored as correct or incorrect (e.g. 
Orientation subitem: correctly state the month) were modeled with a three-parameter 
binary model that accounts for item discrimination, item difficulty, and the probability 
that a subject with no cognitive disability would get the item incorrect.15 Second, tasks or 
task subitems involving words were modeled with a binomial model (uses the number of 
words correctly identified out of the total number possible), with slightly different failure 
probabilities depending on the task (Word Recall: failure probability = three-parameter 
binary model described above; Word Recognition: failure probability = same as for Word 
Recall plus a fourth parameter to account for the maximal probability that a subject with 
severe cognitive dysfunction would correctly categorize words as seen or not).15 All 
words were assumed to hold the same amount of information about underlying 
cognition.15 Third, the Number Cancellation task was modelled using a generalized 
Poisson model, which included the same three test item parameters as the three-parameter 
binary model plus a fourth parameter for dispersion, and a factor to ensure predicted 
scores are in the range of 0 to 40.15 Fourth, tasks on the ADAS-Cog 13 that are rated by 
the examiner (e.g. Comprehension of Spoken Language) were modeled using a 
proportional odds, ordered categorical model with five possible categories (none to 
severe impairment) and parameters for item difficulty and discrimination.15    
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Next, three different means for assessing cognitive change over time were devised. The 
latter two are extensions of the baseline IRT model:   
i) A Least-Square Mean Analysis Model used change in ADAS-Cog 13 score as 
the outcome variable, treatment as the exposure variable, visit as a repeated 
factor, baseline ADAS-Cog 13 score as a covariate, a treatment-by-visit 
interaction term, and a grouping factor of subjects nested within treatment. 
This represents more “traditional” ADAS-Cog scoring methodology.15  
ii) The baseline IRT model was extended to create a Longitudinal IRT Model by 
adding a hidden variable to account for disease progression over time.15 
Disease progression was assumed to be linear (based on a previously 
published model), subject-specific, and modelled through random-effects. A 
hazard function for the probability that a subject will drop out of a longitudinal 
study was also included.15 To assess the performance of the longitudinal IRT 
model, Z-score estimates of underlying cognitive ability for an 18-month long 
clinical trial were translated back to the original ADAS-Cog 13 scoring scale 
and compared with observed ADAS-Cog 13 scores from 322 real subjects in 
the 18-month clinical trial.15 More specifically, two-hundred Monte-Carlo 
simulations from the IRT model and the original clinical trial data were used 
to compare the proportion of subjects from the original data whose task-level 
scores would fall in the 95% prediction interval from the score produced by 
IRT models.15 Total ADAS-Cog 13 score comparisons were done in a similar 
manner, except 200 non-Bayesian simulations were performed and the 95% CI 
for the median, 2.5th, and 97.5th percentile of total simulated scores were 
compared to the clinical trial percentiles.15 ADAS-Cog 13 scores for the 
clinical trial were plotted with the median, 2.5th, and 97.5th percentile of the 
real scores observed in the clinical trial. When plotted on top, the median 
value of the real scores fell within the 95% CI predicted by the IRT model for 
all but the final 18-month follow-up assessment.15 Comparisons were also 
made for drop-out patterns over the course of the clinical trial.15 
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iii) The Pharmacometric Total ADAS-Cog Score Model of analysis was based on 
a previously published disease progression model and modified according to 
the results of goodness of fit plots, residual plots, and visual prediction 
checks.15 This model was further refined and tested using a simulated data set 
from the longitudinal IRT model.15 Similar to the longitudinal IRT model 
analyses whereby estimated ADAS-Cog 11 total scores were compared to 
observed scores in a real clinical trial, the performance of the pharmacometric 
total ADAS-Cog 13 score model was assessed with visual predictive checks of 
whether the 95% CI for the ADAS-Cog 13 scores estimated from the 
pharmacometric model included the 2.5th, 97.5th, and median ADAS-Cog 13 
scores from the ADAS-Cog Longitudinal IRT model based simulated data 
set.15 The final pharmacometric total ADAS-Cog 13 score model assumes a 
linear progression of cognitive dysfunction (increasing scores), and models 
individual subject baseline scores with a Box-Cox distribution and normally 
distributed individual slope parameters correlated with baseline random 
effect.15 
Treatment effect. The longitudinal IRT model was used to simulate 20-month two-arm 
clinical trials with a 20% treatment effect for 100, 200, 400, or 800 subjects with mild to 
moderate AD.15 Five hundred simulations were run for each sample size.15 Type I error 
and power to detect the treatment effect of the three different methods of longitudinal data 
analysis described above were compared.15 The IRT based pharmacometric model 
required 71% fewer subjects than the Least-square mean analysis, and 23% fewer 
subjects than the pharmacometric model, to detect a treatment effect with 80% power and 
no inflation of Type I error.15  
Summary. Using both IRT and pharmacometric modelling demonstrated greater 
precision of cognitive ability estimates at baseline, and appeared more responsive to 
treatment effects in AD, compared to traditional ADAS-Cog scoring and methods of 
analysis. Responsiveness to baseline discrimination and disease progression was not 
assessed.  
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3.3.20 integrated Alzheimer’s Disease Rating Scale 
Wessels et al. (2015) used a theoretical framework to guide the combination of existing 
scales of cognition and function to create a sensitive measure to the natural history of AD 
and to detect treatment effects in clinical trials.85 For subjects with mild AD and MCI, 
preliminary tests found the combination of ADAS-Cog 13 and the FAQ was most 
sensitive, and the combination of the two scales performed better than either one 
individually.85 Data from treatment trials in AD did not have those two measures 
specifically, so they were approximated with the ADAS-Cog 14 and the ADCS-
instrumental Activities of Daily Living (iADL) which formally make up the integrated 
Alzheimer’s Disease Rating Scale (iADRS).85  
iADRS score = [-1(ADAS-Cog 14) + 90] + iADL, where the ADAS-Cog 14 (ADAS-Cog 
11, Delayed Word Recall, Maze, and Digit Cancellation tasks) and iADL are summed 
normally and the total range of the iADRS is 0 to 146 with lower scores indicating worse 
performance.85  
Psychometric analyses showed that the iADRS is composed of two principal components 
(cognition and instrumental function) for assessment at one point in time, and the 
majority of the variability for subjects with MCI was due to cognitive items of the 
ADAS-Cog.85 For change over time, the iADRS items load on a single component, and 
variance of change scores was driven by both cognitive and function items.85  
Disease progression. SRMs with 95% CIs were compared using separate forest plots for 
different levels of disease severity. The iADRS had the largest SRM for MCI and mild 
and moderate AD compared to the ADAS-Cog 11, ADAS-Cog 13, MMSE, FAQ, CDR-
SB, and several other measures of cognition.85  
Treatment effect. For several clinical trials including subjects with MCI or mild AD the 
iADRS was able to detect a statistically significant treatment effect, however the 
magnitude of this effect was not consistently better than that detected by the ADAS-Cog 
14.85  
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Summary. The iADRS was more responsive to disease progression in MCI and AD than 
the ADAS-Cog 11, however it was not more responsive than the ADAS-Cog 14 for 
treatment effects in MCI and mild AD. Comparison of responsiveness to treatment effects 
with the ADAS-Cog 11 was not performed, and baseline discrimination ability was not 
evaluated. 
3.3.21 Straightforward Sensitive Scale 
Huang et al. (2015) designed a scale including cognitive and functional measures for the 
purpose of tracking disease progression over time and detecting potential treatment 
effects in clinical trials for MCI and early AD, while maintaining good reliability and 
validity as subjects progress to more severe stages of AD.86 Selection of measures to 
include in the composite scale was performed in a stepwise manner. First, SRMs of many 
candidate measures were calculated and the candidate measures with the highest SRMs 
were combined to create a composite measure.86 In general, the minimum SRM for a 
candidate measure to be considered was 0.45 for the group of 397 subjects with MCI, 
0.50 for an APOE enriched subgroup, and 0.55 for hippocampal volume and Aβ enriched 
subgroups.86 The SRMs of all possible combinations of candidate measures were 
calculated to determine the composite scale most sensitive to disease progression and 
treatment effects.86 This “straightforward sensitive scale” (SSS) consisted of the CDR-
SB, FAQ, and three ADAS-Cog 13 items (Word Recall, Delayed Word Recall, 
Orientation).86  
Disease progression. The SRM of the SSS in subjects with MCI was greater than that of 
the CDR-SB alone or the ADAS-Cog 13 over 1 year (SRM: SSS=0.62, CDR-SB=0.55, 
ADAS-Cog 13=0.28), two years (SRM: SSS=0.82, CDR-SB=0.74, ADAS-Cog 13=0.56), 
three years (SRM: SSS=0.93, CDR-SB=0.76, ADAS-Cog 13=0.65), and when assuming 
a hypothetical treatment effect delayed disease progression by one year (SRM: SSS=0.37, 
CDR-SB=0.35, ADAS-Cog 13=0.29).86 The SSS maintained the highest SRMs for 
subgroups of subjects with MCI and biomarkers indicating increased risk of disease 
progression.86  
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Treatment effect. The SSS was estimated to require a smaller sample size (n=189) to 
detect a hypothetical treatment effect that slows disease progression by 50% in a two-year 
MCI trial compared to the CDR-SB (n=231) and ADAS-Cog 13 (n=402).86  
Summary. The SSS appeared more responsive to disease progression and treatment 
effects in MCI than the ADAS-Cog 13, but direct comparison with the ADAS-Cog 11 
was not performed nor were tests of baseline discrimination.  
3.3.22 ADAS-Cog 3b 
Podhorna et al. (2016) removed eight tasks from the ADAS-Cog 11 that demonstrate 
ceiling effects in MCI. The three remaining tasks comprise the ADAS-Cog 3b: Word 
Recall, Orientation, and Word Recognition.12 The ADAS-Cog 3b assesses only memory 
and has a scoring range of 0 to 30.12 
Baseline Discrimination. ADAS-Cog 3b scores for 382 subjects with MCI (mean=8.23 
points, SD=3.76) were on average lower than those of 97 subjects with mild AD 
(mean=15.95 points, SD=4.15).12 Podhorna et al. (2016) further divided the 382 subjects 
with MCI into two groups depending on whether CSF and APOEe4 biomarkers of AD 
pathology were present. The enriched MCI subgroup (n=206) had worse scores at 
baseline (mean=9.43 points, SD=3.92) on the ADAS-Cog 3b than the non-enriched MCI 
subgroup (n=176, mean=6.82 points, SD=3.02).12 Podhorna et al. (2016) also found 
scores on the ADAS-Cog 11 were lower in MCI (mean=9.50 points, SD=4.29) than mild 
AD (mean=19.66 points, SD=6.30) groups, and in the non-enriched (mean=7.94 points, 
SD=3.50 points) compared to the enriched MCI subgroup (mean=10.83, SD=4.46).12 
Tests of statistical significance for these differences were not performed.  
Disease progression. Podhorna et al. (2016) found very little change on the ADAS-Cog 
3b in 382 subjects with MCI over 24 months (mean=0.71 points, SD=3.56) and in 169 
subjects with MCI over 36 months (mean=1.23 points, SD=4.00).12 There was very little 
change in the enriched MCI subgroup (mean 24 month change=1.48 points, SD=3.78; 
mean 36 month change=2.55 points, SD=4.40), and almost no change in the non-enriched 
subgroup (mean 24 month change=-0.19 points, SD=3.06; mean 36 month change=-0.25 
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points, SD=5.12).12 Among 97 subjects with mild AD there was also very little change in 
mean ADAS-Cog 3b score over 12 months (mean=1.82 points, SD=3.91) and 24 months 
(mean=3.81 points, SD=5.12).12 The SRM for change over 24 months in 382 subjects 
with MCI was 0.42 (95% CI 0.20, 0.61) for the ADAS-Cog 3b and 0.37 (95% CI 0.15, 
0.57) for the ADAS-Cog 11, adjusting for baseline MMSE, age, sex, APOEe4 allele.12  
The SRM for change over 12 months in 97 subjects with mild AD was 0.81 (95% CI 
0.43, 1.09) for the ADAS-Cog 3b and 0.87 (95% CI 0.46, 1.13) for the ADAS-Cog 11, 
adjusting for baseline MMSE, age, sex, APOEe4 allele.12 SRMs were not statistically 
different from each other (all P>0.10).12  
Summary. The ADAS-Cog 3b appeared able to discriminate between groups of subjects 
with MCI and mild AD, however responsiveness to disease progression in MCI or mild 
AD was not superior to the ADAS-Cog 11. Responsiveness to treatment effects was not 
assessed.  
3.3.23 ADAS-Cog 5 
Podhorna et al. (2016) created the ADAS-Cog 5 by adding to the ADAS-Cog 3b Delayed 
Word Recall, and Digit Cancellation tasks.12 The additional tasks assess attention and 
executive function, and the ADAS-Cog 5 is scored from 0 to 45.12  
Baseline Discrimination. ADAS-Cog 5 scores for 382 subjects with MCI (mean=13.96 
points, SD=6.17) were lower than those of 97 subjects with mild AD (mean=26.20 points, 
SD=5.31).12 The 382 subjects with MCI were further divided into two groups depending 
on whether CSF and APOEe4 biomarkers of AD pathology were present.12 The enriched 
MCI subgroup (n=206) had worse scores on the ADAS-Cog 5 at baseline (mean=16.12 
points, SD=6.28) than the non-enriched subgroup (n=176, mean=11.43 points, 
SD=4.99).12 Statistical significance of the above differences was not tested.  
Disease progression. Podhorna et al. (2016) found almost no change on the ADAS-Cog 
5 in 382 subjects with MCI over 24 months (mean change=1.13 points, SD=4.87) or in 
168 subjects with MCI over 36 months (mean change=1.95 points, SD=5.58).12 There 
was very little difference in the enriched MCI subgroup (mean 24 month change=2.21 
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points, SD=5.58; mean 36 month change=3.82 points, SD=6.03), and in the non-enriched 
subgroup scores there was no meaningful change (mean 24 month change=-0.11 points, 
SD=4.12; mean 36 month change=-0.16 points, SD=4.15).12 Among 97 subjects with 
mild AD there also was very little change on the ADAS-Cog 5 score over 12 months 
(mean change=2.64 points, SD=4.39) and 24 months (mean change=5.48 points, 
SD=6.13).12 The SRM for the ADAS-Cog 5 for 382 subjects with MCI over 24 months 
was 0.42 (95% CI 0.19, 0.63), adjusting for baseline MMSE, age, sex, APOEe4 allele.12 
The SRM for change on the ADAS-Cog 5 over 12 months in 97 subjects with mild AD 
was 0.93 (95% CI 0.52, 1.22), adjusting for baseline MMSE, age, sex, APOEe4 allele.12 
SRMs for the ADAS-Cog 5 were not significantly different than SRMs for the ADAS-
Cog 11, ADAS-Cog 13, or ADAS-Cog 3b (all P>0.10).12  
Summary. The ADAS-Cog 5 appeared able to discriminate between groups of subjects 
with MCI and mild AD, however responsiveness to disease progression in MCI was not 
superior to the ADAS-Cog 11. Responsiveness to treatment effects was not evaluated.  
3.3.24 ADAS-13 Re-Weighted 
Grochowalski et al. (2016) created three different versions of the ADAS-Cog 13 (Section 
3.3.1) using data from 153 subjects with AD and 352 subjects with MCI in an effort to 
improve reliability of ADAS-Cog 13 change scores.87 Improved reliability would reduce 
variability and ultimately improve the ability of the ADAS-Cog 13 to track changes in 
cognition over time. The three versions included a re-weighted ADAS-Cog 13, a 
lengthened ADAS-Cog 13, and a re-weighted and lengthened ADAS-Cog 13.87 To obtain 
these three different variants the ADAS-Cog 13 was divided into three subsections based 
on task scoring procedures.87 Each section was given a separate weight, calculated as the 
number of tasks in that section divided by the total number of tasks in the test.87 This 
resulted in a section of verbal memory with weight 0.10, a section of clinician-rated tasks 
with weight 0.45, and a section for general cognitive tasks with weight 0.45.87 
Lengthening the test, either with or without re-weighting, did not substantially improve 
score reliability so the authors concluded that the ADAS-Cog 13 with re-weighted 
sections was the best variant for improving reliability of change scores (ADAS-13RW).87 
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Criterion validation was performed by analysing correlations between the ADAS-13RW 
and the ADAS-11, ADAS-13, RAVLT, and MMSE.87  
Disease progression. Reliability of change scores of the ADAS-13RW was better than 
the ADAS-Cog 13, but only of an “acceptable” magnitude for change scores defined by 
cut-score dependability (compare subject’s scores to pre-set criterion value of 4 points 
change).87 Relative change score reliability (rank subject’s change relative to another 
subject’s change) and absolute change score reliability (estimate of subject’s true 
individual change score) were not of an acceptable magnitude.87  
Summary. Re-weighting and/or lengthening the ADAS-Cog 13 did not improve the 
reliability of change scores for MCI to a level recommended for assessing meaningful 
clinical change. Assessments of responsiveness were not performed.   
3.3.25 Alzheimer’s Disease Composite Score 
Wang et al. (2016) developed the Alzheimer’s Disease Composite Score (ADCOMS) 
from outcome measures previously shown to be sensitive to AD-specific clinical decline 
and treatment effects in subjects with MCI.88 A partial least squares procedure was used 
to fit a linear model characterizing disease progression and variable importance 
projections (VIP) for numerous candidate items.88 The ADCOMS was derived by 
combining the twelve items that demonstrated a VIP value of 0.8 or greater using their 
partial least squares coefficients as a weighting factor.88 Specific items included four 
ADAS-Cog 12 tasks (Delayed Word Recall, Orientation, Word Recognition, Word 
Finding Difficulty), two MMSE items (Orientation time, Drawing), and six CDR-SB 
items (Personal Care, Community Affairs, Home and Hobbies, Judgement and Problem 
Solving, Memory, Orientation).88 
Disease progression. The 12-month SRM of the ADCOMS (0.419) was larger than that 
of the ADAS-Cog 12 (0.196), MMSE (0.221), and CDR-SB (0.353) for a pooled aMCI 
sample, as well as subgroups of aMCI subjects with genetic or CSF AD biomarkers 
present.88  
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Treatment effect. The ADCOMS was able to detect a statistically significant treatment 
effect for donepezil compared to placebo for aMCI participants (P=0.02), which was also 
found by the MMSE (P=0.02), but not by the ADAS-Cog 12 (P=0.12) or CDR-SB 
(P=0.11).88 The ADCOMS did not find a statistically significant effect for vitamin E in 
subjects with aMCI (P=0.89), nor did the ADAS-Cog 12 (P=0.76), MMSE (P=0.59), or 
CDR-SB (P=0.42).88 The ADCOMS was also able to detect a statistically significant 
treatment effect for donepezil in subjects with mild AD (P<0.0001) as did the ADAS-Cog 
12 (P=0.0008), MMSE (P=0.001), and CDR-SB (P=0.02).88  
Summary. The ADCOMS demonstrated better responsiveness to disease progression and 
treatment effects in MCI than the ADAS-Cog 12, but the ADAS-Cog 11 was not 
analyzed. Tests of baseline discrimination were also not performed. 
3.3.26 Summary of Modifications Made to the ADAS-Cog 11 
A total of thirty-one modifications of the ADAS-Cog 11 were found. Five of these 
modifications altered the scoring methodology for the original ADAS-Cog 11, four 
maintained the original scoring methodology and added additional tasks, and twenty-two 
altered both scoring methodology and included additional item content.  
Results from studies which compared the modified outcome measure to the ADAS-Cog 
11 suggested that 13 modification approaches demonstrated responsiveness to group-level 
between person differences in stage of disease progression at one point in time (baseline 
discrimination), seven improved responsiveness to group-level within-person observed 
change measured over time (disease progression; natural history) for MCI samples, three 
were more responsive to this type of change than the ADAS-Cog 11 for dementia 
samples, and five were more responsive to this type of change than the ADAS-Cog 11 in 
samples with various levels of cognitive ability (mixed dementia and pre-dementia 
syndromes). One modification was found to improve responsiveness to group-level 
between-person differences of within-person observed change over time (treatment 
effect) in subjects with NC, ten were more responsive to treatment effects in subjects with 
MCI, and six were more responsive to treatment effects in subjects with dementia than 
the ADAS-Cog 11. It is possible that several of the other modified versions of the ADAS-
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Cog 11 also improved performance, but these have not yet been evaluated or compared to 
the ADAS-Cog 11. In general, the CV (Section 2.2.5 for more information on CV) for the 
ADAS-Cog 11 and modified versions was reduced as disease severity worsened, and 
several of the modifications reduced the CV within each diagnostic category of NC, MCI, 
and dementia (Appendix A). 
3.4 Summary of Chapter 3 
The ADAS-Cog 11 was developed to assess cognitive dysfunction in moderate to severe 
AD. Since the time of development there has been a shift in the field of dementia research 
towards studying pre-dementia syndromes. The ADAS-Cog 11 continues to be used for 
these pre-dementia studies, however its performance is limited due to ceiling effects, 
suboptimal scoring methodology, and poor content validity. Modifying the scoring 
methodology of the ADAS-Cog 11 improves its responsiveness to several types of 
change, as does adding additional item content. In particular, tasks assessing EF, delayed 
recall, and daily functioning, which are now known to be important components of pre-
dementia disease severity and progression, improve the content validity of the ADAS-
Cog 11 as well as its responsiveness. None of the modifications of the ADAS-Cog 11 
included assessments of motor performance, which has also been shown to be an 
important component of pre-dementia syndromes and disease progression.  
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Chapter 4  
4 Research Question and Objectives 
The purpose of Chapter 4 is to present the research question and objectives of this thesis.   
4.1 Research Question 
Does adding assessments of motor function to the Alzheimer’s Disease Assessment 
Scale-Cognitive Subscale (ADAS-Cog 11) improve responsiveness among older adults 
with pre-dementia syndromes, wherein responsiveness is contextualized by the type of 
change being assessed? 
We hypothesized that adding assessments of motor function to the ADAS-Cog 11 using a 
pooled index approach would improve responsiveness in a sample of older adults with 
Normal Cognition (NC), Subjective Cognitive Impairment (SCI), and Mild Cognitive 
Impairment (MCI).  
4.2 Objectives 
4.2.1 Objective 1 
Use a pooled index approach to develop an outcome measure that can be backwards 
compatible to the ADAS-Cog 11 and includes measures of quantitative gait and dual-task 
gait cost.  
4.2.2 Objective 2 
Compare the responsiveness of the ADAS-Cog 11* and the novel outcome measure to 
group-level between-person differences in stage of pre-dementia disease progression at 
one point in time (baseline discrimination between groups of subjects classified as having 
NC, SCI, MCI). 
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4.2.3 Objective 3 
Compare the responsiveness of the ADAS-Cog 11*, the novel outcome measure, and the 
ADAS-Cog combined, using a pooled index approach, with each individual component of 
the novel outcome measure to group-level within-person observed change over time in 
subjects with pre-dementia levels of impairment (disease progression or measured change 
over the course of a prospective cohort study). 
4.3 Conclusion  
The next chapter provides an overview of the rationale, methods, and results pertaining to 
the research question and objectives.  
*Note: Secondary data analysis was used to achieve these objectives. Due to limitations 
in the availability of data, not all necessary assessments of older adults with pre-dementia 
syndromes were present in a single database. To obtain a preliminary answer to the 
research question, a statistical model was developed and then used to estimate ADAS-
Cog 11 scores in a database with quantitative motor function assessments. Details about 
this “ADAS-Cog-Proxy” model are summarized in Chapter 5 (Section 5.2.2.1), and 
described in detail in Chapter 6 (Section 6.1.1). 
 
 
   106 
 
Chapter 5  
5 Integrated Article: Cognition and Motor Function: The 
Gait and Brain Pooled Index 
Chapter 5 includes a version of a manuscript that will be submitted to the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) for review, and then pending approval by 
ADNI, to the Journals of Gerontology: Medical Sciences for publication. Due to the 
nature of an integrated manuscript thesis format, there is some overlap between the 
information presented in Chapter 5 and the rest of the thesis. Also, in the interest of 
clarity the ADAS-Cog 11 is simply referred to as the ADAS-Cog throughout Chapter 5. 
Please see Chapter 6 for more detailed methods and results, which go beyond what may 
be submitted for a peer reviewed publication.  
In accordance with the ADNI data use agreement, on the by-line of the submitted 
manuscript, after the named authors, the phrase “for the Alzheimer’s Disease 
Neuroimaging Initiative*” will be included, with the asterisk referring to the following 
statement: “*Data used in preparation of this article were obtained from the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the 
investigators within the ADNI contributed to the design and implementation of ADNI 
and/or provided data but did not participate in analysis or writing of this report. A 
complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-
content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf”.  
5.1 Introduction 
The Alzheimer’s Disease (AD) Assessment Scale–Cognitive Subscale (ADAS-Cog) was 
developed in 1984 for the purpose of assessing cognitive dysfunction in AD.1 Since then, 
the ADAS-Cog became widely adopted for use in studies of AD and related disorders, 
and is now considered the ‘gold standard’ for assessing treatment efficacy in clinical trials 
of antidementia medications. However, two shifts in the field since its development have 
called into question the continued use of the original ADAS-Cog. The first shift has been 
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towards studying pre-dementia syndromes, such as Mild Cognitive Impairment (MCI), 
and testing interventions aimed at slowing or preventing progression to dementia rather 
than intervening at the dementia stage. The second shift includes postulating motor 
function as an important component of dementia and pre-dementia syndromes. These 
shifts have elicited the need for an outcome measure that reflects current research focus, 
incorporates all important disease components, and is more responsive than the ADAS-
Cog to clinically important changes in pre-dementia syndromes.  
In short, responsiveness is a form of validity defined as the ability to accurately detect 
change.2–5 Change can be contextualized using three aspects: group versus individual 
level of measurement, between-person versus within-person comparison, and the type of 
change one is interested in detecting.5 The responsiveness of any outcome measure is 
population and context specific.3,5  
While the ADAS-Cog has demonstrated responsiveness to multiple types of change in 
dementia populations, concerns have been raised about its responsiveness at pre-dementia 
stages where changes are subtler in magnitude and slower in rate of progression. Several 
modifications have improved the responsiveness of the ADAS-Cog in pre-dementia 
syndromes. These include alternative scoring applied to the original summation of errors 
made across ADAS-Cog tasks that gives a final score from 0 to 70, removing tasks with 
ceiling effects, and the addition of higher order assessments of delayed word recall, 
executive function, or the ability to perform activities required for daily independent 
living.6–14 The advantage of modified measures that are backwards compatible with the 
original ADAS-Cog is that they maintain consistency with previous studies and do not 
become a limiting factor if one wants to compare novel study findings with the large 
literature base that has used the ADAS-Cog. To ensure backwards compatibility, the 
ADAS-Cog must be administered in its original form so that raw scores may be obtained 
regardless of any modifications made thereafter. 
The emergence of motor function decline as a potential biomarker for dementia and pre-
dementia syndromes opens a unique opportunity for precise objective motor function tests 
to help assess severity or stages of disease impairment not captured by traditional 
cognitive tests.15,16 Poor performance on motor function tests has been associated with an 
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increased risk of disease progression,17-22 and combined cognitive and motor function 
impairments have been associated with a greater risk of further cognitive decline and 
conversion to dementia than either component alone.23,24 The mechanistic rationale for 
motor function being an integral component of dementia and pre-dementia syndromes is 
that neuropathology which contributes to cognitive impairment traditionally associated 
with dementia may also give rise to motor impairment.15,25,26 Brain regions hypothesized 
to underlie simultaneous decline in cognition and motor function, such as gait control, 
includes the frontal and temporal lobes, and frontal-hippocampal and thalamic-striatal 
circuits.15,25,26 Quantitative gait parameters, such as velocity or variability in step time, 
have been associated with concurrent levels of global and domain specific cognitive 
ability, have demonstrated the ability to discriminate between subtypes of MCI, and have 
shown responsiveness to changes in cognition over time.17,19,23,27-30 Changes in gait 
parameters between when a participant is asked to walk as they usually would and while 
performing a cognitive task, termed dual-task cost (DTC), have also been associated with 
cognitive abilities and pre-dementia syndromes.28,31 Importantly, the ability to maintain 
gait control while walking and thinking (low DTC) underlies functionality, defined as the 
ability to perform daily activities required for independent living, such as cooking and 
cleaning.32  
A review of the literature failed to reveal an outcome measure developed for any 
population that includes the addition of single-task motor assessments or DTC to the 
ADAS-Cog. We hypothesized that adding assessments of motor function to the ADAS-
Cog would improve responsiveness among older adults with pre-dementia syndromes. 
Due to the lack of a database with both the ADAS-Cog and quantitative motor 
assessments, we developed a statistical model that uses alternative cognitive outcome 
measures to approximate ADAS-Cog scores (ADAS-Cog-Proxy). This ADAS-Cog-Proxy 
model was applied in a database that includes the necessary alternative cognitive 
measures and quantitative gait assessments. Our objectives were: 1) use a pooled index 
(PI) approach33,34 to develop an outcome measure that can be backwards compatible to 
the ADAS-Cog and includes quantitative gait and DTC assessments, 2) compare the 
responsiveness of the ADAS-Cog-Proxy and the novel PI to group-level between-person 
differences in stage of disease progression at one point in time (baseline discrimination), 
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and 3) compare the responsiveness of the ADAS-Cog-Proxy, the novel PI, and the 
ADAS-Cog-Proxy combined using a PI approach with each individual component of the 
novel PI, to group-level within-person measured change over time in a pre-dementia 
sample (disease progression). 
5.2 Methods 
5.2.1 Study Population  
The Gait and Brain Study (GABS) is an ongoing prospective cohort study based in 
London, Ontario aimed at assessing how changes in gait may precede dementia and falls 
(Research Ethics Board approval number 17200). Participant recruitment began in 2007 
from Geriatrics and Memory clinics at hospitals affiliated with Western University. 
Inclusion criteria were 65 to 85 years old, able to walk 10 meters without assistance, and 
absence of dementia. Exclusion criteria were lack of English proficiency, Parkinsonism or 
other neurological disorder affecting motor function (e.g. stroke), musculoskeletal 
disorders or joint replacements that affect gait performance (clinician assessed), 
osteoarthritis affecting lower limbs, use of psychotropics that can influence motor 
performance (e.g. benzodiazepines), and major depression. Eligible participants were 
divided into three diagnostic categories based on performance in cognitive testing and 
clinical evaluation. Normal Cognition (NC) criteria included normal age-, sex-, and 
education-adjusted scores on the Mini-Mental State Examination (MMSE) and Montreal 
Cognitive Assessment. Subjective Cognitive Impairment (SCI) criteria were the same as 
that for NC, except patients reported persistent decline in cognition that was not 
explainable by an acute event, and answered yes to both, “Do you feel like your memory 
or thinking is becoming worse?” and “Does this concern you?”. MCI criteria included 1) 
a score of 0.5 on the Clinical Dementia Rating (CDR) Scale, 2) subjective cognitive 
complaints, 3) measured cognitive impairment in memory, executive function, attention, 
and/or language domains 4) intact Lawton-Brody Activities of Daily Living, and 5) 
absence of dementia based on Diagnostic and Statistical Manual of Mental Disorders 
version IV-TR or V criteria.35,36 Additional information can be found at clinicaltrial.gov, 
study identifier NTC03020381. 
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5.2.2 Measures 
5.2.2.1 Cognition  
ADAS-Cog-Proxy scores were estimated in GABS using a generalized additive model 
(GAM)37-39 developed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), 
which contains the ADAS-Cog as well as several cognitive measures administered in the 
GABS.  
The ADNI began in 2003 as a public-private study partnership with the primary goal of 
testing whether neuroimaging, biological, clinical, and neuropsychological assessments 
can be combined to measure progression from MCI to early AD (adni.loni.usc.edu). Dr. 
Michael W. Weiner is the Principal Investigator of ADNI, and study sites are located 
throughout North America. Frequently updated information on ADNI can be found at 
www.adni-info.org. ADNI data was downloaded on October 26, 2016. 
The process from ADAS-Cog-Proxy development to estimation in GABS is outlined in 
Figure 7 as five key steps (grey boxes), which are briefly described below. 
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Figure 7 ADAS-Cog-Proxy model development and application. 
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Participants in the first of three ADNI phases (ADNI 1) with NC or MCI were divided 
into a 70% subset for model development and a 30% subset for testing model accuracy 
(Step 1). Five candidate models were constructed in the development subset (Step 2), and 
preliminary accuracy was assessed as the percentage (%) of participants for whom each 
candidate model predicted ADAS-Cog scores within three points of their observed 
(‘true’) score; three points is often considered a clinically relevant change.40 Five ADNI 
participants were missing at least one covariate value for candidate Model 5 (M5) and 
were excluded solely from analyses that included M5. Diagnostics for all candidate 
models were assessed in the development subset (Appendix B, Figures B.1 to B.5). 
The best candidate model was selected based on preliminary accuracy estimates in the 
development subset and on similarity of covariates to ADAS-Cog tasks such that they 
assessed cognitive domains covered by the ADAS-Cog (memory, language, praxis) with 
minimal coverage of additional areas. Accuracy of the best candidate model was 
estimated (Step 3) using ‘new’ ADNI participants in the testing subset as the percentage 
of participants who had scores predicted within three and five points of their true ADAS-
Cog scores. Spearman’s rank correlation (rho) between predicted and observed scores 
was also calculated. The final GAM used for estimation of ADAS-Cog-Proxy scores in 
GABS was built on recombined development and testing subsets (Step 4).38 In order to 
obtain ADAS-Cog-Proxy scores for all participants in GABS, Multivariate Imputation by 
Chained Equations (MICE) was used to impute missing GAM covariate values (Step 
5).41,42 Predictor variable selection was guided by the suggestions of van Buuren et al.41 
and included diagnostic, cognitive, functional, and motor assessments. Five imputed 
datasets were created using the imputation method of predictive mean matching. Imputed 
values were viewed to ensure plausibility, and imputation streams plotted to assess 
convergence (Appendix B, Figures B.6 to B.11). The ADAS-Cog-Proxy GAM was 
applied to each of the five imputed data sets, and the mean of the five estimated scores for 
each participant taken as their final ADAS-Cog-Proxy score. This process of imputing 
missing covariate values, applying the GAM to each completed dataset, and then 
averaging the five estimated ADAS-Cog-Proxy scores was repeated for 6, 12, 24, 36, and 
48 month follow-up visits.  
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5.2.2.2 Motor function  
Quantitative gait performance was assessed under four conditions using an electronic 
walkway system (GAITRite™). To avoid capturing acceleration and deceleration phases, 
start and end points of the walkway were marked one metre away from the ends of a 6-
metre recording distance. The four testing conditions were one single-task condition 
where participants were asked to walk as they usually would, and three dual-task 
conditions (see below). Reliability of gait parameters under single and dual-task 
conditions have been described elsewhere.43 The following spatio-temporal gait 
parameters were captured: velocity (cm/s), stride time (ms), step time (ms), stride length 
(cm), step length (cm), double support time (ms), swing time (ms), stride width (cm), 
stride velocity (cm/s), and cadence (steps/min). The Coefficient of Variation 
(CV=Standard Deviation (SD)/Mean*100) standardizes variability estimates to mean 
values, thus allowing direct comparison of variability across variables measured using 
different units. The CV was calculated for all gait parameters except velocity. 
5.2.2.3 Motor-cognitive performance  
The dual-task gait paradigm was used to capture motor-cognitive performance. The three 
dual-task gait conditions included walking as usual while: i) counting backwards from 
100 by ones, ii) counting backwards from 100 by sevens, and iii) naming animals. 
Participants were not instructed to prioritize the cognitive or walking task. DTC (%) was 
calculated for three gait parameters under all three secondary task conditions, using the 
formula: [(single-task condition – dual-task condition)/single-task condition]*100.31 The 
three parameters of velocity, stride time, and stride time CV were selected based on 
literature supporting their importance in dementia and pre-dementia syndromes.16,28,31,43  
5.2.3 Data Analysis 
5.2.3.1 Outcome measure development  
Advantages of using a PI approach for our outcome measure are that it allows variables 
with different scoring ranges to be combined into a single summary score, and when 
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component variables have low pairwise correlations the SD of the derived score decreases 
as the number of variables increases.34,45 PI scores were obtained by first ensuring all 
variables were coded so that higher values indicate greater dysfunction, calculating Z-
scores for each variable (Z=(observation – group mean) / SD), and then averaging those 
Z-scores.33,45 The statistical advantages of the PI diminish after six component variables, 
and are greatest when pairwise correlations are less than 0.2, and slightly less so up to 
0.4.34  
Variable selection for our PI was thus guided by pairwise correlation coefficients and by 
theoretical considerations. For example, we aimed to include at least one variable from 
each of the categories of cognition, motor function, and motor-cognitive performance, by 
selecting at least one single-task and at least one DTC variable to combine with the 
ADAS-Cog-Proxy. To do this we first assessed pairwise correlations between the ADAS-
Cog-Proxy and each of the single-task and DTC gait variables separately. Variables were 
retained when |rho|<0.2 or when |rho|=0.2 to 0.4 with evidence supporting that 
parameter’s involvement in dementia or pre-dementia syndromes. Pairwise correlation 
coefficients were calculated for all retained single-task gait and DTC variables. In looking 
for at least one weakly intercorrelated pair, when numerical considerations were similar, 
we chose variables that had greater evidence from previous studies supporting their 
involvement in pre-dementia or dementia syndromes. When both numerical and 
theoretical considerations were similar, box plots were created to assess which of the 
contending individual gait or DTC parameters, if any, demonstrated a stepwise 
progression from NC to SCI to MCI diagnostic categories. Scatterplots were consulted to 
ensure low correlations were not the result of a strong non-linear relationship. Ease of 
assessment was also considered for both individual variables and the PI as a whole.  
5.2.3.2 Baseline discrimination  
Due to skewness and small sample sizes non-parametric tests were used to evaluate 
responsiveness to baseline discrimination. Kruskal-Wallis tests were used to assess 
whether the ADAS-Cog-Proxy and PI could detect a significant difference among the 
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diagnostic categories of NC, SCI, and MCI. Mann-Whitney U tests were used to assess 
all pairwise comparisons.  
5.2.3.3 Change over time 
Standardized Response Means (SRM=mean difference score/SD of difference score) 
were calculated for 6, 12, 24, 36, and 48 month follow-up periods for the PI, the ADAS-
Cog-Proxy, and the ADAS-Cog-Proxy plus each individual component of the PI 
combined using a PI approach. Standardization was always performed with respect to the 
baseline distribution of participants present at the follow-up visit of interest. No 
distinction was made between diagnostic categories for SRM calculations.  
All analyses were conducted with RStudio, version 1.0.136.46  
5.3 Results 
5.3.1 Baseline Characteristics 
Baseline characteristics for the 573 ADNI participants used to build the ADAS-Cog-
Proxy GAM can be found in Table 9, and for the 109 participants in GABS in Table 10. 
One GABS participant with SCI did not have single-task gait recorded at baseline and 
was omitted from PI development and subsequent analyses. GABS participants who 
converted to dementia were included in analyses for time points prior to their dementia 
diagnosis. Two participants converted by six months of follow-up, one by 12 months, 
four by 24 months, and one by 36 months. A summary of the number of missing GAM 
covariates that were imputed using MICE can be found in Chapter 6 (Table 14). 
Table 9 Alzheimer's Disease Neuroimaging Initiative Baseline Characteristics 
Characteristic 
Mean (SD) 
Minimum, Maximum 
Number of missing values (if applicable) 
unless otherwise specified 
Overall (n=573) 
Age (years) 75.17 (6.56) 
54.40, 89.60 
Education (years) 15.84 (2.94) 
6.00, 20.00 
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Sex 
Female n (%) 
Male 
 
228 (40%) 
345 
Alzheimer’s Disease Assessment Scale-
Cognitive Subscale 
9.51 (4.63) 
0, 28 
Mini-Mental State Examination 27.78 (1.84) 
23, 30 
Rey Auditory Verbal Learning Test  
(3 trials) 
18.34 (5.64) 
5, 38 
Clinical Dementia Rating Scale-Sum of 
Boxes 
1.02 (1.03) 
0.00, 4.50 
Trail Making Test A 41.41 (20.08) 
17.00, 188.00 
4 
Trail Making Test B 114.8 (65.62) 
34.0, 348.0 
5 
Digit Span Forward Test 6.64 (1.05) 
4, 8 
Digit Span Backward Test 4.71 (1.19) 
0, 7 
 
Table 10 Gait and Brain Study Baseline Characteristics 
Characteristic 
Mean (SD) 
Minimum, Maximum 
Number of missing 
values (if applicable) 
unless otherwise 
specified 
Overall 
(n=109) 
Normal 
Cognition 
(n=12) 
Subjective 
Cognitive 
Impairment 
(n=19) 
Mild 
Cognitive 
Impairment 
(n=78) 
Age (years) 
 
74.22 (6.33) 
63.00, 92.00 
73.50 (4.58) 
67.00, 82.00 
70.00 (4.59) 
65.00, 85.00 
75.36 (6.52) 
63.00, 92.00 
Education 
(years) 
13.85 (2.92) 
6.00, 20.00 
16.33 (3.06) 
10.00, 20.00 
14.42 (2.81) 
10.00, 20.00 
13.33 (2.74) 
6.00, 20.00 
Sex 
Female n (%) 
Male 
 
58 (53) 
51 
 
7 (58) 
5 
 
15 (79) 
4  
 
36 (49) 
42  
Medications (#) 
 
7.62 (4.52) 
0, 21 
6.42 (4.06) 
2, 16 
6.53 (5.26) 
0, 21 
8.06 (4.37) 
0, 21 
Comorbidities 
(#) 
6.06 (2.85) 
0, 13 
4.33 (1.44) 
2, 7 
4.79 (2.02) 
1, 8 
6.64 (2.98) 
0, 13 
Geriatric 
Depression 
Scale 
2.35 (2.14) 
0, 10 
22 
1.60 (1.14)  
0, 3 
7 
2.25 (1.89) 
1, 5 
15 
2.40 (2.21) 
0, 10 
0 
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General 
Physical 
Activity Level 
Vigorous: n (%) 
Moderate: n (%) 
Seldom: n (%) 
Missing: n 
 
 
 
63 (58) 
29 (27) 
16 (25) 
1 
 
 
 
6 (50) 
5 (42) 
1 (8) 
 
 
 
13 (68) 
4 (21) 
2 (11) 
 
 
 
 
44 (56) 
20 (26) 
13 (17) 
1 
Lawton-Brody 
Activities of 
Daily Living 
5.99 (0.11) 
5, 6 
22 
6.00 (0.00) 
6, 6 
7 
5.75 (0.50) 
5, 6 
15 
6.00 (0.00) 
6, 6 
0 
Instrumental 
Activities of 
Daily Living 
7.69 (0.94) 
2, 8 
22 
8.00 (0.00) 
8, 8 
7 
7.75 (0.50) 
7, 8 
15 
7.67 (0.99) 
2, 8 
0 
Basic Activities 
of Daily Living 
0.42 (0.97) 
0, 5 
22 
0.80 (0.84) 
0, 2 
7 
0.75 (0.96) 
0, 2 
15 
0.38 (0.98) 
0, 5 
ADAS-Cog-
Proxy 
9.46 (2.34) 
3, 16 
7.59 (1.32) 
4, 9 
7.96 (1.93) 
3, 12 
10.11 (2.24) 
5, 16 
Montreal 
Cognitive 
Assessment  
24.45 (3.82) 
12, 30 
27.25 (1.48) 
24, 30 
27.89 (2.45) 
21, 30 
23.18 (3.60) 
12, 30 
Mini-Mental 
State 
Examination 
27.74 (2.52) 
18, 30 
28.83 (1.80) 
24, 30 
28.89 (1.45) 
24, 30 
27.29 (2.69) 
18, 30 
Clinical 
Dementia 
Rating Scale 
0.99 (0.89) 
0.0, 4.0 
68 
0.0 (0.0) 
0.0,0.0 
9 
 
 
19 
1.07 (0.88) 
0.0, 4.0 
40 
Rey Auditory 
Verbal Learning 
Test (3 trials) 
17.20 (5.35) 
8.0, 33.0 
29 
23.40 (5.18) 
19.0, 32.0 
7 
24.75 (6.65) 
17.0, 33.0 
15 
16.34 (4.71) 
8.0, 28.0 
7 
Gait Velocity 
(cm/s)  
  
108.40 
21.27 
57.27, 165.2 
1 
124.80 
15.78 
99.65, 155.80 
114.10 
17.59 
82.17, 141.00 
 
104.60 
21.47 
57.27, 165.20 
Stride Time (s)  
 
1.14 (0.10) 
0.93, 1.41 
1 
1.11 (0.08) 
0.95, 1.20 
1.10 (0.08) 
0.97.0, 1.26 
1 
1.16 (0.10) 
0.93, 1.41 
 
Stride Time 
Coefficient of 
Variation (CV) 
(%) 
2.47 (1.48) 
0.62, 9.73 
1 
2.08 (0.76) 
1.14, 4.04 
2.49 (2.02) 
1.16, 9.73 
1 
2.53 (1.43) 
0.62, 7.89 
Dual-Task Gait 
Velocity Cost 
with Counting 
(%) 
5.51 (10.68) 
-16.04, 34.61 
1 
3.10 (11.52) 
-8.16, 34.61 
 
2.58 (5.48) 
-11.05, 10.82 
1 
6.55 (11.35) 
-16.04, 31.12 
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Dual-Task 
Stride Time 
Cost with Serial 
Sevens (%) 
-16.93 (18.42) 
-75.93, 6.30 
3 
-24.06 (29.08) 
-75.93, 3.74 
-8.23 (9.87) 
-38.54, 2.74 
1 
-17.86 (17.37) 
-69.50, 6.30 
2 
Dual-Task 
Stride Time CV 
Cost with 
Naming 
Animals (%) 
-133.40 
(270.66) 
-1382.00, 
77.58 
1 
-214.80 
(416.11) 
-1382.0, 63.87 
-44.54  
(80.73) 
-240.3, 53.55 
1 
-141.30 
(269.59) 
-1200.00, 
77.58 
 
5.3.2 ADAS-Cog Proxy Model 
Covariates for the GAM selected to estimate ADAS-Cog-Proxy scores included the sum 
of the first three trials of the Rey Auditory Verbal Learning Test (RAVLT), the MMSE, 
and the CDR-Sum of Boxes (CDR-SB) score. This ADAS-Cog-Proxy model estimated 
69% of participant scores within three points and 88% of participant scores within five 
points of their observed (‘true’) ADAS-Cog score in the testing subset of ADNI (Figure 
7). Spearman’s rank correlation coefficient between predicted and observed ADAS-Cog 
scores was 0.70 (P<0.001). Baseline ADAS-Cog-Proxy scores in GABS are included in 
Table 10.   
5.3.3 Gait and Brain Pooled Index 
Variables selected for inclusion in the PI include the ADAS-Cog-Proxy, gait velocity 
multiplied by negative one, and DTC for gait velocity with the secondary task of counting 
backwards from 100 by ones. Pairwise correlation coefficients ranged in magnitude from 
0.27 to 0.32 (Chapter 6, Table 20).  
5.3.4 Baseline Discrimination  
Both the ADAS-Cog-Proxy and the PI showed an overall statistically significant 
difference in mean ranks across the three diagnostic categories (ADAS-Cog-Proxy: 
Kruskal-Wallis H(2) value=24.13; PI: H(2)=22.36, both P<0.001). Statistically significant 
pairwise comparisons were found for SCI versus MCI (ADAS-Cog-Proxy: Mann-
Whitney U test statistic=331, P=0.0002; PI: U=348, P=0.0009) and NC versus MCI 
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(ADAS-Cog-Proxy: U=153, P=0.0002; PI: U=148, P=0.0001), but not NC versus SCI 
diagnostic categories (ADAS-Cog-Proxy: U=93, P=0.41; PI: U=75, P=0.17). 
5.3.5 Change Over Time 
Adding only gait velocity to the ADAS-Cog-Proxy using a PI approach always increased 
responsiveness to decline (less negative or more positive SRM), while adding only DTC 
to the ADAS-Cog-Proxy showed mixed results (Table 11). The full PI had a larger SRM 
than the ADAS-Cog-Proxy for 6 month (SRM: ADAS-Cog-Proxy=0.14, PI=0.23) and 48 
month (SRM: ADAS-Cog-Proxy=0.60, PI=0.65), but not 36 month (SRM: ADAS-Cog-
Proxy=0.23, PI=0.18) follow-up periods. For 12 and 24 month follow-up periods the 
ADAS-Cog-Proxy detected overall improvement (SRM: 12 month=-0.08, 24 month=-
0.24), while the full PI detected almost no change (SRM: 12 month=0.04, 24 
month=0.01).  
Table 11 Standardized Response Means: Responsiveness to group-level within-person 
measured change over time 
n Time ADASp ADASp+GV ADASp+DTC ADASp+GV+ 
DTC 
(Full PI) 
86 6m 0.14 0.17 
 
0.18 
 
0.23 
73 12m -0.08 -0.05 
 
0.01 0.04 
55 24m -0.24 -0.11 -0.07 
 
0.01 
35 36m 0.23 0.34 
 
0.11 0.18 
24 48m 0.60 0.68 
 
0.59 
 
0.65 
Notes: Comparisons of the magnitude of standardized response means should only be 
made across rows because due to the nature of using data from an ongoing cohort study, 
not all participants have had the chance to reach all follow-up visits, and participants who 
converted to dementia were only included in calculations before the point of conversion. 
Legend: ADASp=Alzheimer’s Disease Assessment Scale-Cognitive Subscale-Proxy, 
DTC=Dual Task Cost (Gait Velocity (GV) with secondary task of counting backwards by 
ones), PI=Pooled Index, m=months. 
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5.4 Discussion 
A PI approach combining assessments of motor function, specifically gait velocity and 
DTC gait velocity, with an ADAS-Cog-Proxy cognitive measure demonstrated 
comparable responsiveness to baseline discrimination between pre-dementia diagnostic 
categories and generally comparable or increased responsiveness to measured change 
over time as compared to the ADAS-Cog-Proxy cognitive measure alone. 
More specifically, both the PI and ADAS-Cog-Proxy detected statistically significant 
differences between NC and MCI, and SCI and MCI predementia diagnostic categories 
but not between NC and SCI. This latter finding may have been due to small sample sizes 
rather than an inability to distinguish between the two mildest stages of disease 
progression. For all but one follow-up period the PI demonstrated greater responsiveness 
than the ADAS-Cog-Proxy to measured decline over time; however, there were two 
follow-up periods where the ADAS-Cog-Proxy detected improvement while the PI 
detected worsening. This group-level improvement measured by the ADAS-Cog-Proxy 
may be capturing the fact that the cognitive trajectory from NC to dementia is not linear 
such that some of the participants with MCI or SCI may have reverted to more normal 
levels of cognition. Also, excluding participants after conversion to dementia removed the 
participants who are expected to have experienced the largest decline. Further research is 
needed to assess whether the PI is detecting a more realistic overall assessment of the 
change in functionality over time than the ADAS-Cog-Proxy, as both cognitive and motor 
function are important for everyday living.  
The improvements in responsiveness to group-level within-person measured change over 
time that occurred by adding gait and DTC assessments to the ADAS-Cog-Proxy were 
made without adding tests of delayed recall or executive function which have previously 
been found to improve the responsiveness of the ADAS-Cog in pre-dementia 
syndromes.8-11 These cognitive abilities are thought to be important in pre-dementia 
syndromes but are not included on the original ADAS-Cog.1,9,47 Our results align with 
research exploring motor function as a biomarker for cognitive impairment and pre-
dementia syndromes.15,28  
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Key advantages of using quantitative gait assessments for outcome measurement include 
language independence, non-invasive administration procedures, avoidance of ceiling 
effects across the disease spectrum, and when DTC is used to assess the impact of a 
secondary cognitive task each participant serves as their own control. Further advantages 
of gait velocity are that it can be easily measured using only a stop watch and defined 
walking distance.  
In addition to our findings that gait parameter tests of motor function may be valuable 
additions to cognitive assessments for use in pre-dementia studies, the creation of the 
ADAS-Cog-Proxy may provide a framework when there is an appropriate research 
question but not all necessary variables present in a single available database. Using a 
predictive model to obtain estimates of a missing variable allows preliminary tests of 
hypotheses without the time and resources that would be required to collect new data.  
Main limitations of our study include small sample sizes, missing data, and reliance on a 
‘proof of principle’ approach as we were unable to use the original ADAS-Cog. Two 
ADAS-Cog-Proxy GAM covariates were collected one month prior to the ADAS-Cog 
administration, which may have contributed extra noise to the GAM development and led 
to an underestimate of accuracy. Furthermore, the inclusion of only two variables on top 
of the ADAS-Cog-Proxy in our PI did not take advantage of statistical advantages that 
may be gained by including additional lowly correlated yet informative variables, such as 
other gait parameters or cognitive tests. Restricting our PI to only gait velocity single and 
DTC with the ADAS-Cog-Proxy represents the trade-off in information value between 
practicality and measurement intensiveness. The derived units of the PI are also difficult 
to interpret and are not directly comparable to ADAS-Cog scores. Selection bias, such as 
towards highly educated participants, may also limit the generalizability of our results. 
Future steps include re-creating the PI using the original ADAS-Cog, assessing 
responsiveness with new participants across all levels of disease severity from NC to 
dementia, and assessing responsiveness to treatment effects in pre-dementia populations. 
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Chapter 6 
6 Detailed Methods  
The purpose of Chapter 6 is to provide a more detailed description of methods and 
supplementary results that are not presented in Chapter 5. To minimize redundancy not all 
methods details and results presented in Chapter 5 also appear in Chapter 6, but some 
overlap was necessary to maintain comprehension. Chapter 6 is organized according to 
thesis objective, and information on the development of the Alzheimer’s Disease 
Assessment Scale-Cognitive Subscale-Proxy measure (ADAS-Cog-Proxy) is included 
under the first objective.  
6.1 Objective 1 
Objective 1 was completed in a three-step process. First, the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database was used to build an ADAS-Cog-Proxy 
statistical model which could be used to obtain estimates of Alzheimer Disease 
Assessment Scale-Cognitive Subscale (ADAS-Cog 11) scores in the Gait and Brain Study 
(GABS) database. This step was necessary as there is no database with both the ADAS-
Cog 11 and quantitative motor assessments, and developing a proxy measure to use a 
‘proof of principle’ approach to the objectives allows a preliminary test of hypotheses 
before investing time and resources in a new study that could collect all necessary 
measures together. Second, additional measures in GABS were selected to add to the 
ADAS-Cog-Proxy. Third, the selected measures and ADAS-Cog-Proxy were combined 
using a pooled index (PI) approach.  
6.1.1 Step 1: Develop an Alzheimer’s Disease Assessment Scale 
– Cognitive Subscale Proxy 
ADNI wave selection and data obtainment. ADNI contains three waves of participants: 
ADNI 1, ADNI Grand Opportunities, and ADNI 2. Of these, ADNI 1 has the largest 
overlap of available cognitive tests with GABS (Table 12), and therefore was selected to 
build the ADAS-Cog-Proxy.  
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Table 12 Cognitive Tests in Available Databases at Baseline 
Tests GABS ADNI1 
ADAS-Cog 11 Total   X 
ADAS-Cog Items  X 
MMSE Total X X 
MMSE Items  X 
MoCA X  
MoCA Subscores X  
CDR-SB X X 
TMTA X X 
TMTB X X 
Digit Span Forward X X 
Digit Span Backward X X 
Letter Number Sequence X  
RAVLT  
(sum of 3 trials) 
X X (via 
item-level 
data) 
BNT X  
FAB X  
Legend: X indicates the test listed in the leftmost column of the row is present in the 
database at the column head. GABS=Gait and Brain Study, ADNI 1=Alzheimer’s Disease 
Neuroimaging Initiative wave 1, ADAS-Cog 11=Alzheimer’s Disease Assessment Scale-
Cognitive Subscale 11 item version, MMSE=Mini-Mental State Examination, 
MoCA=Montreal Cognitive Assessment, CDR-SB=Clinical Dementia Rating Scale-Sum 
of Boxes, TMTA= Trail Making Test Part A, TMTB=TMT Part B, RAVLT=Rey 
Auditory Verbal Learning Test (immediate recall), BNT=Boston Naming Test, 
FAB=Frontal Assessment Battery. Note that ADNI administered a modified version of 
BNT whereby only odd questions were used. This modified version was not directly 
comparable with the full BNT version administered in GABS, and item level data was not 
available in GABS to create an odd question only version.  
Inclusion criteria for ADNI 1 was Hachinski score less than or equal to 4, aged 55 to 90 
years old, stability of ADNI permitted medications, Geriatric Depression Scale less than 
6, study partner with at least 10 hours of contact with the participant per week, visual and 
auditory acuity adequate for neuropsychological testing, good general health, unable to 
bear children, willing and able to complete three year imaging study including no medical 
contraindications to magnetic resonance imaging, education level of grade 6 or work 
history, fluent English or Spanish speaking ability, agrees to DNA for Apolipoprotein 
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(APOE) e4 allele testing and banking, agrees to blood and urine samples for biomarker 
testing, and not enrolled in other trials or studies. There were further inclusion criteria 
specific to diagnostic categories of Normal Control or Cognition (NC), Mild Cognitive 
Impairment (MCI), and Alzheimer’s Disease (AD) groups. Inclusion criteria for NC was 
no abnormal memory complaints, normal memory function scores on the Logical 
Memory II subscale, Mini-Mental State Exam (MMSE) score between 24 and 30, Clinical 
Dementia Rating (CDR) score of 0 and Memory Box score of 0, and no abnormal levels 
of cognitive function or activities of daily living. Inclusion criteria for MCI categorization 
was memory complaint by the participant or participant’s study partner, abnormal 
memory function score on the Logical Memory II subscale, MMSE between 24 and 30, 
CDR score of 0.5 with Memory Box score of at least 0.5, and insufficient cognitive and 
functional impairment to allow a diagnosis of AD. Inclusion criteria for AD will not be 
reviewed as those participants were excluded from analyses in this thesis.  
The online ADNI database is divided into several data tables, which are defined by the 
types of variables they contain. Some overlap between data tables exists. The “Item Level 
Data (ADAS-Cog, ANART, MMSE, etc) [ADNI1]” and “Key ADNI tables merged into 
one table” data tables were downloaded from the ADNI website 
(http://adni.loni.usc.edu/data-samples/access-data/) on October 26, 2016. All cognitive 
test scores were treated as numeric variables. All cognitive tests of interest were 
administered at a single baseline visit except the MMSE and CDR-SB, which were 
administered one month earlier at the ADNI 1 screening visit.  
Baseline observations for participants in ADNI 1 with NC or MCI diagnostic status were 
retained from the “Key ADNI tables merged into one table” data table. 
Baseline data from the “Item Level Data (ADAS-Cog, ANART, MMSE, etc) [ADNI1]” 
data table was used to create a three trial Rey Auditory Verbal Learning Test (RAVLT) 
score. The RAVLT involves reading a list of 15 words to a participant and then asking 
the participant to recall as many words as possible immediately after the list is read (trial 
1). The same list of words is read a second time, and the participant is given up to four 
more trials (trials 2 to 5) to recall as many of the words as possible. ADNI performed a 
total of five trials while GABS performed three. To create a compatible three trial 
   128 
 
summary score in ADNI, the number of words recalled on the first three trials were 
treated as numerical variables (0=not recalled, 1=recalled for each of the 15 words on 
each of the three trials) and summed together to give a score from 0 to 45. Twelve 
participants without item level RAVLT data were excluded.  
This RAVLT sum of 3 trials score as well as total test scores for the Digit Span Forward 
and Backward Tests, and Trail Making Test parts A and B (TMT A & B), which were 
also included in the “Item Level Data (ADAS-Cog, ANART, MMSE, etc) [ADNI1]” data 
table, were merged with the selected “Key ADNI tables merged into one table” 
observations using Roster Identification Number (RID) such that observations needed to 
be included in both data tables (matching RID) to be retained. This method of merging 
ensured that participants with AD from the “Item Level” data, where diagnostic 
information was not recorded, were excluded. After merging, four participants did not 
have TMT A scores and five did not have TMT B scores. These participants were only 
excluded from analyses which required TMT A or B scores (candidate ADAS-Cog-Proxy 
Model 5).  
Data splitting. ADNI data was split into 70% development (n=401) and 30% testing 
(n=172) subsets using random sampling without replacement via the sample.split 
command from the R package caTools with seed value set at 100.1  
Candidate model building and selection in development subset. Five candidate models 
were built, including one linear model and four generalized additive models (GAM). 
Candidate covariates (the seven cognitive tests available in both ADNI and GABS) were 
added to subsequent GAMs in order of theoretical similarity to the ADAS-Cog 11. 
Rather than requiring a linear function to explain the relationship between the covariate(s) 
and outcome, GAMS allow a degree of nonlinearity in the dependence of the outcome on 
covariates.2,3 This is achieved by summing together smooth functions of covariates. 
Smooth functions are established for individual covariates by selecting a basis. A thin 
plate regression spline basis was used for all smooth functions in all candidate GAMS, 
and the basis dimension, which sets an upper limit to the number of degrees of freedom 
that the smooth function may take on, was set manually for each covariate based on visual 
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assessment of model plots. If a covariate was included in multiple candidate GAMs, the 
basis dimension was reassessed for each GAM as the amount of smoothing appropriate 
for a given covariate is influenced by other covariates in the model. In general, larger 
basis dimensions allow more degrees of freedom, which allows more nonlinearity in the 
smooth function. The amount of this “allowed” nonlinearity actually used (effective 
degrees of freedom (edf)) for a smooth function was selected through generalized cross 
validation as part of the standard model fit process in R. An edf of one indicates that a 
linear term was deemed acceptable by the GAM. R package mgcv was used to implement 
GAMs.4 
The five candidate models were: 
1. A linear model with the MMSE as the sole covariate. The MMSE is a global 
measure of cognition, shares many similar test items to the ADAS-Cog 11, and 
was selected as a starting point as it was expected to be the candidate covariate 
best able to independently predict ADAS-Cog 11 scores. The MMSE was 
included in all candidate models.  
2. A GAM with the MMSE (basis=4, edf=2.7) as the sole covariate. This nonlinear 
model was superior to the previous linear model, so all subsequent candidate 
models were built as GAMs. 
3. A GAM with the MMSE (basis=5, edf=3.7) and RAVLT (basis=10, edf=1.0) tests 
as covariates. The RAVLT is a test of episodic memory and resembles the ADAS-
Cog 11 Word Recall task, which is one of the two items on the ADAS-Cog 11 
where most errors are accumulated in pre-dementia populations. Due to this 
similarity, and the fact that the Word Recall task was identified as one of the most 
important ADAS-Cog 11 sub-items for assessing cognitive ability in pre-dementia 
populations, the RAVLT was the second covariate to be included.  
4. A GAM with the MMSE (basis=6, edf=4.2), RAVLT (basis=10, edf=1.0), and 
CDR-SB (basis=7, edf=4.1) tests as covariates. The CDR-SB contains some 
similar assessments to the ADAS-Cog 11 (memory, orientation), but also includes 
report from a close relative, friend, or caregiver about functional activities 
(judgment, community affairs, home and hobbies, personal care items) that are not 
assessed directly by the ADAS-Cog 11.  
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5. A GAM with the MMSE (basis=6, edf=4.1), RAVLT (basis=10, edf=1.0), CDR-
SB (basis=7, edf=4.1), TMT A (basis=5, edf=1.0), TMT B (basis=5, edf=1.0), 
Digit Span Forward (basis=5, edf=3.4), and Digit Span Backward (basis=5, 
edf=1.6) tests as covariates. The TMT parts A and B are both tests of executive 
function and processing speed, which are cognitive abilities not covered by the 
ADAS-Cog 11. The Digit Span Forwards and Backwards tests assess working 
memory and attention, which are also not directly assessed by the ADAS-Cog 11. 
All four of these tests covering additional cognitive domains were added at once 
to the final candidate GAM to assess how preliminary accuracy was changed by 
adding covariates that theoretically should not be very informative for estimating 
ADAS-Cog 11 scores. 
Model 4 was selected as the best candidate model as it had better preliminary accuracy 
than Model 3, and only slightly worse preliminary accuracy than Model 5.  
Candidate model diagnostics were assessed in the development subset to ensure model fit 
was okay. The corresponding plots can be found in Appendix B (Figures B.1 to B.5). 
Accuracy estimation in testing data.  Candidate Model 4 predicted 68.6% of ADAS-
Cog 11 scores within 3 points of actual observed values (Figure 8, below), and 88.4% 
within 5 points. The Spearman rank correlation between predicted and observed ADAS-
Cog scores was strong (rho=0.70, P<0.001). 
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Figure 8 Residuals between observed and predicted ADAS-Cog scores in the ADNI 
testing data. 
Comparison with previously published model. As a final check of Candidate Model 4 
performance, the accuracy of a previously published univariate linear model for 
converting between MMSE and ADAS-Cog 11 scores was assessed.5 This model was 
developed in a sample of older adults with MCI and AD, which indicates higher levels of 
cognitive dysfunction than the ADNI or GABS sample, suggesting the model may not 
perform well enough for the purpose of approximating ADAS-Cog 11 scores in GABS. 
Indeed, this model predicted 53.2% of ADAS-Cog 11 scores within three points and 
76.1% within five points of observed ADAS-Cog 11 scores on combined development 
and testing ADNI data.  
Building the final ADAS-Cog-Proxy model. Candidate Model 4 was rebuilt on 
combined development and testing ADNI data, and is plotted in Figure 9.  
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Figure 9 ADAS-Cog-Proxy model.  
Shown are plots of the smooth terms (y-axis, number in brackets = effective degrees of 
freedom) against observed data points (x-axis) for each of the ADAS-Cog-Proxy 
generalized additive model covariates.  
 
Assessing similarity of participants in ADNI and GABS. For optimal model 
performance, the participants in ADNI used to build the ADAS-Cog-Proxy model should 
be similar to the participants in GABS whom will be obtaining estimates of ADAS-Cog-
Proxy scores. Given that both ADNI and GABS contain older adults along the pre-
dementia disease continuum from NC to MCI, their cognitive abilities are expected to be 
similar. To ensure this was the case the range of ADAS-Cog-Proxy GAM covariates were 
compared between the ADNI data used to build the GAM, and observed GABS data, as 
presented in Table 13.   
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Table 13 Range of ADAS-Cog-Proxy Covariate Scores in ADNI and GABS 
Covariate 
Range (min, max) 
MMSE 
0, 30 
RAVLT  
0, 45 
CDR-SB 
0, 4.5 
ADNI data used to build ADAS-Cog-Proxy model 
Observed Range  23, 30 5, 38 0, 4.5 
GABS Baseline 
Observed Range  18, 30 8, 33 0, 4 
n below/above 7/0 0  0  
Total n out of range 7 0 0 
GABS 6-month follow-up 
Observed Range  21, 30 5, 34 0, 4  
n below/above 3/0  0 0/0 
Total n out of range 3 0 0 
GABS 12-month follow-up 
Observed Range  20, 30  6, 39  0, 2.5  
n below/above 2 0/1 0/0 
Total n out of range 2 1 0 
GABS 24-month follow-up 
Observed Range  21, 30  9, 43  0.5, 5  
n below/above 2/0 0/1 0/1 
Total n out of range 2 1 1 
GABS 36-month follow-up 
Observed Range  20, 30 6, 38  0.5, 3.5  
n below/above 1/0 0 0/0 
Total n out of range 1 0 0 
GABS 48-month follow-up 
Observed Range  22, 30  5, 38  0.5, 4.0 
n below/above 1/0 0 0/0 
Total n out of range 1 0 0 
 
Multiple Imputation by Chained Equations and ADAS-Cog-Proxy estimation in 
GABS. To allow all participants in GABS to obtain ADAS-Cog-Proxy scores, rather than 
omitting people who had at least one of three missing covariate values, Multiple 
Imputation by Chained Equations (MICE) was used (R package ‘mice’) to impute 
missing covariate values for all timepoints of interest.6-8  
The number of missing ADAS-Cog-Proxy covariate values in GABS can be found in 
Table 14, below. CDR-SB missing values were coded as 999 if no collaborator, and NaN 
if unknown reason for missingness. This distinction in missingness was captured for 
Table 14, and then all missing values coded as NA so that MICE could be run.  
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Table 14 Missing ADAS-Cog-Proxy Covariates in the Gait and Brain Study 
Timepoint  n MMSE RAVLT CDR-SB 
Total (no 
collaborator) 
CDR-SB 
& 
RAVLT 
0 109 0 29 68 (53) 24 
6m 86 0 28 63 (50) 25 
12m 73 0 16 57 (40) 15 
24m 55 0 3 39 (33) 3 
36m 35 0 0 21 (21) 0 
48m 24 0 0 20 (19) 0 
Legend: MMSE=Mini-Mental State Examination, RAVLT=Rey Auditory Verbal 
Learning Test (3 trials), CDR-SB=Clinical Dementia Rating Scale-Sum of Boxes, 
m=months. 
The imputation method of predictive mean matching (default) was using to impute 
missing values for both CDR-SB and RAVLT. Predictive mean matching is a semi-
parametric imputation method which generates a prediction for missing values using 
other variables in the predictor matrix, and then selects an observed value from the 
predictor matrix that is similar to the predicted value. The default visit sequence of 
imputing variables in order from left to right was used, and five multiply imputed datasets 
were created.  
MICE was performed on extracted predictor matrices whereby only the final pooled 
ADAS-Cog-Proxy scores were merged back into the original GABS dataset, rather than 
performing MICE on the entire GABS database, due to multicollinearity and 
computational restrictions.6,7 The creation of predictor matrices for each time point also 
allowed the exclusion of observations that were missing simply because the 
corresponding participants did not have the follow-up visit. Furthermore, it has been 
suggested that there is no advantage in terms of accuracy for imputations when using 
more than 15-25 predictor variables.6 In accordance with published guidelines, predictor 
matrices included all GAM covariates, predictors of the outcome ADAS-Cog scores, 
variables that include a lot of variance as roughly identified by correlation with the target 
variables to be imputed (Table 15), and no variables that had a lot of missing values 
within the subgroup of people with missing RAVLT and CDR-SB scores.6–8 It has also 
been suggested to include variables related to non-response. The main reason CDR-SB 
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scores are missing is if no collaborator was present to report on behalf of the patient; 
however, there was not a variable in the dataset expected to provide indication of this.  
 
Table 15 Correlation Coefficients for Potential Predictor Matrix Variables 
Candidate Predictor Variable  Pearson 
Correlation 
Coefficient 
with CDR 
Pearson 
Correlation 
Coefficient 
with RAVLT 
Include 
variable in 
predictor 
matrix? 
Activities of Daily Living (ADL) NA -0.12 No 
Age (years) 0.07 -0.23 No 
Balance-Rigid Surface Eyes Open 0.28 -0.09 Yes 
Balance-Rigid Surface Eyes Shut 0.11 -0.17 No 
Balance-Disturbed Surface Eyes Open 0.03 -0.11 No 
Balance-Disturbed Surface Eyes Shut 0.06 -0.06 No 
Basic ADL 0.05 0.02 No 
Boston Naming Test -0.40 0.34 Yes 
Clinical Dementia Rating Scale 1.00 -0.46 Yes 
Diagnostic Category NA NA Yes 
Digit Forward Span  0.24 0.20 Yes 
Digit Backward Span -0.21 0.20 Yes 
Education (years) -0.11 0.03 No 
Frontal Assessment Battery -0.55 0.28 Yes 
Gait Velocity  -0.38 0.17 Yes 
Gait Velocity while Counting  -0.29 0.22 Yes 
Geriatric Depression Scale 0.03 -0.05 No 
Instrumental ADL -0.37 0.07 Yes 
Letter Number  -0.32 0.29 Yes 
Mini-Mental State Examination  -0.56 0.28 Yes 
Montreal Cognitive Assessment (MoCA) -0.67 0.38 Yes 
MoCA Attention Index Score -0.26 0.25 Yes 
MoCA Executive Index Score -0.46 0.20 Yes 
MoCA Language Index Score -0.26 0.29 Yes 
MoCA Memory Index Score -0.48 0.41 Yes 
MoCA Orientation Index Score -0.64 0.27 Yes 
MoCA Visuospatial Index Score -0.27 0.02 Yes 
Number of falls in the past 12 months -0.26 0.05 Yes 
Physical Activity Scale for the Elderly -0.09 -0.09 No 
Rey Auditory Verbal Learning Test -0.46 1.00 Yes 
Trail Making Task A 0.28 -0.44 Yes 
Trail Making Task B 0.49 -0.25 Yes 
 
The following variables were included in predictor matrices for each time point: Baseline 
Diagnosis, MMSE, MoCA, MoCAMIS, MoCAEIS, MoCAVIS, MoCALIS, MoCAAIS, 
MoCAOIS, CDR, Trail A, Trail B, Digit Forward, Digit Backward, Letter Number, 
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RAVLT, BNT, FAB, number of falls in past 6 months, IADL, RSEO (balance), Gait 
Velocity, and Gait Velocity while counting backwards by ones, from the time point of 
interest, as well as CDR and RAVLT scores from the previous visit (T6 to T48 visit 
imputations) or a future visit (baseline visit imputations). Participant ID was included in 
the predictor matrix to allow re-merging of data, but was omitted as a predictor variable.  
After model specification and predictor matrix creation, MICE was performed in 3 main 
stages,6,8 and repeated for each timepoint.  
1) The imputation stage created five multiply imputed datasets. Although only CDR-SB 
and RAVLT imputations were required, to remove a variable from being imputed it must 
also be removed as a predictor variable, so imputations were allowed for predictor 
variables that had missing values themselves. Imputations for RAVLT and CDR-SB were 
inspected visually to ascertain the plausibility of imputed values. Convergence of the 
MICE algorithm was also assessed by plotting imputations streams for the mean and 
standard deviation (y-axes) of the five imputations against the iteration number (x-axes), 
as shown in Figures B.6 to B.11 in Appendix B. Imputation streams that are intermingled 
without definite trends may be considered as support for convergence.6 
2) The analysis stage included applying the ADAS-Cog-Proxy GAM to each of the five 
complete datasets, which resulted in five estimated ADAS-Cog-Proxy scores for each 
participant in GABS.  
3) The pooling stage involved taking the mean of the five estimated ADAS-Cog-Proxy 
scores for each participant. These final averaged scores were labelled “T#_ADASproxy” 
and merged back into the GABS database using Participant ID.  
A summary of ADAS-Cog-Proxy descriptive statistics at each time point were assessed to 
ensure merging was performed correctly and to further assess plausibility of the estimated 
scores, and are presented in Table 16.  
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Table 16 ADAS-Cog-Proxy Scores in the Gait and Brain Study 
Timepoint  Minimum Quartile 1 Median Mean Quartile 3 Maximum 
Baseline 2.77 7.89 9.34 9.74 11.36 18.41 
6 Months 3.80 8.24 9.61 9.75 11.36 17.24 
12 Months 2.60 7.34 8.78 9.24 11.04 17.89 
24 Months 0.29 6.85 8.43 8.61 10.62 14.03 
36 Months 2.75 7.93 9.62 9.77 10.88 17.30 
48 Months 5.26 9.05 10.64 10.95 12.36 17.08 
 
6.1.2 Step 2: Select Additional Measures for the Novel Outcome 
Measure  
The overall goal for PI component selection was to select lowly correlated variables, with 
at least one variable from each of the following three categories thought to be important 
components of pre-dementia and dementia syndromes: cognition, motor function, and 
motor-cognitive performance. For simplicity candidate variables were separated into 
these three categories, but in reality these categories are not mutually exclusive. Including 
up to six component variables with low pairwise correlations in a PI has been shown to be 
advantageous in terms of content validation (covering multiple important domains) and in 
terms of reducing the variability of the final PI score.9-11 Although statistically there is 
little or no advantage to including more than six component variables or component 
variables with pairwise correlations higher than about |rho|=0.4 in a PI, doing so does not 
affect the validation of the PI nor preclude potential non-statistical advantages that may 
be gained by including certain measures.9 
To select candidate variables to include in the PI the following steps were followed, using 
baseline GABS data. Correlation coefficients were calculated using all complete pairwise 
correlations.  
1. Treat the ADAS-Cog-Proxy as the “base” of the PI to cover the cognitive domain.  
2. All single-task quantitative gait parameters gathered by the GAITRiteTM 
electronic walkway system were considered for the motor function category of 
potential PI components. Pairwise correlations were calculated between all 
quantitative gait parameters and the ADAS-Cog-Proxy, Table 17: 
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Table 17 Correlation Coefficients for Quantitative Gait Parameters and ADAS-Cog-
Proxy 
Single-Task Gait Parameter Correlation with 
ADAS-Cog-Proxy 
Gait Velocity  -0.32 
Stride Time 0.26 
Stride Time Variability 0.09 
Step Time 0.25 
Stride Length -0.28 
Step Length -0.28 
Double Support Time 0.03 
Swing Time 0.04 
Stride Width -0.06 
Stride Velocity -0.33 
Cadence -0.26 
Step Time Variability 0.08 
Stride Length Variability 0.11 
Step Length Variability 0.13 
Double Support Time Variability 0.12 
Swing Time Variability 0.16 
Stride Width Variability -0.001 
Stride Velocity Variability 0.07 
 
3. Nine Dual-Task Cost (DTC) assessments were selected to be included in the 
functionality category of candidate PI components based on the presence of 
literature supporting their importance for dementia or pre-dementia syndromes. 
Details on the DTC paradigm can be found in Chapter 5. Pairwise correlations 
were calculated between candidate DTC variables and the ADAS-Cog-Proxy, 
Table 18:  
Table 18 Correlation Coefficients for Dual-Task Cost Assessments and ADAS-Cog-
Proxy 
Dual-Task Cost 
(Secondary Task, Gait Parameter) 
Correlation with 
ADAS-Cog-Proxy 
Counting Backwards by Ones, Gait Velocity  0.28 
Counting Backwards by Ones, Stride Time -0.28 
Counting Backwards by Ones, Stride Time Variability -0.30 
Counting by Serial Sevens, Gait Velocity  0.28 
Counting by Serial Sevens, Stride Time -0.22 
Counting by Serial Sevens, Stride Time Variability -0.26 
Naming Animals, Gait Velocity  0.30 
Naming Animals, Stride Time -0.27 
Naming Animals, Stride Time Variability -0.14 
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4. Assess pairwise correlations between single task gait and DTC variables that, in 
Steps 2 and 3, had |rho|<0.2 with the ADAS-Cog-Proxy, or had |rho|=0.2 to 0.4 
with the ADAS-Cog-Proxy and evidence in published literature demonstrating 
importance in dementia or predementia syndromes, or demonstrating significant 
associations with cognition or functionality abilities thought to be important for 
older adults with dementia or pre-dementia syndromes (Table 19). It was also 
ensured that the direction of correlation coefficients was congruent with the 
ADAS-Cog-Proxy scoring of higher indicating worse dysfunction. If a variable 
was scored as higher numbers indicating worse performance, positive correlation 
coefficients were favoured. If a variable was scored as higher scores indicate less 
dysfunction, negative correlation coefficients were favoured.  
 
Table 19 Correlation Coefficients for Single Task and Dual-Task Cost Gait 
Variables that were Retained after Steps One to Three 
 GV ST STV SWT SW DSTV SWV SVV C_GV 7_GV A_GV A_STV 
GV 1.00 -0.63 -0.28 -0.09 -0.09 -0.01 0.06 -0.45 -0.27 -0.28 -0.25 0.11 
ST -0.63 1.00 0.17 0.67 0.07 -0.05 -0.11 0.24 0.13 0.28 0.22 -0.19 
STV -0.28 0.16 1.00 0.04 -0.09 0.15 0.20 0.55 0.17 0.07 0.02 0.25 
SWT -0.09 0.67 0.04 1.00 -0.19 -0.18 -0.02 0.06 0.02 0.21 0.10 -0.18 
SW -0.09 0.07 -0.09 -0.19 1.00 0.11 -0.43 -0.02 -0.09 -0.01 0.03 -0.07 
DSTV -0.01 -0.05 0.15 -0.18 0.11 1.00 -0.05 0.36 0.17 0.10 0.07 0.02 
SWV 0.06 -0.11 0.20 -0.02 -0.43 -0.05 1.00 0.09 0.08 -0.12 -0.03 0.12 
SVV -0.45 0.24 0.55 0.06 -0.2 0.36 0.09 1.00 0.21 0.13 0.15 0.08 
C_GV -0.27 0.13 0.17 0.02 -0.09 0.17 0.09 0.21 1.00 0.64 0.71 -0.28 
7_GV -0.28 0.28 0.07 0.21 -0.01 0.10 -0.12 0.13 0.64 1.00 0.82 -0.45 
A_GV -0.25 0.22 0.02 0.10 0.03 0.07 -0.03 0.15 0.71 0.82 1.00 -0.56 
A_STV 0.11 -0.19 0.25 -0.18 -0.07 0.02 0.12 0.08 -0.28 -0.45 -0.56 1.00 
Legend: GV=Gait Velocity, ST=Stride Time, STV=Stride Time Variability, 
SWT=Swing Time, SW=Stride Width, Double Support Time Variability, Stride Width 
Variability, SVV=Stride Velocity Variability, C_GV=Dual-Task Cost (DTC) for Gait 
Velocity with Counting backwards by ones, 7_GV=DTC for Gait Velocity while 
counting backwards by Serial Sevens, A_GV=DTC for Gait Velocity while Naming 
Animals, A_STV=DTC for Stride Time Variability while Naming Animals.  
 
5. When numerical and theoretical considerations were similar, as described in Step 
4, box plots of the individual gait (Figure 10 to 12) or DTC (Figure 13 to 16) 
variables were created to visually assess distribution between diagnostic 
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categories of NC, SCI, and MCI. Variables showing greater variability and a 
stepwise progression from NC to SCI to MCI were favoured.   
 
Figure 10 Box plot of gait velocity by baseline diagnostic category.  
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild 
Cognitive Impairment.  
 
Figure 11 Box plot of gait stride time by baseline diagnostic category.  
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild 
Cognitive Impairment. 
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Figure 12 Box plot of gait stride time variability by baseline diagnostic category. 
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild 
Cognitive Impairment. 
 
 
Figure 13 Box plot of dual-task gait velocity cost when counting backwards by ones 
against baseline diagnostic category.  
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild 
Cognitive Impairment. 
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Figure 14 Box plot of dual-task gait velocity cost when counting backwards by serial 
sevens against baseline diagnostic category.  
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild 
Cognitive Impairment. 
 
 
Figure 15 Box plot dual-task gait velocity cost when naming animals against baseline 
diagnostic category.  
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild 
Cognitive Impairment. 
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Figure 16 Box plot of dual-task stride time variability cost when naming animals 
against baseline diagnostic category.  
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild 
Cognitive Impairment. 
 
6. When numerical, theoretical, and distributional assessments were similar, 
practical considerations in terms of ease of assessment were taken into account 
both for individual variables and for the PI as a whole. Gait velocity is the only 
quantitative gait parameter that can be measured easily without the use of an 
electronic gait mat. 
7. Scatterplots of the most promising candidate variables and the ADAS-Cog-Proxy 
were assessed to ensure low pairwise correlation coefficients were not in spite of a 
strong non-linear relationship, Figures 17 to 19: 
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Figure 17 Scatterplot of gait velocity against ADAS-Cog-Proxy scores. 
 
Figure 18 Scatterplot of dual-task gait velocity cost with secondary task of counting 
backwards by ones against ADAS-Cog-Proxy scores. 
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Figure 19 Scatterplot of dual-task gait velocity cost with secondary task of counting 
backwards by ones against gait velocity. 
 
The final three variables selected for inclusion in the PI were ADAS-Cog-Proxy, gait 
velocity, and DTC for gait velocity with the secondary task of counting backwards from 
100 by ones. Pairwise correlation coefficients are presented below, in Table 20. 
 
Table 20 Pairwise Correlation Coefficients between Final Pooled Index Components 
 ADAS-Cog-Proxy Gait Velocity Dual-Task Cost 
ADAS-Cog-Proxy 1.00 -0.32 0.28 
Gait Velocity -0.32 1.00 -0.27 
Dual-Task Cost 0.28 -0.27 1.00 
 
6.1.3 Step 3: Combine Measures Using a Pooled Index Approach  
Baseline PI scores (for Objective 2) were calculated according to the following steps9–11: 
1) Multiply gait velocity by -1 so that all variables are coded as higher scores 
indicating worse performance (slower=worse). 
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2) Calculate the baseline mean and Standard Deviation (SD) separately for gait 
velocity, DTC, and ADAS-Cog-Proxy measures.  
3) Calculate standardized scores (𝑍 = (𝑋𝑖 − ?̅?)/𝑆𝐷) for gait velocity, DTC, and 
ADAS-Cog-Proxy measures. 
4) Sum together the three standardized scores and divide by three (take average). 
 
6.2 Objective 2 
A One-Way Analysis of Variance (ANOVA) was the initially planned statistical test to 
assess responsiveness of the ADAS-Cog-Proxy and of the PI to group-level between-
person differences in stage of disease progression at one point in time. Box plots and QQ 
plots, included in Appendix B (Figures B.12 to B.15), were used to assess the suitability 
of parametric tests. Assumptions of normality and homoscedasticity were not supported, 
and there were small sample sizes for NC and SCI categories, so the non-parametric 
Kruskal Wallis test was used instead of an ANOVA to assess whether the three diagnostic 
categories arose from the same distribution. Non-parametric Mann-Whitney U tests were 
then used to assess all pairwise comparisons between diagnostic categories. Results were 
presented in Chapter 5.  
Including Activities of Daily Living. An additional analysis not included in Chapter 5 
includes a Lawton-Brody Instrumental Activities of Daily Living (IADL) test. Although 
the GABS sample contains strictly participants with pre-dementia stages of disease 
progression where by diagnostic definition ADLs must be intact,12 ADLs are a common 
assessment of functionality and have previously been shown to improve responsiveness 
of the ADAS-Cog 11.13 To assess whether it would be beneficial to include an ADL 
measure on top of the motor, DTC, and cognitive measures included in our PI, a four 
component PI was created that included the cognitive, motor function, and DTC variables 
as well as the Lawton Brody IADL assessment (score reversed). Visual evaluation was 
used to compare baseline box plots for the four component PI (Figure 20, below) and the 
three component PI (Figure 21, below). The addition of the IADL assessment did not 
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appear to provide an advantage for baseline discrimination, so the simpler PI version was 
maintained. 
 
Figure 20 Box plot of a pooled index that includes an assessment of instrumental 
activities of daily living against baseline diagnostic category.  
Pooled index components included: ADAS-Cog-Proxy, gait velocity, DTC gait velocity 
with secondary task of counting, and instrumental activities of daily living assessments. 
Legend: CTL=Normal Cognition, SCI=Subjective Cognitive Impairment, MCI=Mild 
Cognitive Impairment.  
 
Figure 21 Box plot of pooled index against baseline diagnostic category.  
Pooled index components included: ADAS-Cog-Proxy, gait velocity, and DTC gait 
velocity with secondary task of counting. Legend: CTL=Normal Cognition, 
SCI=Subjective Cognitive Impairment, MCI=Mild Cognitive Impairment. 
   148 
 
6.3 Objective 3 
 
Standardized Response Mean (SRM) calculations were performed for the ADAS-Cog-
Proxy, the complete PI, and the standardized ADAS-Cog-Proxy combined with each 
individual component of the PI (also using a PI approach) for 6, 12, 24, 36, and 48 month 
follow-up periods. Larger SRM values indicate better responsiveness to measured decline 
over time, and can be calculated with the following formula14:  
SRM = mean(difference score) / SD(difference score) 
PI difference scores (both complete and subcomponent versions) were calculated 
according to the following steps:  
1. Create a variable for DTC at each timepoint. 
2. Create a variable for reversed gait velocity (multiply by -1) at each time point. 
Summary statistics were calculated to check that the reversal was performed 
correctly.  
3. Create subsets of data that correspond to the participants present at each 
follow-up time point. This will allow standardization with respect to the 
baseline distribution of participants who have been enrolled in the study long 
enough to reach the desired follow-up timepoint without dropping out or being 
excluded. 
Steps 4 to 10 were completed for each follow up subset of data.  
4. For each variable, calculate the baseline mean for the subset of participants 
present at the follow-up visit.  
5. For each variable, calculate the baseline SD for the subset of participants 
present at the follow-up visit.  
6. For each variable, calculate a standardized baseline score as:  
𝑍 = (𝑋𝑖,𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 − ?̅?𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒)/𝑆𝐷𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 
7. Calculate baseline PI scores by taking the average of the Z-scores calculated in 
Step 6.  
8. For each variable, calculate a standardized follow-up score as:  
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𝑍 = (𝑋𝑖,𝑓𝑜𝑙𝑙𝑜𝑤−𝑢𝑝 − ?̅?𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒)/𝑆𝐷𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 
9. Calculate follow-up PI scores by taking the average of the Z-scores calculated 
in Step 8. 
10. To get difference scores, subtract the baseline PI score (Step 7) from the 
follow-up PI score (Step 9).  
All SRM results can be found in Chapter 5, Table 11.  
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Chapter 7 
7 Discussion  
The purpose of Chapter 6 is to provide an overview of the findings of this thesis, put these 
findings into the context of peer-reviewed literature, discuss limitations, suggest 
directions for future research, and highlight clinical implications.  
7.1 Summary of Findings  
The purpose of this thesis was to assess use of the present gold standard for assessing 
efficacy of antidementia treatments, namely the Alzheimer’s Disease (AD) Assessment 
Scale–Cognitive Subscale (ADAS-Cog 11), in pre-dementia populations, and to explore 
whether adding motor function assessments to the ADAS-Cog 11 improves 
responsiveness in a pre-dementia sample. 
The literature review (Chapter 3) suggested that the ADAS-Cog 11 is not optimally 
responsive for use in pre-dementia populations. Furthermore, its content validity is 
reduced through research advancements that propose constructs not assessed by the 
ADAS-Cog 11, such as executive function (EF) and motor function, that could be 
understood as important aspects of disease severity. Several modification approaches 
have improved the responsiveness of the ADAS-Cog 11 through altered scoring 
methodology or content, but no modifications incorporating motor function were found. 
This may be, at least in part, due to the apparent lack of a database that contains both the 
ADAS-Cog 11 and high-quality motor function assessments. An ADAS-Cog-Proxy 
measure was developed to address this challenge. The corresponding methods, including 
concurrent criterion validation of the ADAS-Cog-Proxy model with the ADAS-Cog 11 in 
the Alzheimer’s Disease Neuroimaging Initiative database, may be applied in similar 
situations where all desired variables are not present in a single database, but one of the 
key variables is present in a second database with comparable subjects. Both databases 
must contain overlapping variables that are similar to the key variable. After 
approximation of ADAS-Cog 11 scores in the Gait and Brain Study (GABS), a pooled 
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index (PI) approach was used to combine quantitative motor assessments with ADAS-
Cog-Proxy scores. The resulting Gait and Brain Pooled Index (GAB-PI) consists of gait 
velocity, dual-task gait velocity cost (DTC), and the ADAS-Cog-Proxy.  
Overall the GAB-PI showed similar levels of responsiveness as the ADAS-Cog-Proxy to 
baseline discrimination of pre-dementia syndromes, demonstrating that combining the 
ADAS-Cog 11 with motor function assessments did not obscure its ability to detect 
differences between diagnostic categories that were defined based on a primarily 
cognitive conceptualization of the disease. Specifically, both the ADAS-Cog-Proxy and 
GAB-PI demonstrated the ability to discriminate between normal cognition (NC) and 
Mild Cognitive Impairment (MCI), and between MCI and Subjective Cognitive 
Impairment (SCI), but not between NC and SCI groups. Other studies have found similar 
results for the ADAS-Cog 11, and for ADAS-Cog 11 modifications.1–4  
Although diagnostic categories can serve many useful purposes, they do not necessarily 
represent all meaningful changes that may occur during progression, or regression, within 
diagnostic categories. Analyses of responsiveness to disease progression whereby no 
diagnostic classification was used, except to exclude older adults who progressed to 
dementia, found that in general the GAB-PI had comparable or slightly better 
responsiveness than the ADAS-Cog-Proxy. Specifically, for six and forty-eight month 
follow-up periods the GAB-PI detected more decline than the ADAS-Cog-Proxy, while 
for thirty-six months of follow-up the ADAS-Cog-Proxy detected greater decline. For 
twelve and twenty-four month periods the ADAS-Cog-Proxy found overall improvement 
while the GAB-PI found almost no change. Although not common, other studies that 
included older adults with NC or MCI have found improvement over one to two years on 
the ADAS-Cog 11 as well as on ADAS-Cog modifications (ADAS-Cog 12, ADAS-Cog 
13, ADAS-Cog 3, ADAS-Cog 5, ADAS-Rasch, ADNI-Mem, ADAS-Tree).5,6 Treating 
the ADAS-Cog-Proxy as the gold standard, and the cognitive modifications as potential 
improvements thereof, this indicates that the GAB-PI may not be picking up on changes 
in the correct direction. However, in one of the studies where the ADAS-Cog 11 and 
modified versions found improvement over two-years for older adults with NC, the 
Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), which is a well-respected 
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assessment of overall disease severity,7–9 found the largest magnitude of change over 
time, and it was in the direction of worsening.5 Furthermore, knowing that the progression 
from NC to MCI to dementia is not linear,10 but that motor function decline may be 
detectable in advance of further cognitive decline,11,12 and that motor function and 
cognitive ability are both important for functionality,13–16 it is possible that the measures 
detecting decline over time are presenting a more accurate detection of changes in overall 
disease severity. Further validation analyses against clinical indicators of overall disease 
severity may help to clarify this.  
Interestingly, the PI combining only gait velocity with the ADAS-Cog-Proxy increased 
responsiveness to measured decline compared to the ADAS-Cog-Proxy alone for all 
follow-up periods, and demonstrated larger responsiveness than the full GAB-PI for the 
two longest follow-up periods (36 and 48 months). The PI combining only DTC with the 
ADAS-Cog-Proxy was never more responsive than the full GAB-PI, and for at least two 
follow-up periods was less responsive than the ADAS-Cog-Proxy alone. 
These findings were surprising as the DTC paradigm was designed to tap into the limited 
capacity of the brain such that when one is asked to perform an attention demanding task 
while walking, some of the brain capacity that would otherwise be devoted to walking 
(single-task gait can use all available capacity) is reallocated to the secondary task, and 
gait performance worsens.12,17–20 As neurodegeneration progresses en route to dementia, 
there is less and less capacity to devote to the two tasks, and the DTC should 
increase.14,21,22 Previous research on gait assessments alone has found significant 
differences between single- and dual-task gait parameters within MCI and NC 
populations,18,23–26 whereby the disruption is often greater for MCI than NC.17,24,26,27 The 
ability of DTC to discriminate between pre-dementia syndromes is better than single-task 
gait,27,28 and DTC in MCI has been associated with risk of progression to dementia.29  
Hence, more consistent and advantageous results from the addition of a DTC assessment 
to the ADAS-Cog-Proxy for responsiveness to disease progression was expected.  
The cueing effect refers to an improvement in gait under dual-task compared to single-
task conditions, and is thought to occur because the secondary task can serve as a pacer or 
rhythmic auditory stimulation to aid gait.30 The cueing effect, may account for some of 
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the inconsistent influence of the DTC measure on responsiveness to measured change 
over time. A negative DTC, as would be seen if the cueing effect were occurring, was 
present in about one third of the GABS sample at baseline for the DTC on gait velocity 
when counting backwards by ones. Other gait parameters and other secondary tasks that 
were considered for inclusion in the PI also demonstrated non-uniform effects of the 
secondary task on gait (i.e. a mix of participants with positive and negative DTC). A 
complementary explanation that may also account for some of this variability is that the 
current DTC paradigm is only concerned with gait performance and does not include in 
the score any indication for how well an individual performs the cognitive task. In spite of 
being instructed not to try harder on one task or the other, some people may prioritize the 
gait task while others prioritize the cognitive task, which could lead to different DTC 
scores even if brain capacity is similar.23 Although this is more of a concern for 
individual-level than group-level measurement as the majority of people do demonstrate 
the expected gait worsening under dual-task conditions, revising the DTC paradigm to 
lessen some of these individual differences may improve group-level responsiveness of 
the GAB-PI.  
7.2 Comparison with other ADAS-Cog Modifications 
Scoring modification. First, the GAB-PI incorporates a statistical modification to scoring 
by standardizing component variables that originally had different scoring scales. 
Standardization allows these variables to be combined to produce a single final score with 
lower variability than the original raw score of any single component variable. One other 
ADAS-Cog 11 modification used a PI approach to combine the ADAS-Cog 11 with other 
cognitive tests, assessments of mood or behaviour, and assessments of the ability to 
perform activities of daily living. This PI demonstrated better responsiveness to a 
treatment effect in a clinical trial for Alzheimer’s Disease than the ADAS-Cog 11 alone.31 
In pre-dementia populations, three distinct approaches to scoring ADAS-Cog 13 (Section 
3.3.1) data yielded different amounts of responsiveness to disease progression and 
responsiveness to treatment effects in MCI populations.32 In one instance, a re-weighted 
version of the ADAS-Cog 13 demonstrated greater responsiveness to disease progression 
in MCI than a version that included additional assessments of EF and functionality.32 
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Taken together, this demonstrates that the way outcome measure data are analysed, and 
not just the content of that data, is important for outcome measure performance. The 
responsiveness of the GAB-PI may reflect a combination of the measures it comprises, 
and the PI approach used to combine them.  
Additional cognitive assessments. In general, adding memory items to the ADAS-Cog 
11, occasionally accompanied by the removal of other tasks, improved responsiveness to 
disease progression and to treatment effects.3,5,6,33 Adding assessments of EF to the 
ADAS-Cog 11, with or without modifying scoring methodology, and with or without 
additional measures of memory, was found to improve responsiveness to disease 
progression and to treatment effects in MCI populations in all but one instance.6,32–35 It is 
conceivable that at least some of the responsiveness of the GAB-PI to changes in pre-
dementia syndromes is due to gait velocity and DTC picking up on EF or other cognitive 
abilities. For example, gait velocity has been associated with EF,15,18,22,25 and there is 
mixed evidence around the potential association of gait velocity or DTC gait velocity 
with memory.18,23,25  
Adding functionality assessments. It has been stated that ideal measures for MCI and 
early AD should include both cognitive and functional assessments,34,35 and the results of 
the literature review on ADAS-Cog 11 modifications support this. Modifications that 
added items to assess functionality, alone or in combination with other cognitive tests or 
alternative scoring methods, demonstrated superior responsiveness to disease progression 
and to treatment effects in MCI populations than ADAS-Cog 11 modification approaches 
that only modified cognitive content alone or in combination with scoring modification 
techniques.32–34,36 The only exception was that the ADAS-Tree outperformed the ADAS-
Plus-EF&FA for responsiveness to disease progression, although the ADAS-Plus EF&FA 
demonstrated superior responsiveness over the ADAS-Tree to treatment effects32; this 
point also serves to demonstrate the context specificity of responsiveness. The CDR-SB 
alone, which includes assessments of cognition and functionality, was also found to be 
more responsive to measured decline over two years in MCI and NC samples than several 
ADAS 11 modifications that re-weighted scores and/or added cognitive tests but did not 
include any assessment of functionality.5  
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Walking is a complex task,15 and gait velocity in particular has been considered a marker 
of functionality for older adults in the context of cognitive disorders specifically and 
ageing in general.15,16,30,37,38 Gait velocity and DTC are expected to reflect more subtle 
changes in functionality than those captured by the assessments used for previous ADAS-
Cog modifications, such as the Functional Activities Questionnaire (FAQ), which rely on 
categorical response options of how well, if at all, a person can perform certain 
activities.39 For example, the FAQ item assessing, through informant report, a subject’s 
ability to perform “Shopping for clothes, household necessities, or groceries” may not 
capture changes that are noticeable and meaningful to a patient or caregiver but are not 
impactful enough to move from a categorical rating of “normal” to “has difficulty but 
does by self” or to “requires assistance”. Nonetheless, during GAB-PI development it was 
explored whether adding an assessment of instrumental activities of daily living (ADL) to 
the PI would improve distinction between baseline diagnostic categories. This did not 
appear to be the case, so the simpler three item PI was retained (see Appendix B, Section 
B.2 for more information). 
More generally, cognitive ability, the ability to move through one’s environment, and the 
ability to perform mental and motor tasks at the same time, are all important aspects of 
functionality, and may be impacted by dementia and pre-dementia neuropathology. Even 
if a treatment does not alter the underlying pathology causing dementia, it can have a 
substantial impact on a patient’s quality of life, as well as the burden held by caregivers, 
by stabilizing or slowing decline in cognitive ability, in motor function, or in the ability to 
maintain motor control while performing a cognitive task. There are several anecdotal 
reports of caregivers or clinicians noticing overall improvements in a patient when taking 
symptomatic treatments that are not accompanied by changes on standard tests of 
cognitive ability, and pharmacological treatments for dementia that demonstrate only 
modest effects on cognitive tests have been shown to delay admittance to nursing 
homes.40–42 This suggests that cognitive tests alone are not capturing all important 
changes in disease severity. The GAB-PI was developed by selecting one measure to 
cover each of the three aspects of functionality presented above. Specifically, the ADAS-
Cog-Proxy was selected to cover cognitive ability, single-task gait to cover movement, 
and dual-task gait cost to cover simultaneous cognitive and motor performance; however, 
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these three categories are not mutually exclusive. In particular, gait assessments may tap 
into cognitive domains, such as EF, that have been identified as important components of 
pre-dementia syndromes but are not covered by the ADAS-Cog 11.12,15,18,22,23,25,43 This 
introduces the idea that a single measure may serve the dual purpose of assessing both a 
manifest variable (gait velocity) and a latent variable (executive function), where both the 
manifest and latent variables are integral components of a disease, and changes in either 
the manifest or latent variable alone, or in combination, are meaningful. This contrasts 
with most cognitive assessments, including the ADAS-Cog 11, where the questions or 
tasks administered as manifest variable measures (e.g. the ability to draw a circle) are of 
much less importance than the latent variable that the resulting scores are intended to 
assess (e.g. praxis). The potential for gait assessments, under single-task or dual-task cost 
paradigms, to serve as a simultaneous measure of the fundamental bases for 
functionality—latent cognitive domain(s) and manifest motor function—may reduce 
inefficiencies in the measurement process and more closely represent whether treatments 
are having a meaningful impact on overall disease severity. Further research is needed to 
ascertain the validity of this statement, but the results of this thesis put into context with 
findings from other ADAS-Cog 11 modifications, suggest that gait assessments, 
supplemented with additional cognitive assessment, could play a valuable role in future 
studies of pre-dementia populations. 
7.3 Limitations  
The results of this thesis should be interpreted as preliminary, because a statistical model 
was used to approximate ADAS-Cog 11 scores in the GABS. More specific limitations to 
this process include slightly different study samples used to build the ADAS-Cog-Proxy 
from the GABS, and further error that may have been introduced through imputation of 
missing ADAS-Cog-Proxy covariates in the GABS. Furthermore, partly due to the nature 
of using data from an on-going cohort study, there were small sample sizes, especially at 
the longest follow-up time points. When assessing differences between people who did 
versus did not have each follow-up visit, it was found that participants with twenty-four 
and forty-eight month visits had statistically significant differences in gait speed (faster) 
than those who did not reach those follow-up visits. There were no statistically significant 
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differences in baseline gait velocity for the other lengths of follow-up, or for any follow-
up length in age, education, DTC, or ADAS-Cog-Proxy scores.  
When assessing responsiveness to disease progression, the standardized response mean 
(SRM) allows for direct comparison between the PI and the ADAS-Cog-Proxy, but the 
clinical meaningfulness of SRM units is not obvious. Furthermore, although this thesis 
only considered group-level responsiveness for the intended purpose of use in research 
studies, if individual-level responsiveness was of interest, such as for use in a clinical 
setting, a reference population would be needed to perform standardization of the PI 
component variables. It may be difficult to find a suitable pool of reference individuals.   
In terms of the GAB-PI itself, the units are hard to interpret, and scoring calculations are 
more complex than for the ADAS-Cog 11. One major limitation is that the GAB-PI may 
not be useful for people with mobility impairment that is explainable by an event or 
disease other than dementia or pre-dementia syndromes (e.g. severe osteoarthritis of the 
lower limbs, Parkinson’s Disease, amputation, stroke with residual motor deficits), even 
if some assessment of gait could be obtained. Most studies evaluating motor function in 
the context of dementia or pre-dementia syndromes, including the GABS, exclude 
individuals with severe mobility restrictions, which limits the generalizability of results.   
On a broader level, based on the literature review in Chapter 3, the GAB-PI will be the 
thirty-second documented modified version of the ADAS-Cog 11. This thesis does not 
directly address the problem that has led to the creation of so many modifications: 
maintaining the ADAS-Cog 11 as the gold standard for assessing efficacy of treatments 
for dementia and pre-dementia populations, despite knowing it is not optimally 
responsive to important changes at the stages of disease where potential benefit of 
intervention may be greatest. While modifications can be beneficial in terms of within-
study quality, they introduce a level of inconsistency and inefficiency that renders 
between-study comparisons, such as for meta-analyses, difficult; did intervention A find a 
benefit while intervention B did not because intervention A is truly more effective than 
intervention B, or because the ADAS-Cog 11 modification used to assess the efficacy of 
intervention A is more responsive to treatment effects than the one used to assess 
intervention B? Although modifications that maintain backwards compatibility with the 
   159 
 
ADAS-Cog 11 have the potential to produce results on a standard metric, it is often up to 
the researchers of the study to produce these analyses, and the results are not necessarily 
expected to be consistent. By combining the ADAS-Cog 11 (or Proxy substitute) with 
quantitative gait assessments, the GAB-PI contributes to the heterogeneity of ADAS-Cog 
11 modifications in a major way without a clear indication of how to reconcile results that 
may be inconsistent with those found on the ADAS-Cog 11 or other modified versions.  
7.4 Suggestions for Further Research  
Once an appropriate database with both the ADAS-Cog 11 and gait assessments becomes 
available, the PI can be re-built using the ADAS-Cog 11 instead of the ADAS-Cog-
Proxy, and construct validation analyses comparing the GAB-PI to the ADAS-Cog 11 on 
responsiveness to baseline discrimination and to disease progression in a pre-dementia 
sample repeated. Test-retest as well as inter-rater reliability of the GAB-PI as a whole 
should be assessed, even though reliability of the individual components has previously 
been evaluated.44,45 If possible, it may also be of interest to compare the GAB-PI to other 
ADAS-Cog 11 modifications, especially those which incorporate assessments of 
functionality, and to repeat validation and reliability analyses for older adults with mild to 
severe dementia as an ideal outcome measure will be reliable, valid, and responsive to 
changes across the disease spectrum from NC to severe dementia.35,43,46 
The responsiveness of the GAB-PI to pharmacological and non-pharmacological 
treatment effects in pre-dementia populations should also be assessed. Although an 
outcome measure that is responsive to disease progression is often expected to also be 
responsive to treatment effects that slow, stop, or reverse disease progression, this is not 
always the case. For example, if a treatment targets one aspects of a disease that a given 
measure does not assess, that measure may miss important treatment effects but still be 
highly responsive to changes in natural history if it assesses other dynamic aspects of the 
disease that are not affected by the treatment. In the ADAS-Cog literature review most 
ADAS-Cog 11 modifications that demonstrated better responsiveness than the ADAS-
Cog 11 to disease progression in pre-dementia populations also demonstrated superior 
responsiveness to treatment effects,3,5,32,33 but there was at least one notable exception to 
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this trend, which was a modification focused specifically on memory impairment.5 Thus, 
it will be important to assess the responsiveness of the GAB-PI to treatment effects in 
addition to disease progression. Ideally this would be done in the context of a treatment of 
known efficacy, but none exist for pre-dementia syndromes. Instead, the GAB-PI will be 
assessed as a secondary outcome measure for the SYNchronizing Exercises, Remedies in 
Gait and Cognition (SYNERGIC) clinical trial that will assess the effect of aerobic and 
progressive resistance training exercises, combined with cognitive training and vitamin 
D3, in older adults with MCI.47 The SYNERGIC trial is currently recruiting participants 
in Ontario and British Columbia. The GAB-PI may be used to assess change over the 20-
week study period within each treatment group (responsiveness to group-level within-
person observed change over time), as well as between treatment groups (responsiveness 
to group-level between-person differences of within-person observed change over time), 
and compared to other outcome measures including the ADAS-Cog-Plus-EF&FA.  
A final future direction revisits a key motivation behind this thesis, and proposes an 
alternative, more data-driven approach than ADAS-Cog 11 modification to explore the 
potential role of motor function assessments in detecting important changes in pre-
dementia syndromes. The three components of the GAB-PI were selected based on 
theoretical, statistical, and practical considerations. Despite best efforts, these three 
components may not be the combination of measures most responsive to important 
changes in pre-dementia syndromes, such as those that occur between NC and MCI. A 
penalized regression analysis allows the simultaneous consideration of many more 
variables than can be sorted through manually.48 This analysis will be used to obtain a 
model, composed of some subset of a pool of candidate variables, for discriminating 
between older adults with NC or SCI and older adults with MCI in GABS. The candidate 
pool of variables will contain all non-duplicate quantitative gait parameters collected by 
the electronic gait mat used in the GABS, including both those that have been studied 
substantially in the literature and those which have not, under single and the three dual-
task conditions, as well as the DTC for each gait parameter and secondary task; balance 
assessments; the ADAS-Cog-Proxy and other global cognitive tests such as the Montreal 
Cognitive Assessment and domain specific cognitive tests; patient characteristics such as 
age and years of education; and ADL assessments. Given limits in human discernment, 
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this is far more variables than could be considered for inclusion in the GAB-PI, but an 
argument could be made for the potential utility of any of them for baseline 
discrimination purposes. The penalized regression analysis gradually provides the 
opportunity for more and more of these candidate variables to enter the model, and then 
cross validation can be used to obtain the best model, or regression equation, for baseline 
discrimination.48 Further rationale for this analysis, alluded to earlier, is that the results of 
this thesis cannot discern if the addition of gait velocity and DTC to the ADAS-Cog 11 is 
leading to improvements in responsiveness beyond that which could be obtained by 
adding more standard assessments of functionality or additional cognitive tests; gait 
velocity may simply be serving as an assessment of traditional ADLs or EF rather than 
improving responsiveness because motor function is an integral component of the disease 
beyond that which may be captured by previously established outcome measures. Note 
that this would not negate any practical advantages of using gait assessment over more 
traditional outcome measures, such as brevity of assessment and language independence. 
Taking this one step further, from a purely measurement perspective, the ability to detect 
important changes is more important than the explanation about why these changes are 
being detected. The penalized regression analysis is a data-driven method that will help to 
identify whether motor function assessments (and if so, which ones) are selected for 
inclusion in a model for baseline discrimination between pre-dementia syndromes, even 
when the model has the option of global and domain specific cognitive tests, more 
general assessments of functionality, and patient characteristics previously shown to be 
relevant for pre-dementia syndromes. If motor assessments are selected this will further 
support their potential utility for detecting important changes in pre-dementia syndromes, 
but will not identify why this may be the case.   
7.5 Clinical Implications  
As clinical syndromes, dementia and pre-dementia stages of disease involve more than 
cognitive impairment; a key aspect of these syndromes is the impact that cognitive 
deficits have on functionality. Walking, or gait performance, is also important for the 
ability to perform several basic ADLs and has been postulated as a marker of overall 
functionality and a sixth vital sign to be assessed in older adults.16,49 Gait, and particularly 
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dual-task gait performance, has been shown to capture subtle changes during the 
cognitive decline associated with ageing and neurodegeneration, especially in MCI 
populations, which are not always captured by cognitive testing.29 This thesis has shown 
that adding gait assessments to the ADAS-Cog 11 may help to differentiate between 
cognitively defined diagnostic groups, and detect progression in disease severity over 
time. The GAB-PI is also expected to be sensitive to changes in progression due to 
pharmacological and non-pharmacological treatments. To the knowledge of those who 
have contributed to this thesis, this is the first attempt to incorporate motor function 
assessments, which have previously been associated with progression to dementia,50,51 
with the ADAS-Cog 11 which is the gold standard for testing interventions in dementia 
and pre-dementia syndromes.  
7.6 Conclusion 
This thesis has highlighted three challenges related to outcome measurement development 
and use, including those pertaining to the maintenance of a long-standing gold standard in 
a rapidly developing research field, to how outcome measures may be modified for 
improvement, and to the situation of performing secondary data analysis when not all 
necessary outcome measures are present in a single database. These challenges were 
considered in the field of dementia research. Overall this thesis suggests that the gold 
standard ADAS-Cog 11 is not an ideal outcome measure for studies on pre-dementia 
syndromes, and that improvements may be made by adding quantitative gait assessments 
to the ADAS-Cog 11 using a PI approach. 
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Appendices 
Appendix A: Summary Table of ADAS-Cog 11 Modifications 
Outcome 
Measure 
Test Items Scoring 
Modifications 
CV  
NC  
CV  
MCI 
CV  
Dementia 
ADAS-
Cog 111 
Word recall, naming objects and 
fingers, commands, 
constructional praxis, ideational 
praxis, orientation, word 
recognition, language, 
comprehension of spoken 
language, word finding 
difficulty, and remembering test 
instructions 
 0.4912 
0.4683  
0.4684 
0.4528  
0.46825 
 
 
0.3833  
0.3834 
0.3817 
0.3028  
0.4128  
0.45212 
0.37519 
0.38325 
0.38486  
 
0.6271 
0.3942 
0.3353  
0.3394 
0.5176 
0.3907 
0.3338 
0.32012 
0.34613 
0.33919 
0.34125 
 
 
ADAS-
Cog 1370 
ADAS-Cog 11, delayed recall, 
number cancellation or maze 
 0.4323 
0.44725 
0.3333  
0.43912 
0.33925 
0.33786 
0.2633 
0.24912 
0.26725 
VaDAS72,7
3 
ADAS-Cog 11, two number 
cancellation tasks, delayed 
recall, maze, symbol digit 
modalities, digit backwards, 
animal category retrieval task 
 N/A 
 
 
 
 
 
N/A N/A 
ADAS-
127,17,75,76 
ADAS-Cog 11, delayed recall  N/A 0.3437  0.3107  
TE4D-
Cog6 
Commands, 7-word immediate 
recall, semantic memory (name 
seasons and match month to 
season), clock drawing, 
category fluency, orientation 
from ADAS-Cog 11, delayed 
recall 
 N/A N/A 0.7326 
Pooled 
Index77 
Standardized ADAS-Cog 11, 
GDS, DBRI frequency, 
standardized MMSE, ADL, and 
DBRI 
Pooled Index 
approach 
N/A N/A N/A 
ADAS-
Rasch78 
ADAS-Cog 11 Items weighted by 
measurement 
precision and based 
on IRT (OPLM) 
analysis. 
0.7293 
0.72925 
 
0.4663 
0.46625 
 
0.3793 
0.37925 
 
ADAS-
Tree18 
ADAS-Cog 11, delayed word 
recall, number cancellation 
Test items 
reweighted by 
random forest tree-
based algorithm  
0.4433 
0.44325 
0.3213 
0.32125 
0.2313 
0.23125 
cADAS-
Cog79 
ADAS-Cog 11, delayed recall, 
number cancellation, maze 
 N/A N/A N/A 
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tasks; computerized multiphasic 
interactive neurocognitive 
display system for 
administration 
TDAS80 Word recognition, command, 
orientation, visual-spatial 
perception (modified 
constructional praxis), naming 
fingers, object recognition 
(modified naming objects), 
accuracy of the order of a 
process (modified ideational 
praxis), money calculation, 
clock time recognition (non-
digital); computerized version 
of items administered with 
touch panel. 
 N/A N/A N/A 
CAMCOG
-Plus81 
Up to 25 items from CAMCOG 
(18 items in candidate pool), 
neuropsychological tests (12 
items in candidate pool), 
ADAS-Cog (10 tasks in 
candidate pool), and MMSE (11 
items in candidate pool) 
Computer 
algorithm to 
estimate cognitive 
ability. Item 
difficulty estimated 
with OPLM and 
computerized 
algorithm selects 
next questions 
based on previous 
responses and 
continuously 
updates estimate of 
cognitive ability 
until 25 items 
administered or 
standard error of 
measurement for 
cognitive ability 
corresponds to 90% 
precision 
N/A N/A N/A 
ADAS-
Cog -5 
Subset82 
Ideational praxis, remembering 
test instructions, language, 
comprehension, word finding 
difficulty 
Subsetting analysis. 
Compare 
proportion of 
responders: 
responder=1=did 
not get worse over 
time on all items. 
Non-
responder=0=subje
ct got worse (pre-
post diff >0) on at 
least one item 
N/A N/A N/A 
ADAS-
Cog -6 
Subset82 
Word recall task, naming 
objects and fingers, commands, 
constructional praxis, 
orientation, and word 
recognition 
Subsetting analysis: 
Responder=1=did 
not get worse over 
time on all items. 
Non-
responder=0=subje
N/A N/A N/A 
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ct got worse (pre-
post diff >0) 
ADAS-
bifactor3 
ADAS-Cog 13 Bi-factor model 
that accounts for 
residual 
correlations 
between word 
recognition and 
recall and between 
the 4 tasks based 
on interviewer 
report 
N/A N/A N/A 
ADAS-
Cog-Plus-
EF3 
ADAS-Cog 13, category 
(vegetable) fluency 
Bi-factor model N/A N/A N/A 
ADAS-
Plus-
EF&FA 
bifactor 
model3 
ADAS-Cog 13, category 
(vegetable) fluency, TMT A&B, 
DSST, 5 Pfeffer FAQ items 
Bi-factor model 
with methods 
factor for 5 FAQ 
items 
N/A N/A N/A 
Common 
Item 
Pooling20 
Various combinations from 
CAMCOG, ADAS-Cog, 
MMSE, neuropsychological 
tests 
Common item 
pooling whereby 
OPLM used to 
estimate test item 
difficulty and 
subject cognitive 
ability, expressed 
as T-scores 
N/A N/A N/A 
ADNI 
Memory 
Composite
25 
Word Recognition, RAVLT, 
delayed word recall, MMSE 3 
word memory task with 
distractors, logical memory test 
Factor score from 
single factor model 
N/A N/A N/A 
ADAS-
Cog 
IRT83,84 
ADAS-Cog 11 IRT scoring 
methodology 
N/A N/A N/A 
ADAS-319 Word recall, delayed word 
recall, orientation 
 N/A N/A N/A 
CC119 
 
ADAS-3, RAVLT Immediate, 
MMSE 
Accounts for 
directionality of 
change 
N/A 10.93019 0.53319 
CC219 ADAS-3, cognitive portion 
CDR-SB 
 N/A 13.42919 0.53819 
CFC119 CC1, FAQ  N/A 9.27319 0.59219 
CFC219 CC2, FAQ  N/A 7.69219 0.60919 
Parmacom
etric 
ADAS-
Cog 1315 
ADAS-Cog 13 Pharmacometric 
scoring 
methodology 
N/A N/A N/A 
IRT& 
Pharmaco
metric 
ADAS-
Cog 1315 
ADAS-Cog 13 IRT and 
Pharmacometric 
scoring 
methodology   
N/A N/A N/A 
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iADRS85 ADAS-Cog 14, iADL OR 
substitute in ADAS-Cog 13, 
FAQ 
[ADAS-Cog 14 = ADAS-Cog 
11, maze, digit cancellation, 
delayed recall] 
[-1(ADAS-Cog14) 
+ 90] + iADL 
N/A N/A N/A 
Straightfor
ward 
Sensitive 
Scale86 
Word recall, delayed word 
recall, orientation, FAQ, CDR-
SB 
 N/A N/A N/A 
ADAS-
Cog 3b12 
Word recall, orientation, word 
recognition 
 N/A 0.45712 0.26012 
ADAS-
Cog 512 
ADAS-Cog 3b, delayed word 
recall, digit cancellation. 
 N/A 0.44212 0.20312 
ADAS-
13RW87 
ADAS-Cog 13 Reweight 
subsections as: 
memory = 0.10, 
clinician-rated 
tasks = 0.45, 
general cognitive 
tests = 0.45 
N/A N/A N/A 
ADCOMS
88 
Orientation, word recognition, 
word finding difficulty, delayed 
word recall, two MMSE items 
orientation time, drawing, and 
CDR-SB personal care, 
community affairs, home and 
hobbies, judgement and 
problem solving, memory, 
orientation) 
Weighted linear 
combination based 
on partial least 
squares coefficients 
N/A 0.45988  N/A 
Abbreviations (in order of appearance): CV=Coefficient of Variation (Standard 
Deviation/Mean); NC=Normal Cognition; MCI=Mild Cognitive Impairment; ADAS-
Cog=Alzheimer’s Disease Assessment Scale-Cognitive Subscale; VaDAS=Vascular 
Dementia Assessment Scale; N/A=Not Available; GDS=Geriatric Depression Scale; 
DBRI=Dysfunctional Behaviour Rating Instrument; MMSE=Mini Mental State 
Examination, ADLActivities of Daily Living; IRT=Item Response Theory; OPLM=One 
Parameter Logistic Model; cADAS-Cog=Computerized ADAS-Cog; TDAS=Touch Panel 
Type Dementia Assessment Scale ; CAMCOG=Cambridge Cognitive Examination;  
EF=Executive Function; FA=Functional Assessment; TMT=Trail Making Test; 
DSST=Digit Symbol Substitution Test; FAQ=Functional Assessment Questionnaire; 
ADNI=Alzheimer’s Disease Neuroimaging Initiative; RAVLT=Rey Auditory Visual 
Learning Test; CC=Cognitive Composite; AVLT-Immed=Auditory Visual Learning 
Test–Immediate; CDR-SB=Clinical Dementia Rating Sum of Boxes; CFC=Cognitive 
Functional Composite; iADRS=Integrated Alzheimer’s Disease Rating Scale; 
iADL=Instrumental Activities of Daily Living; ADAS-13RW=ADAS-Cog 13 Re-
weighted; ADCOMS=Alzheimer’s Disease Composite Score. Note: Superscripts refer to 
reference numbers at the end of Chapter 3. 
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Appendix B: Supplementary Figures 
 
Figure B.1 Diagnostic plots for ADAS-Cog-Proxy Candidate Model 1.  
 
Figure B.2 Diagnostic plots for ADAS-Cog-Proxy Candidate Model 2.  
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Figure B.3 Diagnostic plots for ADAS-Cog-Proxy Candidate Model 3.  
 
Figure B.4 Diagnostic plots for ADAS-Cog-Proxy Candidate Model 4.  
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Figure B.5 Diagnostic plots for ADAS-Cog-Proxy Candidate Model 5.  
 
 
 
Figure B.6 Imputation streams for baseline assessment. Mean and standard deviation 
(SD) are for imputed values. Each line represents one imputation stream.  
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Figure B.7 Imputation streams for six-month follow-up assessment. Mean and 
standard deviation (SD) are for imputed values. Each line represents one imputation 
stream.  
 
 
Figure B.8 Imputation streams for twelve-month follow-up assessment. Mean and 
standard deviation (SD) are for imputed values. Each line represents one imputation 
stream.  
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Figure B.9 Imputation streams for twenty-four-month follow-up assessment. Mean 
and standard deviation (SD) are for imputed values. Each line represents one imputation 
stream.  
 
 
Figure B.10 Imputation streams for thirty-six-month follow-up assessment. Mean 
and standard deviation (SD) are for imputed CDR-SB values. Each line represents one 
imputation stream.  
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Figure B.11 Imputation streams for forty-eight-month follow-up assessment. Mean 
and standard deviation (SD) are for imputed CDR-SB values. Each line represents one 
imputation stream.  
 
 
Figure B.12 Box plot summarizing distribution of ADAS-Cog-Proxy scores in each 
baseline diagnostic category (CTL=Normal Cognition, SCI=Subjective Cognitive 
Impairment, MCI=Mild Cognitive Impairment).  
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Figure B.13 Box plot summarizing distribution of Pooled Index scores in each 
baseline diagnostic category (CTL=Normal Cognition, SCI=Subjective Cognitive 
Impairment, MCI=Mild Cognitive Impairment).  
 
 
Figure B.14 QQ plots to assess normality of baseline ADAS-Cog-Proxy scores.  
 
Figure B.15 QQ plots to assess normality of baseline Pooled Index scores.  
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